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ABSTRACT 
INTER-INDIVIDUAL VARIATION IN RESPONSE TO ESTROGEN AND 
IMPLICATIONS FOR BREAST CANCER RISK 
 
MAY 2020 
 
AMYE L. BLACK, B.S., UNIVERSITY OF CONNECTICUT 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: D. Joseph Jerry 
 
Breast cancer is the second leading cause of cancer related death among women 
and the most prevalent cancer type in women worldwide.  Many risk factors for breast 
cancer are related to estrogen exposure, including early menarche, late menopause, 
nulliparity, hormone replacement therapy, and high serum estrogen levels.  These factors 
all involve prolonged or high levels of estrogen exposure.  However, estrogen exposure 
during early pregnancy lowers risk by up to 50% and high dose estrogen treatment is an 
effective antitumor treatment in postmenopausal women.  The mechanisms behind 
estrogen’s paradoxical role in both contributing to and reducing breast cancer risk are 
currently unknown.  We hypothesized that a subset of women may be more sensitive to 
estrogen exposure, and the following experiments were designed to test this hypothesis and 
determine if sensitivity to estrogen is due to estrogen receptor levels or downstream 
regulation of estrogen signaling using 3 human breast tissue or cell models.   
 Our first model used to characterize responses to estrogen treatment was the human 
breast ex-vivo explant model.  Donor human breast explants were treated with control or 
estrogen for 4 days and then transcriptional and functional responses were compared 
between individuals.  Up to 80 or 100-fold variation in estrogen receptor alpha (ERα) and 
estrogen receptor beta (ERβ) mRNA levels were observed in explants.  Responses to 
 vii 
estrogen also varied among individuals, although estrogen receptor target gene expression 
(AREG, PGR, and TGFβ2), progesterone receptor protein (PR) expression, proliferation, 
and irradiation induced apoptotic responses were not significantly correlated with estrogen 
receptor levels.  These results indicated that there are variable responses to estrogen 
exposure among individuals but that these responses do not appear connected to estrogen 
receptor expression levels.  Our second model, conditionally immortalized primary human 
mammary epithelial cells (ciHMEC), also demonstrated variable responses in luciferase 
reporter assays with estrogen and xenoestrogen treatment, though the responses were more 
consistent than those observed in the human breast explant model.  This was likely due to 
transfection of saturating levels of estrogen receptor. 
 Lastly, we examined estrogen-induced responses in 4 inducible ERα HMEC cell 
lines.  While all 4 lines were able to activate luciferase reporter assays and expressed ERα 
protein, only 3 out of 4 demonstrated a proliferation response to estrogen.  Expression of 
estrogen receptor target genes (AREG and PGR) however, was not regulated by estrogen 
treatment.  Conditioned growth media assays demonstrated that this proliferative response 
was not due to secretion of factors into the media but is instead driven by intracellular 
factors.  As others have implicated the pioneer factors FOXA1 and GATA3 in restoring 
estrogen-induced responses, we examined mRNA expression of these factors in our cells 
and found no correlation with estrogen-induced proliferation.  These results imply that 
while FOXA1 and GATA3 are not sufficient to induce biological responses to estrogen.  
Collectively, our work demonstrated individual variation in estrogen receptor expression 
and estrogen and xenoestrogen-induced responses.  Sensitivity to estrogen treatment was 
not driven by estrogen receptor expression levels.  Further, our results suggest intracellular 
 viii 
factors, such as estrogen receptor coregulators, are important for modulation of estrogen-
induced biological responses.   
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CHAPTER 1 
INTRODUCTION 
Estrogen Exposure and Breast Cancer Risk 
Breast cancer is the most prevalent cancer type among women worldwide and the 
second leading cause of cancer related death in women (Siegel et al., 2019).  Known risk 
factors for breast cancer include age, genetics, obesity, increased breast density, early onset 
of menarche, late menopause, nulliparity, and late full-term pregnancy (Travis and Key, 
2003; Samavat and Kurzer, 2015; Brooks et al., 2018).  Many of these risk factors are 
related to endogenous estrogen levels.  Chronic lifetime exposure to estrogen, through early 
menarche (RR = 1.3), late menopause (RR = 1.2-2.0), hormone replacement therapy with 
estrogen and progesterone (RR = 1.2), or having the highest quartile of serum estrogen 
levels (RR = 1.8-5.0) all increase breast cancer risk in women (Brinton et al., 1983, 1988; 
Trichopoulos et al., 1972, 1983; Clemons and Goss, 2001; Rossouw et al., 2002; Eliassen 
et al., 2006; Dall and Britt, 2017).  These reproductive risk factor suggest that longer 
lifetime exposure to estrogen increases breast cancer risk.  Accordingly, treatment with 
selective estrogen receptor modulators (SERMs) to inhibit estrogen activity in the breast 
has been shown to lower breast cancer incidence (Cuzick et al., 2013).  Estrogen is also 
known to contribute to breast tumor initiation and growth (Russo and Russo, 2006; Tian et 
al., 2018). 
Strikingly, while a full-term pregnancy after the age of 35 increases breast cancer 
risk, a full-term pregnancy before the age of 20 decreases breast cancer risk by up to 50% 
(MacMahon et al., 1970; Trichopoulos et al., 1983; Rosner et al., 1994; Lambe et al., 1996). 
The effectiveness of parity in reducing breast cancer risk after an early pregnancy is 
 2 
mimicked in mice with estrogen and progesterone treatment (Thordarson et al., 1995; 
Sivaraman, 1998; Guzman et al., 1999; Rajkumar et al., 2007; Dunphy et al., 2008), further 
illustrating that estrogen can reduce breast cancer risk.  High dose estrogen treatment is an 
effective antitumor therapy in postmenopausal women with breast cancer, possibly due to 
increased sensitivity to estrogen after the decrease estrogen levels during menopause 
(Lonning et al., 2001; Coelingh-Bennink et al., 2017).  Treatment of breast tumors with 
SERMs may also sensitize tumors to estrogen-induced apoptosis (Yao et al., 2000; Song 
et al., 2001).  This evidence suggests that high levels of estrogen exposure, depending on 
context, have antagonistic effects on breast cancer risk.   
 
Familial Breast Cancer Risk 
Familial breast cancer risk, or genetic susceptibility to breast cancer, is another 
major breast cancer risk factor.  Genetic susceptibility to breast cancer varies widely among 
individuals.  Twin studies suggest that hereditary factors account for approximately 27-
30% of overall breast cancer risk (Peto and Mack, 2000; Southey et al., 2013; Mucci et al., 
2016).  High penetrance BRCA1, BRCA2, and TP53 mutations account for 16-20% of 
inherited risk, but are rare in the general population (Peto et al., 1999; Anglian Breast 
Cancer Study Group, 2000; Thompson and Easton, 2004; Antoniou and Easton, 2006; 
Lalloo and Evans, 2012).  Moderate penetrance mutations (CHEK2, ATM, BRIP1, and 
PALB2) make up approximately 3-5% of inherited breast cancer risk (Peto et al., 1999; 
Anglian Breast Cancer Study Group, 2000; Thompson and Easton, 2004; Rahman et al., 
2007).  These mutations are more common than BRCA1, BRCA2, or TP53 mutations but 
still occur in less than 1% of the population (Adank et al., 2011; Renwick et al., 2006; Seal 
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et al., 2006; Rahman et al., 2007).  Genome wide association studies (GWAS) have also 
identified low penetrance mutations (CASP8, FGFR2, TOX3, MAP3K1, and LSP1) and 
single nucleotide polymorphisms (Easton et al., 2007; Ahmed et al., 2009; Kuchenbaecker 
et al., 2014; Michailidou et al., 2017) which are estimated to account for 8-15% of inherited 
breast cancer risk.  However, the mechanisms of these sites identified through GWAS have 
are still unclear.  These known inherited risk factors account for approximately 30-40% of 
inherited breast cancer, but the remaining 60-70% are due to currently unknown inheritable 
factors.    
 
Estrogen Sensitivity in Rodents 
Previous work has identified rodent strains with increased sensitivity or resistance 
to mammary tumor development in response to carcinogen or estrogen treatment.  These 
rodent strains do not contain any previously known breast cancer risk genes, such as 
BRCA1 or BRCA2.  In DMBA induced models of mammary tumors, the Wistar-Kyoto rat 
strain is resistant to tumor development while the Wistar-Furth strain is uniquely 
susceptible (Gould, 1986; Lan et al., 2001).  For estrogen-induced mammary tumor models, 
the ACI strain is uniquely susceptible to estrogen-induced mammary tumors while the 
Copenhagen and Brown Norway strains are resistant (Shull et al., 1997; Spady et al., 1998; 
Dennison et al., 2015; Shull et al., 2018).  Treatment of susceptible ACI rats with tamoxifen 
reduces the development of estrogen-induced mammary tumors (Li et al., 2002; Singh et 
al., 2011), demonstrating the involvement of estrogen receptor signaling in mammary 
tumor development in the ACI strain.  These studies have also identified quantitative trait 
loci (QTL), regions of the chromosomes linked to mammary tumor susceptibility and 
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resistance (Lan et al., 2001; Haag et al., 2003; Gould et al., 2004; Schaffer et al., 2006).  
Several of these QTLs have been mapped to human orthologs previously identified in 
GWAS for breast cancer risk loci (Schaffer et al., 2013; Colletti et al., 2014).  Additionally, 
deletion of the mouse ortholog to a human breast cancer susceptibility locus, 8q24, reduces 
mammary tumor incidence in rats (Homer-Bouthiette et al., 2018).  Taken together, these 
results illustrate the potential for estrogen to contribute to breast cancer development in 
certain genetic backgrounds, suggesting unique sensitivity to estrogen exposure.   
In mice, BALB/c and C57BL/6 strains are also known to differ in susceptibility to 
estrogen-induced mammary tumor formation but also in other estrogen-induced responses 
in the mammary gland, including proliferation and apoptosis (Montero Girard et al., 2007; 
Aupperlee et al., 2009).  As estrogen is known to promote breast cancer risk in humans, we 
propose that some women may be uniquely susceptible to this exposure based on their 
genetic backgrounds, like the rodent strains mentioned previously.  Further, some women 
may also be more sensitive to estrogen exposure, which may be linked to increased breast 
cancer risk.  Increased breast density is a known risk factor for breast cancer which is 
positively correlated with higher serum estrogen levels (Brooks et al., 2018) and may 
indicate estrogen sensitivity.  Specific SNPs in the ESR1 gene are associated with increased 
breast cancer risk, resistance to anti-estrogen treatment, and poor overall prognosis 
(Schubert et al., 1999; Conway et al., 2005; Herynk et al., 2007; Abbasi et al., 2012).  
Included in this list of SNPs with increased breast cancer risk are 908A/G (K303R) and 
1608T/A (Y537N) ESR1 polymorphisms, which produce estrogen receptor protein that is 
hypersensitive to estrogen treatment or constitutively active (Conway et al., 2007; 
Jeselsohn et al., 2014).  Based on this data, if a subset of women is uniquely sensitive to 
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estrogen exposure because of their genetic background, it may be connected to increased 
breast cancer risk. 
 
Estrogen Receptors Alpha and Beta 
Biological responses to estrogen exposure are mediated through the two estrogen 
receptors: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) (Heldring et al., 
2007; Nilsson et al., 2001).  ERα and ERβ are ligand activated transcription factors in the 
steroid nuclear receptor family encoded by ESR1 and ESR2 respectively (Heldring et al., 
2007).  ESR1 is located on chromosome 6q24-27 and ESR2 is on chromosome 14q22-24.  
Both ERα and ERβ contain similar protein domains: an activation function (AF-1) domain, 
DNA binding domain, a ligand binding domain, and an AF-2 domain (Figure 1.1) (Nilsson 
et al., 2001; Leitman et al., 2010).  The AF-1 and AF-2 domains are both known to be 
involved in gene regulation (Kumar and Thompson, 1999) and binding of estrogen receptor 
coregulators (Webb et al., 1998; Tremblay et al., 1999; Benecke et al., 2000; Maggi, 2011).   
The DNA binding domain of ERα and ERβ is required for the binding of these 
receptors to DNA, at estrogen response elements (EREs), to initiate estrogen-responsive 
gene transcription (Gruber et al., 2002; Heldring et al., 2007; Yasar et al., 2017).  In mice 
with a mutated ERα DNA binding domain, mammary gland development is impaired, and 
uterine and mammary gland phenotypes resemble those observed in the full ERα knockout 
mice (Lubahn et al., 1993; Bocchinfuso and Korach, 1997; Ahlbory-Dieker et al., 2009), 
suggesting that DNA binding is essential to ERα function.  The DNA binding domains of 
ERα and ERβ are 97% homologous, indicating that they likely bind to many of the same 
regions of the DNA to control transcription.  However, ERβ has lower affinity for EREs 
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than ERα and lower transactivation of ERE-reporters in luciferase assays with estrogen as 
a ligand (Hall and McDonnell, 1999; Yi et al., 2002). 
 The ligand binding domain is crucial for estrogen receptor function.  17β-estradiol 
(E2) is the most prevalent estrogen in women (Gruber et al., 2002; Mukherjee et al., 2005) 
and acts as a ligand for both ERα and ERβ equally.  Ligand binding to estrogen receptors 
initiates a conformational change, which allows for receptor dimers to form (Kumar et al., 
2011; Vrtačnik et al., 2014).  These receptors can form homodimers or heterodimers.  The 
ligand binding domain of ERα and ERβ are 55% homologous (Witkowska et al., 1997; 
Gruber et al., 2004; Leitman et al., 2010), suggesting that it is possible for these receptors 
to be activated by different ligands.  Accordingly, several estrogen receptor specific 
agonists exist (Figure 1.2).  Propyl pyrazole triol (PPT) is an ERα specific agonist, with 
410-fold selectivity for ERα over ERβ (Stauffer et al., 2000).  Multiple ERβ have been 
developed, including ethenyl-2-(3-fluoro-4-hydroxyphenyl)-benzoxazolol (ERB041) and 
diarylpropionitrile (DPN); ERB041 has 200-fold selectivity for ERβ over ERα and DPN 
has 170-fold selectivity for ERβ (Harris et al., 2003; Meyers et al., 2001).   
One class of endocrine disrupting chemicals, xenoestrogens, can also act as ligands 
for the estrogen receptors.  Endocrine disrupting chemicals can disrupt normal hormone 
signaling by mimicking or antagonizing the effects of endogenous hormones and also by 
disrupting the synthesis and metabolism of endogenous hormones and their receptors 
(Sonnenschein and Soto, 1998; Fernandez and Russo, 2010).  Xenoestrogens have 
estrogenic activity, suggesting the potential to activate estrogen signaling in the breast 
(Singleton and Khan, 2003).  They are common in food, drinking water, and personal care 
products such as lotions, cosmetics, and sunscreens (Mortensen et al., 2014; Soni et al., 
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2001).  Xenoestrogens, therefore, have the potential to disrupt estrogen receptor signaling 
by acting as ligands for ERα and/or ERβ and could affect the balance between the 
protective and risk promoting effects of estrogen exposure on breast cancer risk. 
  
Estrogen Receptor Signaling 
Classical estrogen receptor signaling involves direct binding of ligand-bound 
estrogen receptor dimers to EREs, which then recruit coactivators or corepressors to control 
target gene transcription (Figure 1.3).  Other pathways for estrogen signaling have been 
identified, including tethered, non-genomic, and ligand-independent pathways (Figure 
1.4) (Heldring et al., 2007).  The tethered pathway involves ligand-bound estrogen receptor 
dimer binding to other transcription factors bound to DNA, instead of EREs (Gaub et al., 
1990; Saville et al., 2000).  Non-genomic estrogen receptor signaling involves either 
membrane bound estrogen receptors or other membrane bound receptors which in turn 
activate the estrogen receptors (Heldring et al., 2007; Levin, 2009).  Membrane bound 
estrogen receptors are not sufficient to rescue mammary gland development in ERα 
knockout mice (Pedram et al., 2009), however, and thus does not likely play a significant 
biological role.  Ligand-independent pathways involve estrogen receptor phosphorylation 
by kinases activated by growth factor signaling and are hypothesized to be involved in 
hormone-independent growth of breast tumors (Kato et al., 1995; Coutts and Murphy, 
1998; Shim et al., 2000).  More recent work has highlighted the increased complexity of 
classical estrogen receptor signaling, where estrogen receptors can control the expression 
of genes without EREs or other transcription factor binding sites through long range 
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chromatin looping, which brings distant genes into close proximity to where estrogen 
receptors are bound (Figure 1.5) (Fullwood et al., 2009).  
Data from estrogen receptor knockout mice suggest that ERα function is crucial to 
mammary gland development, while ERβ is not.  ERα knockout mice (αERKO) have 
rudimentary ductal mammary gland development similar to newborn mice (Bocchinfuso 
and Korach, 1997).  Conversely, ERβ knockout mice (βERKO) mammary glands are 
indistinguishable from wild type mice (Krege et al., 1998).  Therefore, the function of ERβ 
in the breast has long been questioned and is still partially unanswered.  It is known that 
ERβ, including its multiple isoforms, can form heterodimers with ERα (Moore et al., 1998).  
The question, therefore, was whether ERβ could act as a modulator of ERα activity.  Early 
work demonstrated that ERβ was able to act as a dominant inhibitor of ERα activity (Hall 
and McDonnell, 1999).  Later studies confirmed the ability of ERβ to repress estrogen 
mediated proliferation in breast cancer cell lines (Williams et al., 2008), ERα induced 
activation of target genes pS2 and PGR, promoter binding, and recruitment of cofactors 
(Matthews et al., 2006).  ERβ is thought to block estrogen-induced proliferation through 
activation of MAPK and PI3K signaling (Cotrim et al., 2013) or in combination with p53 
(Bado et al., 2017, 2018).  However, while this work was done with the main ERβ isoform 
(ERβ-1), other work has demonstrated a truncated ERβ isoform (ERβ-2, or ERβcx) is also 
capable of repressing ERα activity and coactivator recruitment while not influencing ERβ-
1 function (Ogawa et al., 1998).  Accordingly, ERβ loss during breast cancer progression 
is associated with poorer prognosis (Omoto et al., 2001; Sugiura et al., 2007), resistance to 
tamoxifen treatment (Hopp, 2004), and increased risk of advanced tumor progression 
(Roger et al., 2001; Shaaban et al., 2003; Skliris et al., 2003).  Contradictory results are 
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obtained in other studies, however, which show poor prognosis with ERβ expression 
(Novelli et al., 2008; Shaaban et al., 2008) even in ERα positive breast tumors (Saji et al., 
2002).  For these reasons the exact function of ERβ is still unclear, especially regarding 
breast cancer development.  It is accepted, though, that the role of ERα can potentially be 
modulated by ERβ and the ratios of ERα to ERβ may be important for determining the 
effects of estrogen treatment within a cell. 
 
Pioneer Factors, Coregulators, and Estrogen Receptor Signaling 
Pioneer factors and coregulators are essential determinants of estrogen receptor 
signaling and mammary gland development.  Pioneer factors are transcription factors 
which can bind to specific sites in the chromatin and recruit other transcription factors or 
histone modifying enzymes to enhance or restrict transcription (Zaret and Carroll, 2011).  
Forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA3) are considered 
estrogen receptor pioneer factors, and FOXA1, GATA3, and ERα interaction is thought to 
maintain luminal epithelial cell phenotype in the mammary gland.  FOXA1 regulates 
expression of ERα, terminal end bud formation, and ductal outgrowth during puberty 
(Bernardo et al., 2010).  GATA3 is also involved in terminal end bud formation as well as 
luminal cell differentiation and loss of GATA3 results in expansion of luminal progenitors 
(Kouros-Mehr et al., 2006; Asselin-Labat et al., 2007).  GATA3 and ERα have a cross-
regulatory feedback loop and GATA3 is crucial for estrogen-induced growth in breast 
cancer cells (Eeckhoute et al., 2007).  Attempts to generate ER negative breast cell lines 
expressing exogenous ESR1 have shown that FOXA1 and GATA3, along with ESR1, are 
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necessary for recovery of estrogen-induced phenotypes, including proliferation (Kong et 
al., 2011). 
Estrogen receptor coregulators interact with FOXA1 and GATA3 pioneer factors 
as well as ERα and ERβ to modify estrogen receptor signaling.  Many of these coregulators 
are important for different developmental stages of mammary gland development (Figure 
1.6).  Coactivators typically facilitate the recruitment of transcriptional machinery to the 
receptors while corepressors repress this recruitment, both acting through binding with the 
AF-1 and AF-2 domains of the estrogen receptors (Heery et al., 1997; Nilsson et al., 2001; 
Heldring et al., 2007).  A total of over 200 estrogen receptor coregulators are known, most 
identified through interactions with ERα.  Fewer coregulators have been examined for ERβ.  
Known coactivators for the estrogen receptors include SRC1-3, BRCA1 and BRCA2, 
CITED-1, Ccdn1, NCOA1-3, TIF2, PELP1, CBP, p300, CARM1, RIP140, p/CIP, and 
PRMT1.  Known co-repressors include NCOR, SMRT, NRIP1, MTA1, NFIB, and YBX1 
(Kurebayashi et al., 2000; Maggi, 2011; Merrell et al., 2011; Jiang et al., 2013; Vrtačnik et 
al., 2014; Campbell et al. 2018).   
Though affinity for estrogen is equal for both receptors, there is differential 
recruitment of coregulators by ERα and ERβ, and this can be affected by phosphorylation 
of these receptors (Nguyen et al., 2012; Tharun et al., 2015).  In MCF7 cells, recruitment 
of SRC3 and RIP140 to the PGR gene is higher in cells expressing ERα, slightly lower in 
ERα and ERβ expressing cells, and lowest in cells with ERβ only (Jiang et al., 2013).  
Similar results were obtained for other ER target genes FOS, TFF1, and CASP7 (Chang et 
al., 2008).  Recruitment of coregulators by estrogen receptors also differs for target genes 
that are up or down regulated.  pS2, an ER target gene upregulated by E2 treatment in 
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MCF7 cells, shows increased recruitment of SRC1 and p/CIP coactivators and decreased 
recruitment of NCoR, NRIP1, and SMRT corepressors; the opposite results are observed 
for ER target genes that are downregulated (PSCA, SLC35A1) (Merrell et al., 2011).  These 
changes are associated with histone deacetylation and RNA polymerase II docking.   
Previous studies have demonstrated tissue specific expression of nuclear receptor 
coregulators and are hormonally regulated (Misiti et al., 1998; Shang and Brown, 2002; 
Molenda et al., 2003).  These differences have also been suggested to influence the tissue 
specific antagonist/agonist actions of tamoxifen (Smith et al., 1997; Shang and Brown, 
2002).  Knockdown of NCOA3 was shown in MCF7 cells to prevent estrogen-induced 
proliferation, but knockdown of other similar coactivators NCOA1 and NCOA2 had no 
such effect (Karmakar et al., 2009).  Overexpression of CARM1 in MCF7 cells also results 
in inhibition of estrogen-induced proliferation and target gene regulation (Al-Dhaheri et 
al., 2011).  Expression of NFIB and YBX1 can inhibit luciferase reporter activity and 
change target gene expression in ERα positive MCF7 breast cancer cells as well as promote 
estrogen independent growth (Campbell et al., 2018).  Because expression of these 
coactivators and corepressors are known to have cell/tissue specific expression and can 
regulate estrogen receptor signaling, including modulation of proliferation, we hypothesize 
that individual expression of these coregulators could influence sensitivity to estrogen. 
 
Estrogen Receptor Levels in Normal Breast Epithelium 
ERα and ERβ are both expressed in the epithelial cells of the human breast (Figure 
1.7).  ERα is restricted to the luminal epithelial cells of the ducts, whereas ERβ is expressed 
in basal epithelial, luminal epithelial, stromal, lymphocytes, and endothelial cells of the 
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breast (Speirs 2002).  Previous studies of ERβ expression in the normal human breast are 
limited by the availability of reliable ERβ antibodies (Andersson et al., 2017; Nelson et al., 
2017).  Much work, however, has been done to quantify the ERα protein levels in the 
normal human breast.  A summary of these studies is shown in Table 1.1.  ERα protein is 
detectable in approximately 32-68% of human samples and is known to increase with age 
(Battersby et al., 1992; Söderqvist et al., 1993; Gabrielson et al., 2016).  The general 
consensus is that ERα positive cells make up no more than 5-10% of the normal human 
breast luminal epithelial population, in contrast to mouse epithelium where 15-40% of 
luminal epithelial cells may be ERα positive depending on strain (Montero Girard et al., 
2007; Raafat et al., 2012).  The proportion of ERα positive luminal epithelial cell is also 
known to increase in premalignant breast lesions and in the majority of breast cancers 
(Shoker et al., 1999a; Quong et al., 2002).  Interestingly, it is thought that, although ERα 
positive cells respond to estrogen treatment by releasing growth factors that stimulate 
proliferation, only the ERα negative cell population responds by proliferating in the normal 
breast.  This is referred to as the paracrine hypothesis for estrogen mediated proliferation 
(Shoker et al., 1999b; Mallepell et al., 2006; Ciarloni et al., 2007).  In breast cancer cells 
this is perturbed, as multiple ERα breast cancer cell lines increase proliferation when 
treated with estrogen. 
 
Human Models for Estrogenic Responses in the Normal Breast 
The original studies determining responses to estrogen exposure in the normal 
human breast were based on population studies using human breast tissue at different stages 
of the menstrual cycle or at different life stages.  One large drawback to these studies is 
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that the levels of endogenous estrogen vary among women and responses to estrogen 
treatment may vary as well.  To overcome this obstacle, 2D human breast epithelial cell 
models have been developed.  Breast cancer cell lines, such as MCF7 and T47D, express 
high ERα levels and have been useful for studying the effects of estrogen receptor signaling 
in a breast cancer setting.  They are not, however, an appropriate model for estrogen 
receptor signaling in the normal human breast due to many perturbations that occur during 
carcinogenesis and the heterogenous expression of ERα in normal human breast 
epithelium.  Induced pluripotent stem cell lines have been used in the study of tissue 
development and function, but these cell lines are difficult to differentiate into breast 
epithelial cells (Cravero et al., 2015).  Recently, improved protocols were developed to 
differentiate induced pluripotent stem cells into breast epithelial cells, but the widespread 
application of this technique is yet to be seen (Qu et al., 2017).   
After optimization of culture conditions, it became possible to propagate normal 
human breast epithelial cells in 2D culture which now serve as an alternative to breast 
cancer cell lines.  Early work with human mammary epithelial cells (HMECs) was hindered 
by early senescence.  Methods to bypass this senescence were developed, including 
transformation with HPV E6 and E7, human telomerase (TERT), Myc, SV40 large T-
antigen, zinc-finger protein ZNF217, and BMI-1.  However, abnormal cell cycle 
progression in these immortalized cells is attributed to loss of p53, retinoblastoma protein, 
and p16INK4a, which perturb the underlying biology of these cells (Wang et al., 1998; 
Dyson et al., 1989; Münger et al., 1989; Scheffner et al., 1990; Huschtscha et al., 2001; 
Nonet et al., 2001; Dimri et al., 2002; Martinez-Zapien et al., 2016; Fischer et al., 2017).  
These immortalized lines also can exhibit signs of transformation, including anchorage 
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independent growth, reduced apoptotic responses, and altered gene expression (Wang et 
al., 1998; Thibodeaux et al., 2009).  Despite these changes, stably immortalized HMECs 
are still one of the better options for studying normal breast biology. 
An alternative approach to stably immortalization called conditional 
reprogramming, or conditional immortalization, allows the expansion of HMECs through 
coculture with irradiated mouse fibroblasts and addition of a rho-associated protein kinase 
(ROCK) inhibitor (Liu et al., 2012; Palechor-Ceron et al., 2013).  With this method, 
removal of feeder cells and ROCK inhibitor results in removal of the conditionally 
reprogrammed phenotype.  These reprogrammed cells are suggested to represent a stem 
cell like epithelial population (Suprynowicz et al., 2012, 2017), though it has been noted 
that HMEC cells in other culture methods can also lose expression of differentiation 
markers (Breindel et al., 2017).  Comparison of these conditionally immortalized HMECs, 
or ciHMECs, isolated from breast tumors shows similar expression profiles to the original 
tissue sample (Mahajan et al., 2017).  Some groups have successfully used this method to 
expand ERα positive luminal epithelial cells, but this population decreases in culture over 
passaging (Jin et al., 2017).   
Although conditional immortalization and stable immortalization methods have 
enhanced the expansion of HMECS, one key issue that remains is the loss of estrogen 
receptor positive cells in 2D culture conditions.  Multiple groups have reported the loss of 
ERα expressing luminal epithelial cell populations during passaging (Fridriksdottir et al., 
2015; Jin et al., 2017; Lee et al., 2018), and it is known that luminal epithelial cells only 
make up a small population (10-25%) of epithelial cells isolated from human breast tissue 
(Garbe et al., 2009).  This population may be greater in breast tissue of older women (Lee 
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et al., 2015).  As only 5-10% of luminal epithelial cells express ERα, it is not surprising 
that most epithelial cells isolated from breast tissue lack ERα expression.  There are 
multiple hypotheses explaining why ERα positive luminal epithelial cells are difficult to 
grow in culture.  It is thought that the luminal epithelial cell population is lost in 2D culture 
due to reduced adherence (Soule and McGrath, 1986; Keller et al., 2010), faster growth of 
basal epithelial cells (Keller et al., 2010; Fridriksdottir et al., 2015), triggering stress 
responses in luminal epithelial cells (Lee et al., 2018), changes to the microenvironment 
(Miyano et al., 2017), or epigenetic reprogramming that results in the loss of the 
differentiated phenotype (Keller et al., 2010; Breindel et al., 2017).  Calcium levels may 
also be important as one group noted the growth of free-floating cells in low calcium 
containing media, though these cells are thought to be less differentiated as they can form 
ductal structures when placed in collagen gels (Soule and McGrath, 1986).  It has been 
noted that luminal epithelial cells grow better in serum containing media, as opposed to 
basal epithelial cells which grow in serum free media (Kao et al., 1995), though growth in 
serum containing media can lead to permanent senescence (Stampfer and Bartley, 1985).  
Luminal epithelilal cells may be more sensitive to microenvironment changes and grow 
better in mixed cell type populations (Miyano et al., 2017).  Even with optimal media 
conditions, ERα positive luminal epithelial cells are lost in early passages and the number 
of passages is ultimately limited by the original percentage (Lee et al., 2018).   
More recent work has focused on the creation of 3D breast organoid cultures from 
primary HMECs of normal and cancerous breast tissue (Sokol et al., 2016; Sachs et al., 
2018; Djomehri et al., 2019; Florian et al., 2019; Goldhammer et al., 2019).  Breast 
organoids contain both luminal and basal epithelial cells, retain the ERα expressing 
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population, and are responsive to hormone treatment.  Our lab has found, however, that 
propagation of breasts organoids from normal human breast tissue is limited, as 
proliferation ceases after a few passages.  We have had more success with human breast 
explant ex-vivo models, which can be maintained in culture for up to 4 weeks and retain 
all breast cell types (Zhuang et al., 2003; Eigeliene et al., 2006, 2008, 2012, 2016; Tanos 
et al., 2013; Dunphy et al., 2020).  The ERα expressing population is maintained in this 
model as well as response to hormone treatment.  Studies with these tissues, however, are 
limited by the amount of available breast tissue from donors.  Ultimately, all these breast 
tissue and cell models remove some of the confounding factors of individual hormone 
levels when a single breast biopsy is taken, and each have unique advantages and 
disadvantages. 
 
 
Hypothesis and Objectives 
We hypothesize that a subset of women is uniquely sensitive to estrogen exposure, 
and thus may be at increased risk for breast cancer.  This increased sensitivity may be due 
to differing levels of estrogen receptors, parity, or differing estrogen receptor coregulator 
expression.  First, a human breast explant model is utilized to determine the level of 
variation in estrogen receptor expression among women, characterize transcriptional and 
functional responses to estrogen, and determine if these are correlated with estrogen 
receptor expression.  Next, conditionally immortalized primary human mammary epithelial 
cells are explored as a model for capturing variation in estrogen sensitivity, as well as 
determining if xenoestrogen sensitivity also varies among individuals.  Lastly, inducible 
ERα human mammary epithelial cell lines are developed and utilized to probe estrogen 
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receptor induced activation of biological responses and differences in response between 
normal and breast cancer cells.  If our hypothesis is correct, it has the potential to provide 
additional insight into the paradoxical roles of estrogen in breast cancer risk and suggests 
that this subset of individuals may be more susceptible to breast cancer through increased 
endogenous estrogen exposure.  The models used in this work can be utilized in future 
studies to further identify factors mediating estrogen sensitivity. 
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Table 1.1: ERα expression in the human breast 
Literature review of ERα positivity in human breast epithelium. 
 
First Author Year % ERα positive cells 
Antibody 
Used 
Dilution 
Petersen 1987 7% 
ER-ICA kit, 
Abbot 
Laboratories 
Not Stated 
Ricketts 1991 0-20%, but up to 65% H222 Not Stated 
Battersby 1992 38-47% had detectable protein  
ER-ICA kit, 
Abbot 
Laboratories 
Not Stated 
Soderqvist 1993 
32-68% had detectable protein, 
5% in luteal phase, 18% in 
follicular phase 
ER-ICA kit, 
Abbot 
Laboratories 
Not Stated 
Khan 1994 
Unspecified, 
57% of patients were positive  
(defined as >50%) 
ER-ICA kit, 
Abbot 
Laboratories 
Not Stated 
Clarke 1997 10-15% 1D5, Dako UK 1:75 
Khan 1998 7.7% H222 Not Stated 
Anderson 1998 12-13% 
Unclear 
(possibly 1D5) 
Not Stated 
Lawson 1999 
14% in Australian women, 
9% in Japanese women 
1D5, Dako UK Not Stated 
Shoker 1999 
11% in < 46 years old, 
27% in 46-55 years old, 
34% in > 55 years old 
1D5, Dako UK Not Stated 
Shoker 1999 
6.8% in premenopausal, 
42% in postmenopausal (large 
variation) 
1D5, Dako UK 1:75 
Russo 1999 
7% in Lob 1, 4% in Lob 2, 1% 
in Lob 3 
ER1D5, 
 Amac Lab 
1:400 
Khan 2002 5-20%, but up to 40% 6F11 1:100 
Eigeliene 2006 
67% of patients had ER, 10% 
positive after culturing explants 
(7 days) 
1D5, Dako 
Denmark 
1:2000 
Eigeliene 2008 
21% in premenopausal,  
17.3% in postmenopausal 
1D5, Dako 
Denmark 
1:2000 
Eigeliene 2016 20% (in explant culture) 
1D5, Dako 
Denmark 
1:400 
Gabrielson 2016 
Detected protein in 61% of 
samples, mean 30.4% (range 4-
56.8%), women 41-76 years old 
1D5, Dako 
Sweden 
1:60 
Chamberlin 2017 
Premenopausal women: 0-50% 
Postmenopausal women: 10-
45% 
F-10, Santa 
Cruz (sc-8002) 
1:200 
 19 
 
 
 
 
Figure 1.1: ERα and ERβ domains and homology 
Structural domains of Estrogen Receptor alpha (ERα) and Estrogen Receptor beta (ERβ). 
The DNA binding domains (C) are 97% homologous, indicating these receptors bind to the 
same regions of DNA. The ligand binding domain (E) is only 55% homologous, which 
allow for differences in ligand specificity between these two receptors.  Adapted from 
Leitman et al. 2010, Curr Opin Pharmacol. 
 
 
 
 
 
 
 
 
Figure 1.2: ERα and ERβ agonists 
17β-estradiol is an estrogen receptor agonist with equal affinity for both ERα and ERβ.  
Propyl-pyrazole-triol (PPT) is a selective ERα agonist, while diarylpropionitrile (DPN) and 
ERB041 are both selective ERβ agonists.  Xenoestrogens benzophenone-3 (BP3) and 
propylparaben (PP) are potential estrogen receptor agonists. Selectivity is indicated.  
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Figure 1.3: Estrogen receptors mediate the actions of estrogen 
Canonical estrogen receptor signaling overview.  (a) 17β-estradiol (E2) binds to ERα 
and/or ERβ in the cell nucleus, which triggers receptor dimerization.  Homodimers or 
heterodimers then bind to estrogen response element (ERE) sequences in the DNA to 
trigger transcription of estrogen receptor target genes, such as AREG and PGR.  (b) 
Estrogen receptor recruitment of transcriptional machinery to EREs depends on the 
presence of coactivators (such as FOXA1 and GATA3) or corepressors (example not 
shown).  
a b 
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Figure 1.4: Pathways for estrogen receptor signaling  
Overview of ligand-dependent and independent mechanisms of estrogen receptor 
signaling.  Direct, ligand-dependent signaling involves ligand-bound estrogen receptor 
dimers binding to estrogen response elements in the DNA.  Tethered estrogen receptor 
signaling involves ligand-bound receptor dimers binding to other transcription factors on 
the DNA, such as AP-1 or SP-1.  Nongenomic estrogen receptor signaling is thought to 
involve membrane bound estrogen receptors or other membrane bound receptor which 
activates the estrogen receptors.  Ligand-independent signaling involves other growth 
factor activation, which activates kinases and leads to phosphorylation of the estrogen 
receptors.  Adapted from Heldring et al. 2007, Physiological Reviews.  
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Figure 1.5: Looping model of chromatin interaction in estrogen receptor signaling 
Proposed model of ERα signaling through chromatin interactions.  Chromatin looping 
brings genes together for ERα induced transcriptional regulation.  Genes near the anchored 
chromatin are more highly expressed, due to close proximity to transcriptional machinery.  
Genes far from the anchor site are expressed at lower levels.  Adapted from Fullwood et 
al. 2009, Nature. 
 
 
 
 
 
 
 
 
 
Figure 1.6: Coregulators involved in mammary gland development 
Overview of several coregulators of estrogen receptor signaling known to be required for 
each stage of mammary gland development, including pioneer factors FOXA1 and GATA3.  
Adapted from Manavathi et al. 2014, Frontiers in Cell and Developmental Biology. 
 
 
 23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Overview of human breast epithelium 
The breast epithelium consists of ductal structures formed by layers of breast epithelial 
cells.  Myoepithelial (basal) cells make up the outer epithelial layer of the duct while the 
luminal epithelial cells are the inner layer, with a lumen in the center.  Surrounding the 
ducts are stromal cells, including fibroblasts, as well as adipose tissue.  Adapted from 
Visvader et al. 2009, Genes and Development. 
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CHAPTER 2 
INTER-INDIVIDUAL VARIARION IN ESTROGEN-INDUCED RESPONSES IN 
HUMAN BREAST EXPLANT CULTURES 
 
Introduction/Rationale 
Epidemiological studies have identified lifestyle, environmental, and reproductive 
risk factors for breast cancer. Early menarche (RR = 1.3), late menopause (RR = 1.2-2.0), 
or having the highest quartile of serum estrogen levels (RR = 1.8 – 5.0) are all reproductive 
risk factors linked to lifetime estrogen exposure (Brinton et al., 1983, 1988; Clemons and 
Goss, 2001; Dall and Britt, 2017).  Exogenous estrogens and use of hormone replacement 
therapy containing both estrogen and progesterone also increases breast cancer risk (RR = 
1.2)(Rossouw et al., 2002).  These results suggest that longer lifetime exposure to estrogen 
increases breast cancer risk.  Estrogen has been demonstrated to contribute to breast tumor 
infiltration and promote the growth of breast cancer cells (Russo and Russo, 2006; Tian et 
al., 2018).  In addition, treatment with selective estrogen receptor modulators to inhibit 
estrogen activity in the breast has been shown to reduce breast cancer incidence (Cuzick et 
al., 2013). 
However, estrogen may also reduce breast cancer risk.  A full-term pregnancy after 
age 35 increases breast cancer risk, but a full-term pregnancy before age 20 decreases risk 
by up to 50% (Albrektsen et al., 2005; Lambe et al., 1996; MacMahon et al., 1970; 
Trichopoulos et al., 1983).  This protective effect of early parity has been replicated in 
rodent models with estrogen and progesterone treatment (Dunphy et al., 2008; Guzman et 
al., 1999; Moon, 1969; Russo and Russo, 1980; Sivaraman, 1998; Thordarson et al., 1995).  
High dose estrogen treatment can be an effective antitumor therapy in postmenopausal 
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women with breast cancer (Lonning et al., 2001).  It is hypothesized that a decrease in 
endogenous estrogen after menopause or treatment with selective estrogen receptor 
modulators may sensitize tumors to estrogen (Yao et al., 2000).  Accordingly, estrogen 
treatment can induce apoptosis in long-term estrogen deprived breast cancer cells (Song et 
al., 2001).  Therefore, the effects of estrogen exposure appear to have paradoxical effects 
on breast cancer risk. 
The effects of estrogen are mediated by the two estrogen receptors: estrogen 
receptor alpha (ERα) and estrogen receptor beta (ERβ).  Estrogen binds as a ligand to the 
two estrogen receptors, which form homodimers or heterodimers, and then bind to DNA 
to initiate target gene transcription (Gruber et al., 2002; Heldring et al., 2007b; Yasar et al., 
2017).  Target gene transcription is modulated by estrogen receptor dimer combination and 
the recruitment of transcriptional coregulators (Chang et al., 2008).  ERα expression is 
limited to luminal epithelial cells in the breast, while ERβ is expressed in luminal epithelial 
cells, basal epithelial cells, and stromal cells (Speirs et al., 2002).  Expression of ERα in 
normal breast epithelial cells is positively correlated with breast cancer risk and age 
(Gulbahce et al., 2017; Shoker et al., 1999a, 1999b; Umekita et al., 2007).  The expression 
of ERα is known to vary widely among women (Battersby et al., 1992; Söderqvist et al., 
1993), which suggests women vary in exposure to estrogen as well as estrogen receptor 
expression.  Estrogen mediated responses are carried out by ERα and ERβ and having more 
receptor may indicate increased estrogen signaling.   
It is estimated that 1 in 8 women will be diagnosed with breast cancer during their 
lifetime.  This also implies, however, that 7 out of 8 women will not develop breast cancer.  
Are some women more sensitive to estrogen exposure?  It is known in rodent models that 
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certain mouse and rat strains are more sensitive to estrogen-induced responses and/or 
mammary tumors.  Mice strains exhibit differences in estrogen-induced proliferation, 
apoptosis, and mammary tumor formation (Montero Girard et al., 2007; Aupperlee et al., 
2009; Jerry et al., 2018).  Copenhagen and Brown Norway rat strains are resistant to 
estrogen-induced mammary tumors while the ACI strain is susceptible (Dennison et al., 
2015b; Shull et al., 2001, 2018). 
We hypothesized that specific individuals may be more sensitive to estrogen 
exposure, and that this increased sensitivity may be due to increased ERα and ERβ levels, 
age, parity, or differing expression of estrogen receptor signaling coregulators.  To examine 
this, we utilized an ex-vivo human breast explant model to compare estrogen receptor 
levels, transcriptional responses, and functional responses in individual women.  Human 
breast explants retain luminal and basal epithelial cells, stromal cells, and adipose cells and 
the interactions between those cells.  They have also been shown to be maintained in culture 
for up to 2-4 weeks and are responsive to hormone treatment (Eigeliene et al., 2016; Tanos 
et al., 2013; Eigeliene et al., 2012, 2008; Eigėlienė et al., 2006; Zhuang et al., 2003).  The 
human breast explant model also allows for the clearing of endogenous hormones, so that 
responses to a single consistent dose of estrogen can be measured.   
We observed significant changes in estrogen receptor expression with age in breast 
tissue from over 100 donors.  In explant donors, levels of ESR1 and ESR2 varied by more 
than 80-fold.  Estrogen-induced target gene responses (AREG, PGR, and TGFβ2), 
regulation of progesterone receptor protein levels, proliferation, and irradiation-induced 
apoptosis were not significantly correlated with estrogen receptor levels.  Parity influenced 
sensitivity to estrogen treatment, as nulliparous donor explants had consistent up-
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regulation of estrogen mediated target genes while parous had more variable expression.  
Collectively, these data suggest that estrogen receptor expression does not correlate with 
sensitivity to estrogen exposure.  We propose that differing expression of estrogen 
signaling coactivators and corepressors may contribute to individual estrogen sensitivity 
and estrogen-induced responses. 
 
Materials and Methods 
Sample Collection   
Human breast tissue samples used for microarray analysis were collected from 
female donors, age 14-70 years, undergoing reduction mammoplasty surgery at Baystate 
Medical Center in accordance with the Institutional Review Boards at Baystate Medical 
Center and the University of Massachusetts, Amherst (Troester et al., 2009; Sun et al., 
2012; Rotunno et al., 2014). Donated tissue was snap frozen in liquid nitrogen and stored 
at -80oC at the Pioneer Valley Life Sciences Institute (PVLSI). Donor demographics and 
reproductive history were recorded after tissue collection.  
Human breast tissue for explants was gathered through the Rays of Hope Center 
for Breast Cancer Research at the PVLSI according to IRB approval #286173 and #132204. 
Tissue was collected from female donors (n=31) ages 18-62 years undergoing reduction 
mammoplasty surgery. Donor information including age and parity status were recorded 
(Table 2.1). 
Microarray Analysis   
Microarrays were performed at the University of North Carolina at Chapel Hill as 
described previously (Troester et al., 2009; Sun et al., 2012; Rotunno et al., 2014). Briefly, 
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100mg of frozen tissues were homogenized for RNA isolation using RNeasy kits.  RNA 
quality and concentration were determined using an Agilent 2100 Bioanalyzer and a ND-
1000 Nanodrop spectrophotometer.  Two-color 4x44K Agilent whole genome arrays were 
performed.  Data are publicly available through the Gene Expression Omnibus 
(GSE:16113 and GSE:33526).  When multiple probe sets for a gene were present, we used 
the probe with expression values for the most donor samples.  Trends were analyzed using 
linear regression analysis in Graphpad Prism (GraphPad Prism version 7, La Jolla, CA). 
Explant Culture   
See Figure 2.3 for overview of model.  Fresh breast tissue was cut into 
approximately 1x1x4mm sections using a Stadie-Riggs microtome.  For each donor, tissue 
sections were frozen or fixed immediately for time zero (T=0) samples.  The remaining 
sections were placed on top of surgical foam (Ethicon) in 60mm plastic dishes and cultured 
for a total of 7 days.  The explants were kept in a humidified incubator with 5% CO2 at 
37oC.  Explants were cultured in basal media for 3 days to clear endogenous hormones and 
then cultured in basal or E2 media for an additional 4 days.  Basal culture media consisted 
of phenol red free DMEM:F12 (Sigma-Aldrich), 10% charcoal stripped FBS (FB-04, 
Omega Scientific), 10ng/mL human EGF (21-8356-U100, Tonobo Biosciences), and 
antibiotic-antimycotic (15240-062, Gibco).  E2 treatment media included basal media with 
the addition of 10nM 17β-estradiol (E2758-250MG, Sigma-Aldrich). 4,4’,4”-(4-Propyl-
[1H]-pyrazole-1,3,4-triyl)trisphenol-treatment media (PPT; ERα specific agonist) or 7-
Ethenyl-2-(3-fluoro-4-hydroxyphenyl)-5-benzoxazolol (ERB041; ERβ specific agonist) 
included basal media with the addition of 200nM PPT or 200nM ERB041; respectively 
(Tocris, Minneapolis, MN). Half of the tissue from each donor was irradiated with 5Gy 6 
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hours prior to tissue collection on day 7 of culture.  Half of the explant sections intended 
for histological endpoints were fixed in 10% NBF overnight and transferred to 70% ethanol 
before processing and paraffin embedding.  The other half of the explant samples were 
snap frozen and stored at -80oC for later RNA isolation.  Table 2.2 summarizes the 
experimental analyses performed on each individual donor sample. 
RT-qPCR 
RNA isolation was performed using TRIzol according to manufacturer’s 
recommendation (15596018, ThermoFisher Scientific).  cDNA was synthesized using 2 g 
of RNA with the Transcriptor First Strand cDNA synthesis kit (04-379-012-001, Roche).  
cDNA was diluted 1:10 before use in RT-qPCR.  RT-qPCR was performed in a 
thermocycler (Mastercyler Epgradient S model 5345, Eppendorf).  See Table 2.3 for 
primer sequences.  Statistical analysis was performed using 2-way ANOVA in Graphpad 
Prism (GraphPad Prism version 7, La Jolla, CA). Expression is relative to mean control or 
to an inter-run calibrator (IRC) consisting of pooled cDNA from a subset of T=0 (not 
cultured) samples. 
Hematoxylin and Eosin Staining   
Hematoxylin and eosin (H&E) staining were performed on paraffin-embedded 4-
micron sections.  Briefly, sections were deparaffinized in xylenes and rehydrated in graded 
ethanols.  Sections were stained with Mayer’s modified hematoxylin (S216-32OZ, Poly 
Scientific) and eosin phloxine alcohol working solution (S176-32OZ, Poly Scientific).  
After dehydration in graded ethanols and clearing with xylenes, slides were cover-slipped.  
Images were obtained under 200x magnification (BZ-X700 microscope, Keyence, Itasca, 
IL). 
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Immunohistochemistry 
Immunohistochemistry (IHC) was performed on paraffin-embedded 4-micron 
sections using a DakoCytomation autostainer (Dako, Carpinteria, CA) and the antibodies 
listed in Table 2.4.  Sections were deparaffinized in xylenes, rehydrated in graded ethanols, 
and rinsed in phosphate buffered saline (PBS) before antigen retrieval.  For ERβ detection, 
antigen retrieval was performed in heated 0.01M citrate buffer for 10 minutes.  Using the 
Acuity polymer detection system, primary antibody incubation was performed at room 
temperature for 30 minutes, followed by incubation with horse-radish peroxidase (HRP) 
polymer and chromogen detection.  For ER, PR and PCNA detection the Envision HRP 
Detection system was used (Dako).  Antigen retrieval was performed by heating in 0.01M 
citrate buffer (pH 6) for 10 minutes for PR and 20 minutes for ER and PCNA. Primary 
antibody incubation was performed for 30 minutes.  Primary antibody information and 
dilutions are listed in Table 2.4.  Incubation with secondary antibody (K4001 or K4003, 
Dako) was performed according to manufacturer’s instructions (Dako, Carpinteria, CA).   
Immunoreactivity was visualized with chromogen diaminobenzidine (DAB) incubation for 
10 minutes.  Sections were counterstained with hematoxylin.  Images were obtained under 
200x magnification (model BZ-X700 microscope).  Positive cells were quantified (ImageJ 
software, https://imagej.nih.gov/ij/) as the percentage of positive luminal cell nuclei in a 
total of 600-1200 cells). 
Immunofluorescence 
 Freshly cut 4-micron paraffin-embedded sections were deparaffinized/rehydrated 
(3X xylenes 5 min, 2X 100% ethanol for 5 min, 95% ethanol for 3 min, 70% ethanol for 3 
min). Samples were rinsed with PBS. Antigen retrieval was performed by boiling slides in 
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0.1mM EDTA for 30 minutes. Samples were cooled to RT and treated with SSC 0.2X with 
gentle shaking at RT for 20 minutes. Samples were blocked in 5% BSA/PBS with 0.5% 
Tween-20 for 1 hr. Primary antibody incubation was done with monoclonal S9.6 antibody 
(1:100, ENH0001 Kerafast) or anti-H2AX (1:100, 9718S Cell Signaling ) overnight at 
4oC. After primary incubation, samples were washed 3 times with PBS containing 0.5% 
Tween-20 and then incubated with secondary antibody for 1 hr. Samples were washed 2-3 
times with PBS containing 0.5% Tween-20 and then mounted with Vectashield mounting 
medium containing DAPI (H-1200, Vector Laboratories). Slides were imaged at 60X with 
Nikon A1 Spectral Confocal microscope. Analysis of S9.6 or H2AX foci per nucleus were 
calculated using Nikon analysis software. 
Terminal Deoxynucleotide Transferase dUTP Nick-End Labeling (TUNEL) 
TUNEL was performed on 4-micron sections.  Sections were deparaffinized in 
xylenes and rehydrated in graded ethanols.  The Apoptag Plus Peroxidase in Situ Apoptosis 
Detection kit was used according to manufacturer’s instructions to label apoptotic cells 
(S7101, MilliporeSigma).  Sections were rehydrated in ethanols and cleared in xylenes 
before adding cover slips.  Images were taken at 200x (model BX40 microscope, Olympus, 
Tokyo, Japan) using a MicroPublisher 3.3RTV camera (QImaging, Surrey, British 
Columbia, Canada).  Positive cells were quantified using ImageJ as the percentage of 
positive luminal epithelial cells. 
 
 
 32 
Results 
Variation in Estrogen Receptor Expression 
Previous studies have demonstrated that ERα protein levels in normal human breast 
tissue increase with age.   To determine if this trend could be observed also at the transcript 
level, fresh breast tissue was collected from 129 women undergoing reduction 
mammoplasty.  We used cDNA synthesized from these samples in a microarray to examine 
ESR1 mRNA levels.  To account for variation in epithelial content between samples, we 
normalized ESR1 by KRT18 expression (Figure 2.1a).  Linear regression analysis of this 
data revealed ESR1 levels significantly increase with age (p < 0.05), corresponding with 
observed protein expression data.  Variation in ESR1 mRNA level was high, as indicated 
by a low R2 value for the line of best fit (R2 = 0.115).  We next wanted to determine if 
ESR2 expression was also correlated with age.  Examination of ESR2 mRNA levels 
normalized to KRT18 (Figure 2.1b) in these same patients from our microarray data 
revealed a significant increase in expression with age (p < 0.001).  There was also a weak, 
but positive correlation between ESR1 and ESR2 (Pearson Correlation Coefficient 0.378, 
p < 0.001) in this data set.  
While ERα is expressed only in luminal epithelial cells of the breast, ERβ 
expression has been observed in luminal epithelial cells, myoepithelial cells, stromal cells, 
endothelial cells, and lymphocytes.  To examine ERβ expression in luminal epithelial cells, 
we performed IHC using the PGG5/10 mouse anti-human ERβ1 monoclonal antibody in a 
subset of 45 samples (Figure 2.2).  We observed ERβ positive cells in the stroma as others 
have found, as well as in basal and luminal epithelial cells of the ducts (Figure 2.2a).  
Linear regression analysis of ERβ positive epithelial cells revealed a significant decrease 
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in ERβ protein expression with age (Figure 2.2b, p < 0.05).  Both ESR2 mRNA and ERβ 
protein levels had a high level of variance with low R2 values of 0.068 and 0.106, just as 
observed with ESR1 mRNA levels (Figure 2.2 and Figure 2.1, respectively).  This data 
demonstrates age-related changes in expression of both estrogen receptors and that the 
effect is highly variable among individuals. 
 
Human Breast Explant Model 
It has previously been shown that estrogen receptor expression fluctuates with the 
menstrual cycle.  ER expression is highest at the follicular phase of the estrus cycle.  Our 
prior microarray data on ESR1 and ESR2 expression was performed using tissue from both 
premenopausal and postmenopausal women, with the majority being premenopausal.  As 
we do not know the stage of the estrus cycle for each donor, this could significantly impact 
the levels of ESR1 and ESR2 we observed (Figure 2.1).  In order to observe responses to 
E2 treatment ex vivo, we utilized a human breast explant model (Figure 2.3).  This model 
allows us to study responses to estrogen in a human ex vivo system, where each donor can 
be compared to their own basal control.  Donor information, including age and parity status, 
is shown in Table 2.1.  The donor explant samples collected in our initial culture conditions 
will be referred to as set 1.  A list of analyses performed on these samples is included in 
Table 2.2.   
One benefit of the human breast explant model is that stromal, epithelial, and 
adipose cells are all present in culture, so cell-cell interactions can occur between these cell 
types.  Culture conditions are important for maintaining this tissue architecture.  In order 
to confirm that our culture conditions were not leading to degradation of the breast tissue, 
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we compared tissue architecture from tissue that was fixed within 2 hours of the reduction 
mammoplasty (T=0) to explant tissue after 7 days in culture (Figure 2.4).  In this first set 
of explant samples, we did not observe tissue degradation or gross apoptotic nuclei in the 
epithelial ducts.  Normal breast architecture was maintained, with cuboidal luminal and 
basal epithelial cells, surrounding stromal cells, and adipocytes.  Nulliparous individuals 
consisted of smaller lobular structures (Figure 2.4a-d) than parous explants, which had 
more complex ductal lobular structures (Figure 2.4e-f) as previously reported (Russo et 
al., 1992).  This tissue architecture is retained by the explants after 7 days in culture. 
 
Optimization for RT-qPCR in explants 
Breast tissue composition is known to vary greatly between individuals, which 
affects the amount of epithelium collected in each tissue fragment and overall RNA yield.  
Women with dense breast tissue have greater amounts of stromal and epithelial cells 
compared to women with less dense breast tissue, who have more adipose and less 
epithelium.  ERα is known to be restricted to the luminal epithelial cells of the breast 
epithelium.  Expression of ERα protein can be detected by immunohistochemistry (IHC), 
but quantification is complicated.  Representative ERα IHC images from one explant donor 
illustrate the heterogenous distribution of ERα protein (Figure 2.5).  One lobule from 
donor 234 shows relatively high and contiguous ERα positive cells (Figure 2.5a), but 
another lobule from the same donor contains almost no ERα positive cells (Figure 2.5b).  
Because of the heterogenous distribution of ERα and the limited amount of donor tissue 
we receive for explant cultures, IHC quantification of ERα protein is unreliable in explant 
cultures.   
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For this reason, we sought to optimize our RT-qPCR procedure for our human 
breast explant model.  To account for differing amounts of epithelium between donors and 
between tissue sections, we used keratin 18 as a normalizer for epithelial content, which is 
expressed in luminal epithelial cells of the breast epithelium.  To test this method, we took 
multiple pieces of flash-frozen breast tissue from several donors which had not been 
cultured and used them in separate RNA isolations.  We then used RT-qPCR to determine 
KRT18, ESR1, and ESR1 normalized to KRT18 (Figure 2.6).  While fragments from donors 
177 and 185 were consistent, fragments from donor 178 demonstrated marked variability 
in both KRT18 and ESR1 expression.  KRT18 expression in fragment 178b is 6-fold greater 
and fragment 178d is 2.7-fold greater than fragment 178a.  This is also reflected in ESR1 
expression, but when normalized to KRT18, ESR1 expression is consistent across all donor 
fragments.   
Using this method, we then were able to compare the amount of ESR1 between 
multiple donors (Figure 2.7a).  Donor 178 had the lowest ESR1 expression, while donor 
177 had the highest expression.  Donor 185 had 2-fold higher ESR1 expression than donor 
178 (p < 0.05).  Donor 177 has 3.8-fold higher ESR1 expression than donor 178 (p < 0.01) 
and 1.8-fold higher expression than donor 185 (p < 0.05).  We next sought to examine 
whether ESR1 expression is lost in our explant cultures, as is the case in primary breast 
epithelial cell 2D culture.  Comparing fresh tissue samples (T=0) to tissue which had been 
cultured for 5 days (T=5), we looked at ESR1 expression normalized to KRT18 for two 
donors, referred to as donor A and donor B (Figure 2.7b).  Donor B had approximately 2-
fold higher expression of ESR1, but both donor A and donor B ESR1 levels were similar 
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between T=0 and T=5.  There was no difference in ESR1 expression in explant tissue which 
had been cultured in basal or 10nM E2 media.   
 
Transcriptional Responses to Estrogen 
In order to determine if estrogen receptor levels correspond with estrogen-induced 
transcriptional responses, we examined ESR1 and ESR2 expression in our donor explant 
samples.  Although previous work in breast cancer cell lines has suggested that E2 
treatment decreases estrogen receptor expression, we did not notice any difference in ESR1 
or ESR2 levels between basal and E2 treated explants (Figure 2.8, p = 0.18).  Four 
individual donors showed an increase of 1.6-3.1-fold for ESR1 and 1.2-5.6-fold for ESR2.  
For 8 out of 12 donors, ESR1 and ESR2 expression was decreased.  Parity status did not 
appear to influence ESR1 and ESR2 expression in this subset.  In agreement with our 
previous microarray data, we observed variation in estrogen receptor mRNA levels among 
our explant donors.  We observed an over 80-fold variation in ESR1 expression and over 
100-fold variation in ESR2 expression.   
It has previously been shown that the opening of chromatin during estrogen-
induced transcription leads to the formation of R-loops, DNA: RNA hybrids, which if not 
resolved are sites of potential DNA damage (Stork et al., 2016).  As a measure of global 
transcription, we examined R-loop formation after estrogen treatment in our explants using 
the S9.6 antibody in immunofluorescence (Figure 2.9).  In basal control treated explants, 
we observed low levels of R-loop formation indicative of basal transcription levels (Figure 
2.9a).  After estrogen treatment, there was an increase in the overall number of detectable 
R-loop foci per nucleus, suggesting an increased level of transcription (Figure 2.9b).  
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Quantification of R-loop foci per nucleus revealed no significant decrease in basal treated 
explants compared to T=0 samples, but there was a significant 4-fold increase after E2 
treatment in the group of 5 donor samples (Figure 2.9c, p < 0.01).  For each donor there 
was a similar fold increase in R-loop formation with estrogen treatment, apart from donor 
237 which had significantly lower R-loop foci/nucleus than the other 4 donors (Figure 
2.9d, p < 0.01).  These results indicate an estrogen-induced transcriptional response in all 
5 donors, with similar levels of induction in four out of five donor samples. 
After determining that there was a global increase in transcription after estrogen 
treatment in a small subset of our explant samples, we sought to look at estrogen receptor 
target genes as a more specific endpoint of estrogen responsiveness.  RT-qPCR of estrogen 
receptor target genes AREG, PGR, and TGFβ2 in a set of combined nulliparous and parous 
explant donors at first revealed no significant changes with estrogen treatment.  However, 
after separating the nulliparous and parous explants, we observed significant increases in 
AREG (p < 0.05) and TGFβ2 (p < 0.05) and an increase in PGR (p = 0.059) in nulliparous 
explants using 2-way ANOVA to account for individual variation (Figure 2.10a-c).  In 
nulliparous explants, AREG expression increased from 0.39+/-0.23 to 1.14+/-0.34 (Figure 
2.10a, p < 0.05).  PGR increased from 0.30+/-0.15 to 1.53+/-0.37 (Figure 2.10b, p < 0.06).  
TGFβ2 expression increased from 0.46+/-0.25 to 1.68+/-0.34 (Figure 2.10c, p < 0.05).  
Response among parous women was more variable, with no overall significant increase in 
AREG, PGR, or TGFβ2.  Notably, in certain parous explants, expression of one or more 
target genes increased while other individuals had decreased expression or little change 
(Figure 2.10a-c).   
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Pearson correlation analysis of ESR1 and ESR2 mRNA levels and fold-change in 
target gene (AREG, PGR, TGFβ2) expression after E2 treatment revealed no significant 
correlation (Figure 2.11 and Table 2.5).  ESR1 levels were positively and significantly 
correlated with ESR2 (Table 2.5, p < 0.05).  This data suggests that estrogen receptor levels 
do not correlate with individual sensitivity to estrogen-induced transcriptional responses. 
 
Functional Responses to Estrogen 
To determine if estrogen receptor levels correlate with functional responses to 
estrogen, we examined protein expression of PR, proliferation, and apoptosis in a larger 
set of explant donor samples.  PR protein was detected in T=0, basal, and E2 treated 
explants (Figure 2.12a).  Quantification of PR positive luminal epithelial cells revealed a 
mean of 11.52% +/-2.55 positive cells in 14 T=0 samples (Figure 2.12b).  Basal treated 
explants had a mean of 7.9% +/-1.38 positive cells, which was not significantly different 
from the T=0.  Estrogen treated explants had a mean of 3.44% +/-0.94 which was not 
significantly different from basal treated explants but was significantly lower than in T=0 
samples (p < 0.05).   
Although in other models estrogen induces a proliferative response, we did not 
detect significant differences in proliferation as measured by PCNA expression between 
T=0 (24.64%+/-5.78), basal (17.21%+/-3.6) or E2-treated (26.74+/-3.47) explants (Figure 
2.13a-b).  There was a trending increase in proliferation in the E2-treated explants 
compared to the basal, but it was not significant (p = 0.067).  We observed no significant 
changes in proliferation with age or parity status within this sample set using linear 
regression analysis (Figure 2.13c).  Interestingly, some donors appeared insensitive to E2-
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induced proliferation, despite having low or high initial proliferative levels.  Other donors 
showed a marked increase in proliferation after E2 treatment. 
Our last endpoint of estrogen mediated functional responses was apoptotic response 
detected by TUNEL assay (Figure 2.14a-b).  In our basal and E2 treated explants, we 
examined both spontaneous apoptosis and irradiation induced apoptosis.  Both basal and 
E2 treated explants showed a significant increase in the number of apoptotic cells 6 hours 
after exposure to 5Gy of irradiation (Figure 2.14c, p < 0.05).  Basal treated explants 
increased from 1.36 +/-0.34 to 4.53% +/-1.2 while E2 treated explants similarly increased 
from 1.14 +/-0.33 to 2.94% +/-0.55.  This response was not enhanced by estrogen 
treatment, and there was no observable difference between nulliparous and parous explants.  
To determine if there was an increase in DNA damage after irradiation due to estrogen 
treatment, we performed immunofluorescence for γH2AX in basal and E2 treated explants 
(Figure 2.15a-b).  While apoptotic cells showed high levels of γH2AX staining, we only 
quantified the γH2AX foci in viable nuclei.  Basal treated explants had 0.56 γH2AX foci 
per nucleus at baseline levels but with irradiation increased to 1.06 foci per nucleus (Figure 
2.15c, p < 0.05).  Due to variable γH2AX foci levels among the E2 treated explants, there 
was no significant increase in γH2AX after E2 treatment.  However, the E2 irradiated 
explants had significantly higher γH2AX foci per nucleus (2.3 foci/nucleus) than the basal 
unirradiated explants (p < 0.05). 
Pearson correlation analysis of the functional responses to E2 treatment in this set 
of explant samples did not find any significant correlation with ESR1 or ESR2 levels.  There 
was a significant positive correlation of spontaneous apoptosis and proliferation in the 
explants (Table 2.6).  These results imply that functional E2 responses in human breast 
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explants are also not correlated with estrogen receptor mRNA levels, suggesting that ESR1 
and ESR2 levels do not alone determine sensitivity to estrogen. 
 
ERα and ERβ in human breast explants 
As another model to study how both ERα and ERβ contribute to the regulation of 
estrogen-induced responses among individuals, we expanded the scope of our human 
breast culture model.  In order to study ERα and ERβ induces responses separately, we 
treated with PPT, an ERα specific agonist, or ERB041, an ERβ specific agonist, in addition 
to estrogen and control media.  We compared expression of ER target genes AREG, PGR, 
and TGFβ2 in two initial donors treated with these agonists (Figure 2.16).  Donor 1 had 
higher baseline expression of all 3 genes compared to donor 2, though the relative levels 
varied by gene.  E2 treatment only significantly increased PGR expression in donor 1, but 
PPT treatment significantly increased AREG and PGR expression (p < 0.05).  Interestingly, 
ERB041 significantly decreased all 3 genes in donor 1 (p < 0.05).  E2 treatment in donor 2 
increased expression of AREG and TGFβ2, while PPT and ERB041 significantly increased 
all 3 genes (p < 0.05).  These donors indicate that both ERα and ERβ are involved in the 
regulation of these ER target genes and that these transcriptional responses differ between 
individuals. 
 
Discussion 
Breast cancer is the most prevalent cancer type and second leading cause of cancer 
related death in women (Siegel et al., 2019).  Reproductive risk factors for breast cancer, 
including early menarche, late menopause, high serum estrogen levels, and pregnancy after 
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age 35 are all related to lifetime estrogen exposure.  Paradoxically, estrogen is also capable 
of decreasing breast cancer risk, including through early parity.  Periods of increased 
estrogen exposure or prolonged lifetime exposure, depending on context, have differing 
consequences for breast cancer risk in women.  We demonstrate that in addition to varying 
in their exposure to estrogen, women also vary in their sensitivity to estrogen treatment.  It 
is worth noting that increased breast density is also a risk factor for breast cancer and is 
positively correlated with higher serum estrogen levels, and therefore may correlate with 
estrogen sensitivity (Brooks et al., 2018).  Identification of women who are more sensitive 
to estrogen exposure may reveal a subpopulation at increased risk for breast cancer.  
Mutations in ESR1, such as 908A/G (K303R) and 1608T/A (Y537N), are known to 
produce ERα proteins which are more sensitive to estrogen treatment or constitutively 
active and are associated with increased breast cancer risk (Abbasi et al., 2012; Conway et 
al., 2005, 2007; Herynk et al., 2007; Jeselsohn et al., 2014). 
Our goal was to utilize the ex-vivo human breast explant model to examine 
variation in estrogen receptor expression and sensitivity to estrogen detected by estrogen-
induced transcriptional and functional responses.  We sought to determine if estrogen 
sensitivity is correlated with estrogen receptor levels using a single dose of 10nM E2 vs 
control media in each individual donor.  Transcriptional responses to estrogen included the 
detection of R-loops and quantification of AREG, PGR, and TGFβ2 target genes.  
Functional responses to estrogen were regulation of PR, proliferation, irradiation-induced 
apoptosis, and DNA damage.  We then performed correlation analyses to determine if these 
responses were correlated with estrogen receptor levels. 
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Previous work quantifying estrogen receptor levels in luminal epithelial cells of 
normal human breast tissue have shown that ERα expression increases with age and is 
detectable in 32-68% of samples (Battersby et al., 1992; Söderqvist et al., 1993; Gabrielson 
et al., 2016).  In our microarray data of fresh normal breast tissue from over 100 donors, 
we also observed a significant increase in ESR1 mRNA with age (Figure 2.1a).  ESR2 
mRNA expression was also significantly increased with age (Figure 2.1b), although ERβ 
expression decreased with age (Figure 2.2b).  ERβ is expressed in luminal epithelial, basal 
epithelial, and stromal cells (Figure 2.2a) and the amount of stromal cells increases with 
age (Goyal et al., 2016).  The increase in ESR2 mRNA with age is likely affected by the 
increased stromal cell population, even after normalizing to KRT18 for luminal epithelial 
cell levels.  It is also possible that our ERβ antibody, PPG5/10, detected another nuclear 
protein as many ERβ antibodies are not specific for ERβ (Andersson et al., 2017; Nelson 
et al., 2017).   
Recent publications have questioned the validity of multiple commonly used ERβ 
antibodies.  Earlier reports with the PPG5/10 ERβ antibody confirmed effectiveness 
through western blots detecting a 60kDa protein, which correspond to the ERβ 1 isoform, 
and through in vitro work with ERβ overexpression in U2OS cells (Shaaban et al., 2008; 
Wu et al., 2012).  These studies also confirmed ERβ expression in both epithelial cells and 
stromal cells, as we observed in our work.  More reports suggest that the PPG5/10 ERβ 
antibody is not specific for ERβ.  Using rapid immunoprecipitation mass spectrometry of 
endogenous protein, a 2017 paper demonstrated that the PPG5/10 antibody does have 
specificity for ERβ but also binds non-specifically to a 77kDa band in western blots 
(Nelson et al., 2017).  Another 2017 paper states that the PPG5/10 antibody does not bind 
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ERβ but instead binds to other nuclear proteins (Andersson et al., 2017).  Regardless of 
ERβ antibody specificity, we observed a high degree of variability in both ESR2 and ERβ 
levels among women.  This was also true for ESR1 expression, suggesting individual 
variation in estrogen receptor expression.   
In our human breast explant samples, we sought to correlate estrogen receptor 
levels with estrogen-induced responses.  We aimed to quantify ERα expression by IHC; 
ERβ detection by IHC is unreliable with current available antibodies.  We found that ERα 
detection was highly variable both within an individual sample and between donors 
(Figure 2.5).  One lobule within a patient sample exhibited high ERα expression while 
other lobules expressed almost no ERα (Figure 2.5a and b, respectively).  This agrees with 
previous work showing that, in normal human breast tissue, expression of ERα may be 
contiguous, within a single lobule, or scattered (Battersby et al., 1992; Goyal et al., 2016).  
Due to these issues with the quantification of ERα protein and the limited amount of donor 
tissues we received for explant cultures, we examined mRNA expression of ESR1 and 
ESR2 using KRT18 normalization to optimize for the amount of epithelium in each sample 
(Figure 2.6 and Figure 2.7).  In 12 explant donor samples, we observed up to 80-fold 
variation in ESR1 and up to 100-fold variation in ESR2 expression, which was not 
significantly changed with 10nM E2 treatment (Figure 2.8). 
Examination of individual explant donors revealed a trending decrease in ESR1 and 
ESR2 expression in 8 donors and increase in 4 donors (Figure 2.8).  This suggests that 
negative feedback inhibition of estrogen receptor may be prevalent in certain donors in our 
study.  In human breast cancer cell lines, some studies have observed negative feedback of 
estrogen receptor while others are unchanged.  T47D breast cancer cells show an increase 
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in ESR1 mRNA levels and no change in ERα protein with estrogen treatment (Berkenstam 
et al., 1989; Read et al., 1989; Pink and Jordan, 1996).  MCF7 cells, in culture conditions 
with estrogen containing serum, decrease ESR1 mRNA and ERα protein (Eckert et al., 
1984; Saceda et al., 1988; Read et al., 1989; Pink and Jordan, 1996).  However, MCF7 
cells cultured in media with charcoal stripped serum, to remove estrogens, no longer 
decrease estrogen receptor expression with estrogen treatment (Read et al., 1989).  Our 
results therefore fit in with these previous studies, as some individual donors demonstrate 
E2-mediated repression of ESR1 while others show an increase.  This regulation likely 
depends on previous estrogen exposure and genetic background. 
Estrogen receptor signaling pathways activate transcription of numerous estrogen 
receptor target genes (Gruber et al., 2002; Carroll et al., 2005; Heldring et al., 2007b; Yasar 
et al., 2017).  In breast cancer cells and normal mammary epithelial cells, estrogen 
treatment is known to cause the formation of transient DNA:RNA hybrids known as R-
loops (Stork et al., 2016; Belotserkovskii et al., 2018; Vanoosthuyse, 2018; Majhi et al., 
2020).  The formation of these R-loops is dependent on estrogen receptor induced 
transcription.  R-loop formation has been observed at estrogen receptor target genes in 
MCF7 cells (Stork et al., 2016).  Our lab has shown the presence of R-loops in T47D cells 
and in normal mouse mammary epithelial cells (Majhi et al., 2020).  Human mammary 
epithelial cells, such as MCF10A and 76N Tert, do not form R-loops with estrogen 
treatment (Stork et al., 2016; Majhi et al., 2020).  However, addition of estrogen receptor 
into these cells results in measurable R-loop formation upon estrogen treatment (Majhi et 
al., 2020).  As R-loops are dependent on estrogen receptor expression and estrogen-induced 
transcription, we used R-loop detection as a measurement of global transcription in our 
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human breast explants.  We observed a significant increase in R-loop formation with 
estrogen treatment, which was consistent across donors (Figure 2.9).  This demonstrates 
that explants response to estrogen treatment in culture by activating transcription, as in 
mouse mammary glands and breast cancer cell lines.   
Next, we examined specific transcriptional responses in our explants by RT-qPCR 
analysis of ER target genes AREG, PGR, and TGFβ2.  AREG and PGR are common ER 
target genes induced upon E2 treatment in mice and in human breast cancer cell lines 
(Ciarloni et al., 2007; Peterson et al., 2015).  TGFβ2 is also an ER target gene and is 
downregulated in MCF7 cells with E2 treatment (Putnik et al., 2012).  In nulliparous 
explants, we observed significant increases in AREG and TGFβ2 and a trending increase 
in PGR (Figure 2.10).  Parous explants had overall more variable responses in these 3 
target genes, with some increasing, decreasing, or remaining unchanged (Figure 2.10).  
These results were somewhat surprising, as we had expected to observe increases in AREG 
and PGR and a decrease in TGFβ2.  This may be due to the limited number of ER positive 
cells in our heterogeneous explant samples and that many of these target genes were 
identified in breast cancer cell lines.   
Human breast organoids are thought to contain 7-10% ER positive cells (Meng et 
al., 2019), which is comparable to the 5-20% in normal human breast tissue.  In human 
breast organoids E2 treatment upregulates PGR expression, but not AREG (Meng et al., 
2019).  In human breast explants, AREG protein expression was increased with 10nM E2 
treatment, which agrees with our data at the mRNA level in nulliparous explants (Eigeliene 
et al., 2012).  Expression of estrogen responsive genes, therefore, may be diluted by the 
limited number of ER positive cells in the overall cell population in human breast organoids 
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and our human breast explants.  ER positive breast cancer cell lines have more homogenous 
expression of ERα, and accordingly have consistent target gene responses.  Although we 
hypothesized that donors with greater estrogen receptor expression would be more 
sensitive to E2 treatment, there was no correlation between ESR1 and ESR2 expression and 
E2-induced changes in AREG, PGR, and TGFβ2 (Figure 2.11 and Table 2.5).  These 
estrogen receptor target genes are more diversely regulated in normal human breast 
explants than in ER positive breast cancer cell lines, suggesting individual estrogen 
mediated transcriptional responses. 
ESR1 and ESR2 were also not correlated with function responses to E2 treatment.  
PR protein expression is detectable by IHC in more than 80% of human breast samples 
(Battersby et al., 1992; Söderqvist et al., 1993), but we did not observe a significant change 
in PR expression between our basal control and 10nM E2 treated explants (Figure 2.12).  
E2 treated explants had significantly lower PR than T=0 fresh breast tissue.  Previous work 
in human breast explants also demonstrated no change in control vs E2 treated samples 
(Eigeliene et al., 2008).  Additionally, PR expression studies in human breast tissue 
collected during the follicular and luteal phases of the menstrual cycle, where estrogen 
levels fluctuate, demonstrated no change in PR (Battersby et al., 1992; Söderqvist et al., 
1993).  Responses in our human breast explants differed compared to human explants in 
nude mice, however, where E2-treatment induced increases in PR expression (Laidlaw et 
al., 1995).  Of the 5 explant donors included in detection of both PGR and PR, one donor 
(185) exhibited very little change in either mRNA or protein expression, one donor (238) 
had an increase in mRNA and no change in protein, and three donors (179, 231, 234) had 
an increase in mRNA and a decrease in protein with estrogen treatment.   
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These PGR results are unexpected, as previous reports using breast cancer cell lines 
have suggested progesterone receptor mRNA and protein levels are closely correlated 
(Read et al., 1989; Cho et al., 1994; Fazzari et al., 2001).  However, it has also been 
demonstrated that PR regulation is controlled by several factors including cyclic adenosine 
monophosphate, serum factors, and growth factors (Cho et al., 1994).  One other study in 
T47D cells also proposed, depending on the subline of breast cancer cells and basal PR 
protein levels, as their T47D line showed estrogen-induced increase in PGR but no change 
in PR protein (Vegeto et al., 1990).  In most breast tumors examined, mRNA levels 
correlated with protein activity, but in a subset of tumors (8%) this was not the case.  
Regardless, 3 of 5 of our explants illustrate an apparent dysregulation of PGR mRNA and 
PR protein, which could be due to increased protein turnover.  However, our small sample 
size makes it difficult to make any definitive conclusions. 
E2-induced proliferation, detected by PCNA, was also not correlated with either 
ESR1 or ESR2 mRNA levels (Figure 2.13).  In human breast cancer studies, Ki67 is often 
used as a marker for proliferation.  The range of Ki67 positive cells in the normal human 
breast, however, is very low (0.3-2.6%) (Shoker et al., 1999b).  Another specific marker 
for S/M phase of the cell cycle, phospho-histone H3, is also very lowly expressed in normal 
breast (<0.05%) and did not report E2-induced proliferative responses (Tanos et al., 2013).  
In our human breast explants, we found that Ki67 expression was very low (<2% of cells), 
and with the limiting number of epithelial cells in our samples decided to use PCNA 
instead.  PCNA is expressed in the S and G2 phases of the cell cycle (Juríková et al., 2016; 
Qiu et al., 2019), and has been used previously by our lab in ovariectomized mice to detect 
estrogen-induced proliferation (Becker et al., 2005).  In mice, we observed 60% PCNA 
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positive cells with E2 treatment compared to 5% in control.  Our human explants also 
showed much higher levels of PCNA than Ki67, with a range of 3-58% (Figure 2.13b).  
We observed a trending increase in proliferation in E2 treated explants in most donors, 
though some with high basal levels were not responsive.  Though it has been shown that 
proliferation in the human breast is reduced in parous individuals and with age, we did not 
find any relationship between PCNA positive cells and age or parity (Figure 2.13c).   
Our lab has shown that parous BALB/c mice are more sensitive to irradiation 
induced apoptosis than nulliparous mice and that this effect is enhanced by estrogen and 
progesterone treatment (Becker et al., 2005; Dunphy et al., 2008).  In our human breast 
explants, while we observed a significant increase in apoptosis with irradiation, we did not 
observe a significant difference in irradiation-induced or spontaneous apoptosis between 
basal control and estrogen treated explants (Figure 2.14).  It is known that spontaneous 
apoptosis does not vary during the menstrual cycle, which supports the results observed 
here (Navarrete et al., 2005; Potten et al., 1988).  However, estrogen treatment has been 
shown to repress spontaneous apoptosis in human breast explants (Eigėlienė et al., 2006).  
Deficiency in DNA damage response pathways is correlated with increased breast cancer 
risk (Venkitaraman, 2001; Roy et al., 2011), so we also examined a marker of DNA damage 
(γH2AX) in our explants to detect any accumulation of damage from irradiation or estrogen 
treatment.  We observed a significant increase in DNA damage after irradiation in both 
control and estrogen treated samples, but there was no increase with estrogen treatment 
(Figure 2.15).  This suggests that, in our explants, there was no notable accumulation of 
DNA damage after 4-day estrogen treatment.   
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We treated a preliminary set of explants with ER specific agonists, PPT and 
ERB041, to characterize the role of ERα and ERβ in the variable estrogen-induced target 
gene activation.  In our two parous explant donors, we observed variable responses in 
AREG, PGR, and TGFβ2 (Figure 2.16).  PPT, an ERα specific agonist, induced AREG and 
PGR expression in both explants (p < 0.05).  In donor 2, PPT treatment increased TGFβ2 
expression (p < 0.05), but in donor 1 TGFβ2 was unchanged.  Donor 1, who had higher 
basal expression of all 3 target genes, showed a significant decrease in all 3 genes with 
ERB041, an ERβ specific agonist, treatment (p < 0.05).  This agrees with reports that ERβ 
opposes the actions of ERα (80-82).  Interestingly, in donor 2, who had lower basal 
expression of these genes, the reverse was observed; ERB041 significantly increased 
expression of all 3 genes (p < 0.05).  Both donor 1 and donor 2 exhibited modest target 
gene induction with estrogen treatment, which could be attributed to the ratios of ERα and 
ERβ in the breast epithelium of each individual (Chang et al., 2008; Covaleda et al., 2008). 
Our work with the human breast explant model illustrates the inter-individual 
variation in estrogen receptor expression as well as estrogen-induced transcriptional and 
functional responses.  In agreement with previous literature, we observed significant 
increases in ESR1 and ESR2 with age which had only been shown at the protein level.  
While global transcription, reported by R-loop detection, increases similarly among 
individuals, specific estrogen receptor target gene responses vary and are influenced by 
parity.  Similarly, functional responses to E2, including regulation of PR and induction of 
proliferation, varied by individual.  Neither transcriptional nor functional responses were 
correlated with ESR1 and ESR2 expression, indicating that the level of estrogen receptors 
expressed do not dictate estrogen sensitivity.  We propose that differences in estrogen 
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receptor signaling, mediated by coactivators and corepressors, may modulate estrogen 
sensitivity and have important implications for breast cancer risk.   
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Table 2.1: Donor information for first set of human breast explants 
Donor information for all nulliparous, parous, and unknown parity donors used in the 
human breast explant model (set 1).  Collected by Dr. Karen Dunphy. 
 
 
Nulliparous  Parous  Unknown 
Donor 
Number 
Age  
Donor 
Number 
Age 
Age at 
First Birth 
 
Donor 
Number 
Age 
237 18  186 26 20  239 35 
237 18  189 27 25  176 37 
240 18  225 35 27    
231 26  234 35 23    
184 27  181 39 19    
249 28  178 43 39    
187 29  243 45 21    
180 47  185 49 17    
179 61  241 50 18    
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Table 2.2: List of analyses performed on first set of explant donor tissues 
Summary donor information and experiments performed on RNA or tissue sections of 
explant donor tissues from set 1.  Experiments included R-loop detection, qPCR analysis 
of ER and ER target genes, progesterone receptor (PR) IHC, PCNA IHC for proliferation, 
TUNEL assay for detecting irradiation induced apoptosis, and irradiation induced DNA 
damage by γH2AX detection. 
 
 
 
  
Donor 
Number 
Age Parity 
R-
loop 
IF: 
qPCR 
analysis: 
PR 
IHC: 
PCNA 
IHC: 
TUNEL: 
γH2AX 
IF: 
ss237 18 Nulliparous Yes Yes Yes Yes Yes Yes 
ss238 18 Nulliparous No Yes Yes Yes Yes No 
ss240 18 Nulliparous No No No No Yes No 
ss231 26 Nulliparous No Yes Yes Yes Yes No 
ss184 27 Nulliparous Yes No Yes Yes Yes Yes 
ss249 28 Nulliparous No No Yes Yes No No 
ss187 29 Nulliparous No No Yes Yes Yes No 
ss180 47 Nulliparous No Yes No No Yes No 
ss179 61 Nulliparous No Yes Yes Yes Yes No 
ss250 62 Nulliparous No No Yes No No No 
ss186 26 Parous No Yes No Yes Yes No 
ss189 27 Parous No No No Yes Yes No 
ss225 35 Parous No No No No Yes No 
ss234 35 Parous Yes Yes Yes Yes Yes Yes 
ss181 39 Parous No Yes Yes No Yes No 
ss178 43 Parous No No Yes Yes Yes No 
ss243 45 Parous Yes No No Yes No Yes 
ss185 49 Parous No Yes Yes Yes Yes No 
ss241 50 Parous Yes No No Yes Yes Yes 
ss244 56 Parous No No Yes No Yes No 
ss177 58 Parous No Yes No Yes Yes No 
ss239 35 Unknown No 
Yes (ER 
only) 
No No No No 
ss176 37 Unknown No 
Yes (ER 
only) 
No No No No 
ss379 21 Parous No Yes No No No No 
ss438 51 Parous No Yes No No No No 
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Table 2.3: RT-qPCR primer sequences 
Primer sequences used in RT-qPCR of human explant samples.  Used on Eppendorf 
thermocycler.   
 
 
Gene Sequence: 5’ to 3’ 
Keratin 18 (KRT18) 
Fwd – CAC AGT CTG CTG AGG TTG GA 
Rev – GAG CTG CTC CAT CTG TAG GG 
Estrogen receptor 1 (ESR1) 
Fwd – TTA CTG ACC AAC CTG GCA GA 
Rev – ATC ATG GAG GGT CAA ATC CA 
Estrogen receptor 2 (ESR2) 
Fwd – GTT TGG GTG ATT GCC AAG A 
Rev – TCC ATC CCC TTG TTA CTG G 
Amphiregulin (AREG) 
Fwd – CGG AGA ATG CAA ATA TAT AGA GCA C 
Rev – CAC CGA AAT ATT CTT GCT GAC A 
Progesterone receptor (PGR) 
Fwd – TTT AAG AGG GCA ATG GAA GG 
Rev – CGG ATT TTA TCA ACG ATG CAG 
Transforming growth factor 
β2 (TGFβ2) 
Fwd – ATA GAC ATG CCG CCC TTC TT 
Rev – CTC CAT TGC TGA GAC GTC AA 
 
 
 
 
 
 
Table 2.4: Antibody information for IHC 
Antibodies used in IHC on human explant samples. 
 
 
Target 
Name of Antibody, 
Catalog Number 
Manufacturer 
Dilution 
Used 
Species 
Estrogen 
receptor alpha 
(ERα) 
1D5, MA5-13191 
Thermo Fisher 
Scientific 
1:200 
Mouse, 
monoclonal 
Estrogen 
receptor beta 
(ERβ) 
PPG5/10, M7292 Dako 1:200 
Mouse, 
monoclonal 
Progesterone 
receptor (PR) 
Progesterone receptor 
A/B, D8Q2J 
Cell Signaling 1:500 
Rabbit, 
monoclonal 
Proliferating cell 
nuclear antigen 
(PCNA) 
PC10,  
ab29 
Abcam 1:10,000 
Mouse, 
monoclonal 
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Table 2.5: E2-induced gene response does not correlate with estrogen receptor 
expression 
Results of Pearson correlation analysis comparing ESR1 or ESR2 mRNA expression with 
fold change in AREG, PGR, and TGFβ2 expression induced by estrogen treatment 
compared to basal controls.  ESR1 and ESR2 were not positively or negatively correlated 
with E2-induced change in AREG, PGR, and TGFβ2 expression (p > 0.05) as indicated by 
correlation coefficients close to zero.  ESR1 is positively correlated with ESR2 expression 
(p < 0.05), indicated by a correlation coefficient close to 1. 
 
 
Correlation Coefficient ESR1 ESR2 
AREG -0.138, p = 0.705 0.016, p = 0.965 
PGR -0.126, p = 0.729 -0.036, p = 0.921 
TGFβ2 -0.096, p = 0.792 0.005, p = 0.989 
ESR2 0.702, p = 0.024 --- 
 
 
 
 
Table 2.6: ER mRNA levels do not correlate with functional responses to E2 
Results of Pearson correlation analysis comparing ESR1 or ESR2 mRNA expression with 
E2-induced increase in PGR protein expression, proliferation, spontaneous apoptosis, or 
irradiation induced apoptosis.  ESR1 and ESR2 were not positively or negatively correlated 
with E2-induced functional endpoints (p > 0.05) as indicated by correlation coefficients 
close to zero.  Spontaneous apoptosis was significantly positively correlated with 
proliferation. 
 
 
Correlation 
Coefficient 
ESR1 ESR2 PGR PCNA 
Spontaneous 
apoptosis 
(no IR) 
Irradiation 
induced 
apoptosis 
PGR 
0.090,  
p = 0.910 
-0.368,  
p = 0.632 
--- 
-0.202,  
p = 0.798 
-0.744,  
p = 0.256 
-0.226, 
p = 0.774 
PCNA 
0.116,  
p = 0.784 
0.222,  
p = 0.597 
-0.202,  
p = 0.798 
--- 
0.817,  
p = 0.013 
0.027,  
p = 0.954 
Spontaneous 
apoptosis  
(no IR) 
0.332,  
p = 0.348 
0.404,  
p = 0.248 
-0.744,  
p = 0.256 
0.817,  
p = 0.013 
--- 
0.349,  
p = 0.357 
Irradiation 
induced 
apoptosis 
0.126,  
p = 0.678 
0.297,  
p = 0.438 
-0.226,  
p = 0.774 
0.027,  
p = 0.954 
0.349,  
p = 0.357 
--- 
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Figure 2.1: ESR1 and ESR2 expression diversity among women. 
Agilent microarray data of human breast tissue collected from donors undergoing reduction 
mammoplasty surgery.  Expression of (a) ESR1 is shown in 111 donor samples and (b) 
ESR2 from 102 donor samples, both normalized to KRT18 expression.  Linear regression 
analysis showed a significant increase in both ESR1 (p < 0.001) and ESR2 (p < 0.01) levels 
with age.  Dotted lines indicate 95% confidence intervals and solid lines indicate the best 
fit line.  R2 values for best fit lines are indicated, and low values indicate high variability 
between donors.  Microarray data provided courtesy of Dr. Melissa Troester. 
 
 
 
 
 
Figure 2.2: ERβ protein expression decreases with age. 
IHC using ERβ antibody (PPG5/10) was performed on paraffin-embedded sections from 
45 donor samples.  Representative image (a) with arrows indicating representative positive 
cells: yellow arrows indicate positive luminal epithelial cells, red indicate positive basal 
epithelial cells, and black indicate positive stromal cells.  Scale bar is 50uM.  (b) 
Quantification of ERβ positive ductal epithelial cells.  Linear regression analysis shows a 
significant decrease in ERβ with age (p < 0.05).   Dotted lines indicate 95% confidence 
intervals and solid lines indicate the best fit line.  R2 values for best fit lines are indicated.  
Data provided courtesy of Dr. Karen Dunphy and Dr. Sallie Schneider.  
a b 
a b 
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Figure 2.3: Overview of human breast explant model 
Tissue obtained from donors undergoing reduction mammoplasty were sectioned into 
strips.  Some strips were flash frozen or fixed in 10% neutral buffered formalin (NBF) for 
time 0 (T=0) samples.  All other strips were placed on surgical foam in tissue culture dishes 
and cultured in basal control media for 3 days to clear endogenous hormones.  After 
clearing, the explants were treated with either basal control or 10nM E2 media for an 
additional 4 days.  Six hours prior to collection, half of the samples were irradiated.  At 
collection, tissue strips were either flash frozen for later RNA isolation or fixed in 10% 
NBF for later IHC. 
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Figure 2.4: Explant tissue architecture at T=0 and T=7  
Representative H&E images from four explant donors comparing tissue architecture at T=0 
(a, c, e, g) and T=7 (b, d, f, h) for nulliparous (a-d) and parous (e-h).  Donors are from set 
1.  No apoptotic nuclei were observed.  Scale bar is 50uM. 
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Figure 2.5: Heterogenous expression of ERα protein 
Representative IHC images from donor 234 showing one lobule with high (a) and one 
lobule with low (b) expression of ERα.  Scale bar is 50uM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Optimization of RT-qPCR with KRT18  
3-4 separate 100ug pieces of flash-frozen tissue from three donors (177, 178, and 185) were 
treated as separate samples and used for RT-qPCR analysis of ESR1, KRT18 and ESR1 
expression normalized to KRT18.  Data provided courtesy of Dr. Karen Dunphy.  
a b 
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Figure 2.7: Comparison of ESR1 expression between donors and during culture 
Gene expression analysis of (a) ESR1 normalized to KRT18 between three parous donors, 
demonstrating variation between individuals.  Data provided courtesy of Dr. Karen 
Dunphy.  (b) Normalized ESR1 expression of two explant donors using tissue collected at 
T=0 and tissue from T=5 treated with either basal or 10nM E2 media.  ESR1 expression 
for each donor appears stable during culture. 
 
 
  
Donor A Donor B 
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Figure 2.8: ESR1 and ESR2 expression in nulliparous and parous explants 
RT-qPCR analysis of basal and 10nM E2 treated explant samples for ESR1 and ESR2 using 
KRT18 normalization.  Expression shown relative to control mean.  Circles represent 
nulliparous explants, squares parous explants, and triangles explants with unknown parity 
status.  Parity and age are shown next to donor ID.  Individual fold change in gene 
expression is indicated.  No significant difference in ESR1 or ESR2 expression was 
observed between basal and E2 treated explants (p > 0.05).   
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Figure 2.9: E2 induces R-loop formation in human breast explants 
Representative images of S9.6 (R-loop) immunofluorescence in (a) basal and (b) E2 treated 
explants from donor 184.  (c) Quantification of R-loop foci per nucleus in basal and luminal 
epithelial cells demonstrates increased R-loop formation with E2 relative to T=0 or basal 
treatment (n=5 for each treatment group).  (d) R-loop foci per nucleus in basal and E2 
treated explants from five donors.  Error bars indicate SEM.  Significance was determined 
using ANOVA (p < 0.01 **).  Data collected in collaboration with Aman Sharma. 
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Figure 2.10: AREG, PGR, and TGFβ2 expression in nulliparous and parous explants 
RT-qPCR analysis of basal and 10nM E2 treated explant samples for AREG, PGR, and 
TGFβ2 normalized to KRT18.  Expression is shown relative to basal mean.  Circles 
represent nulliparous explants and squares represent parous explants.  Donor age and parity 
status is shown in parentheses next to donor ID.  Four-day E2 treatment significantly 
increased (a) AREG (p < 0.05), increased (b) PGR (p = 0.059), and significantly increased 
(c) TGFβ2 (p < 0.05) in nulliparous explants, but not in parous explants.  Significance was 
calculated using 2-way ANOVA analysis.  Data provided courtesy of Dr. Karen Dunphy.  
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Figure 2.11: E2-induced target gene responses do not correlate with ER mRNA 
expression 
Heatmaps representing (top) the fold change in PGR, AREG, and TGFβ2 expression in 
basal vs E2 treated explants and (bottom) the expression of ESR1 and ESR2 for each donor 
explant relative to the overall mean.  All values are normalized to KRT18.  Hierarchical 
clustering was used to group donors by target gene response.  Correlation analysis was 
performed using Pearson correlation coefficients in Graphpad Prism.  Heatmaps were 
created in R studio using heatmap2 package.  Donor number, parity status, and age are 
indicated.   
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Figure 2.12: PR regulation by E2 in human breast explants 
Representative (a) progesterone receptor IHC and (b) quantification.  E2 treatment 
significantly decreased PR expression compared to T=0 samples (p < 0.05), but there was 
no difference between T=0 and basal or basal and E2 treated explants.  Circles represent 
nulliparous explants and squares parous explants.  Parity and age are shown next to donor 
ID.   
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Figure 2.13: E2-induced proliferation in human breast explants 
Representative (a) proliferating cell nuclear antigen (PCNA) IHC and (b) quantification.  
E2 treatment did not significantly increase proliferation in nulliparous or parous explants 
(p > 0.05).  Linear regression analysis (c) shows no significant changes in E2-mediated 
proliferation due to age. Each individual donor is indicated by a color (see key): square 
indicates E2-treated; circle indicates basal-treated. Black arrowhead identifies individuals 
that are insensitive to E2-mediated proliferation. White arrow identifies individuals that 
are highly sensitive to E2-mediated proliferation (compare to same color circle below 
square). 
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Figure 2.14: Irradiation induced apoptosis in human breast explants 
Representative terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
images from (a) basal and (b) E2 treated explants irradiated with 5Gy 6 hours prior to 
collection to induce apoptosis.  Quantification (c) revealed a significant increase in 
apoptotic nuclei in irradiated explants compared to unirradiated (p < 0.05), but E2 treatment 
did not enhance the apoptotic response (p > 0.05).  Circles represent nulliparous explants 
and squares parous explants.  Parity and age are shown next to donor ID.  Data provided 
courtesy of Dr. Karen Dunphy and Zida Li. 
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Figure 2.15: γH2AX foci formation in human breast explants 
Representative images of γH2AX foci from (a) basal IR and (b) E2 IR explants, with inset 
indicated.  Scale bars are 50uM.  Large arrows indicate apoptotic cells and small arrows 
show an example of γH2AX foci.  Quantification (c) of γH2AX foci per nucleus in five 
donor explant samples showed an increase in γH2AX foci in basal treated explants (p < 
0.05) but not in E2 treated explants (p > 0.05).  Data collected in collaboration with Aman 
Sharma. 
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Figure 2.16: Effect of estrogen receptor specific agonists PPT and ERB041 on 
AREG, PGR, and TGFβ2 target gene response 
Two explant donors (379 and 438) from set 1 were treated with basal, E2, ERα specific 
agonist PPT, or ERβ specific agonist ERB041 and examined for expression of estrogen 
receptor target genes.   
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CHAPTER 3 
COMPARISON OF ESTROGENIC RESPONSES IN PRIMARY HMECS  
 
Introduction/Rationale 
Many epidemiological studies have identified risk factors for breast cancer, such as 
early menarche (RR = 1.3), late menopause (RR 1.2-2.0), or having high serum estrogen 
levels (RR = 1.8-5.0), which are linked to increased levels of estrogen and/or increased 
duration of exposure (Brinton et al., 1983, 1988; Clemons and Goss, 2001; Dall and Britt, 
2017).  Conversely, estrogen exposure can also reduce breast cancer risk through early full-
term pregnancy by up to 50% (MacMahon et al., 1970; Trichopoulos et al., 1983; Lambe 
et al., 1996; Albrektsen et al., 2005) and can be an effective antitumor therapy in 
postmenopausal women with breast cancer (Lonning et al., 2001).  These results 
demonstrate that estrogen exposure, depending on context, can have conflicting effects on 
breast cancer risk.  Exposure to xenoestrogens, a class of endocrine disrupting chemicals, 
may affect this delicate balance between the protective effects of estrogen and its 
contribution to breast cancer risk.  Endocrine disrupting chemicals are able to disrupt 
normal hormone signaling by mimicking or antagonizing the effects of endogenous 
hormones and also by disrupting the synthesis and metabolism of endogenous hormones 
and their receptors (Fernandez and Russo, 2010; Sonnenschein and Soto, 1998b).  
Xenoestrogens are present in food, drinking water, ambient air, and many are found in 
personal care products such as cosmetics and sunscreens (Soni et al., 2001; Mortensen et 
al., 2014).  Xenoestrogens have estrogenic activity, meaning they act as ligands for 
estrogen receptors and thus can potentially regulate estrogen-responsive target genes in a 
manner similar to estrogen (Singleton and Khan, 2003).   
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Recent work has identified the potential for environmental chemical exposures to 
contribute to breast cancer risk.  Two xenoestrogens, benzophenone-3 (BP3) and 
propylparaben (PP) have been detected in > 95% of the U.S. population (Ye et al., 2006; 
Calafat et al., 2008, 2010).  Not much is yet known about potential breast cancer risk from 
BP3 or PP exposure.  BP3 is a UV-filter used in personal care products, including 
sunscreens, while PP is an antimicrobial agent used in food packaging and personal care 
products.  Studies with MCF7 and T47D breast cancer cell lines, which express ERα, have 
shown that 1uM concentrations of BP3 act as a weak agonist for ERα in reporter assays 
(Schlumpf et al., 2001; Kerdivel et al., 2013; Schlotz et al., 2017).  BP3 exposure during 
pregnancy and lactation in mouse models results in altered mammary gland ductal 
structures, and these alterations remain for weeks after the exposure has ended (LaPlante 
et al., 2018).  While some studies have shown that BP3 does not increase proliferation of 
breast cancer cell lines (Schlotz et al., 2017; Majhi et al., 2020), others have indicated that 
long term high dose exposure may increase cancer cell motility (Alamer and Darbre, 2018).  
PP is also an ERα agonist in reporter assays but was also able to increase estrogen 
responsive target gene expression and increase proliferation in MCF7 cells at 1uM levels 
(Byford et al., 2002) and increased cell motility in short and long term exposures (Khanna 
et al., 2014).  Our lab has confirmed that BP3 and PP act as agonists for ERα and that only 
PP is able to increase cell proliferation (Majhi et al., 2020).  BP3 and PP can also induce 
the formation of DNA:RNA hybrids (R-loops) in breast cancer cells, normal HMEC lines, 
mouse mammary epithelial cells in vivo, and human breast epithelial cells in explant 
culture which have the potential to create DNA double strand breaks if not resolved.   
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Rodent studies have identified strains which have increased susceptibility to 
estrogen-induced mammary tumor development (Shull et al., 1997; Spady et al., 1998; 
Dennison et al., 2015; Shull et al., 2018) and have increased sensitivity to estrogen-induced 
responses (Montero Girard et al., 2007; Aupperlee et al., 2009).  These strains do not have 
mutations in any well-known breast cancer risk genes such as BRCA1, BCRA2, or TP53 
(Anglian Breast Cancer Study Group, 2000; Antoniou and Easton, 2006; Lalloo and Evans, 
2012; Peto et al., 1999; Thompson and Easton, 2004).  We have demonstrated in human 
ex-vivo breast culture that there is significant inter-individual variation in response to 
estrogen that is not correlated with estrogen receptor expression levels (Dunphy et al., 
2020).  This data supports the hypothesis that a subset of women may be more sensitive to 
estrogen exposure, and potentially more sensitive to xenoestrogen exposure as well.   
Genetic variation between individuals is known to affect responses to therapeutic 
drugs (Roden et al., 2011).  Individual variation has also been demonstrated to influence 
cell metabolism and responses to cytokines in human mammary epithelial cell (HMEC) 
models (Schneider et al., 2017).  Additionally, genetic variation affects irradiation 
sensitivity and apoptosis responses in human cells and mice (Smirnov et al., 2009, 2012; 
Snijders et al., 2012; Yard et al., 2016).  Gene by environment (gene-environment) 
interactions are also known to influence breast cancer risk.  SNPs in regions associated 
with breast cancer risk increased risk further when combined with alcohol consumption, 
height, hormone replacement therapy, and high body mass (Gonzales et al., 2018; Rudolph 
et al., 2018).  The increased risk from gene-environment interactions follows a 
multiplicative model of increased risk (Travis et al., 2010; Nickels et al., 2013; Barrdahl et 
al., 2014; Rudolph et al., 2015; Maas et al., 2016).  In related research, SNPS in specific 
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genes involved in the metabolism of carcinogens predispose individuals who smoke or 
drink alcohol to colon cancer development (Garcia-Closas et al., 2005; Wu et al., 2012a), 
which emphasizes how gene-environment interactions can influence the potential risk of 
environmental compounds. 
It is important, therefore, to create a normal human breast model in which exposure 
to xenoestrogens or other compounds can be characterized.  Induced pluripotent stem cell 
(iPS) lines are useful for differentiating into multiple cell types, but limited success with 
iPS lines has been observed in mammary epithelial cell development (Cravero et al., 2015; 
Qu et al., 2017).  3D breast organoid models are reliable for breast cancer cell expansion 
and characterization, but we have found limited success with normal HMEC cells.  
However, others have had success expanding basal and luminal mammary epithelial cells 
in organoid culture which retain luminal epithelial cells with expression of ERα (Sokol et 
al., 2016).  Human explant culture models preserve all cell types in the mammary gland, 
maintain estrogen receptor levels, and are hormonally responsive but have a limited 
lifespan (2-4 weeks) which limits their use for characterization of xenoestrogen-induced 
responses (Dunphy et al., 2020; Eigeliene et al., 2008, 2012, 2016; Eigėlienė et al., 2006; 
Tanos et al., 2013).  
HMEC models for studying normal breast biology have been limited by the early 
senescence of HMECs in 2D culture.  Transformation with adenovirus E6/E7, human 
telomerase (TERT), Myc, SV40 large T-antigen, zinc-finger protein ZNF217, and BMI-1 
can be used to bypass this senescence, but ultimately these methods perturb the biology of 
the cells.  Loss of retinoblastoma protein, p53, and p16INK14a in these methods results in 
abnormal bypass of cell cycle checkpoints (Wang et al., 1998; Dyson et al., 1989; Münger 
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et al., 1989; Scheffner et al., 1990; Huschtscha et al., 2001; Nonet et al., 2001; Dimri et al., 
2002; Martinez-Zapien et al., 2016; Fischer et al., 2017).  Myc immortalized lines exhibit 
morphological changes, anchorage independent growth, reduced apoptotic responses, and 
altered gene expression (Wang et al., 1998; Thibodeaux et al., 2009).   
In our work, we sought to use an alternative approach, which we refer to as 
conditional immortalization.  The conditional immortalization process for mammary 
epithelial cells involves coculture of mammary epithelial cells with irradiated mouse 
fibroblasts and addition of a rho-associated protein kinase (ROCK) inhibitor (Liu et al., 
2012; Palechor-Ceron et al., 2013).  Other research has characterized conditionally 
immortalized HMECs (ciHMECs) and found similar expression profiles to original tissue 
samples (Mahajan et al., 2017).  Some studies found that conditionally reprogrammed cells 
are representative of an adult stem-like epithelial population and express specific stem cell 
markers (Suprynowicz et al., 2012, 2017).  Using this method, one group was able to 
expand a population of ERα positive cells with luminal epithelial markers, but they noted 
that this population decreased dramatically with passaging (Jin et al., 2017).  Expansion of 
ERα positive epithelial cells may be restricted by transforming growth factor beta (TGFβ) 
signaling, as treatment with inhibitors for this pathway was shown to enhance the growth 
of ERα positive HMECs (Fridriksdottir et al., 2015).   
The overall goal for this aim was to characterize inter-individual variation in 
estrogenic responses in primary cell lines, representative of individual patients, and to use 
this information to investigate possible mechanisms contributing to estrogen and 
xenoestrogen sensitivity.  To do this, we utilized a ciHMEC panel.  We performed dual 
luciferase assays after transiently transfecting ciHMEC lines with estrogen receptor and a 
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reporter construct to measure individual responses.  While we did observe up to 3-fold 
variation in response to E2, BP3, and PP, we only observed subtle differences in responses 
between HMECs.  Due to difficulties with the conditionally immortalized HMEC lines, 
further work was not continued. 
 
Materials and Methods 
Cell culture 
All Rays of Hope Registry cell lines were obtained from Dr. Sallie Schneider at 
PVLSI.  Primary cells were passaged in F-media (250 mL DMEM (- pyruvate), 250 mL 
Ham’s F12, 5% FBS, 250 ng/mL hydrocortisone (Sigma), 10 ng/mL Epidermal Growth 
Factor murine submaxillary (Sigma), 8.6 ng/mL Cholera Toxin Vibrio (Sigma), 1 µg/mL 
human Insulin solution (Sigma), and 1X Antibiotic-Antimycotic (100X) (Lonza Basal, 
Switzerland).   
MCF10A, ME16C2, 76N Tert, HMECC, and H16N2 stably immortalized breast 
cell lines (references) were also grown in F-media.  NIH 3T3 mouse fibroblasts (gift of 
Bruce Jacobson) were cultured in DMEM with 10% FBS and 15 ug/mL gentamycin.  All 
cells were incubated at 37°C with 5% CO2 and passaged every 2-4 days. 
Conditional immortalization 
NIH 3T3 cells were treated with 30-gray (Gy) of gamma radiation.  Cells were then 
plated in F media and allowed to adhere for 1-2 hours.  HMEC cells were plated on the 
feeder layer with 10uM ROCK inhibitor (Y27632, StemCell Technologies).  
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RT-qPCR 
RNA was isolated from cells using TRIzol according to manufacturer’s 
instructions.  RT-qPCR  was performed using the Mx3005P real-time PCR system 
(Agilent, Santa Clara, CA).  Reactions were performed using the 1-Step Brilliant SYBRIII 
Green QRT-PCR Master Mix Kit (Agilent) and 200 nM forward primer, 200 nM reverse 
primer, and 10 ng RNA.  Expression was set relative to universal mRNA control consisting 
of 5 donors with normal tissue (BioChain, San Francisco CA).  See Table 3.2 for primers 
used. 
Mammosphere Extreme Limiting Dilution Assay  
A preliminary mammosphere forming assay was conducted to identify cell lines 
that have primary mammosphere forming capability.  Cells were cultured in ultra-low 
attachment 96-well plates (Corning, NY) in 100 µL of F-media at differing concentrations: 
250, 500, 1000, and 2000 cells/well.  Cell lines that developed primary mammospheres 
after 7 days were selected for extreme limiting dilution assay.  For extreme limiting dilution 
assays, each cell line was cultured in 100 µL of F-media in 96-well ultra-low attachment 
plates for 7 days.  Each line was cultured at 4 concentrations ranging from 25 to 2000 
cells/well with 8 replicates per concentration.  Concentrations varied between lines based 
on initial preliminary mammosphere forming assay.  After 7 days, positive wells containing 
mammospheres were counted in each concentration for each cell line. Mammosphere 
forming cell frequency (±95% confidence interval upper and lower limit) was calculated 
using online software (bioinf.wehi.edu.au/software/elda16). 
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ERE-Luciferase Assays 
HMECs were plated in 24 well tissue culture plates at densities ranging from 7 x 
104 to 1 x 105 cells/well in F-media with 10 uM Y27632. After an overnight incubation, 
growth media was replaced with 0.3 mL/well Opti-MEM reduced serum media (11058-
021, Gibco).  Plasmid DNA and Lipofectamine 2000 reagent (11668019, ThermoFisher) 
were diluted in Opti-MEM media before adding 200 µL/well. Cells were transfected with 
0.125 µg of either ESR1, ESR2, or both ESR1 and ESR2 expression plasmids, 1.5 µg of 3X 
ERE-TATA-Luciferase reporter plasmid, and 0.02 µg of pRL-CMV Renilla plasmid using 
lipofectamine 2000 (Invitrogen). As a receptor-negative control, 6 wells were transfected 
with 1.5 µg 3x ERE-TATA-Luc reporter plasmid and 0.02 µg pRL-CMV plasmid; half 
were treated with control media and the other half with 17β-estradiol (E2) media.  For 
Fugene 6 transfections, 0.01ug/well of pRL-CMV-Renilla, 0.6ug/well of 3X ERE-TATA-
Luciferase and 0.02ug/well ESR1 were as above.  1.8uL/well of Fugene 6 (E2691, 
Promega) was used for transfection.   
After 6 hours of transfection, transfection media was replaced with 0.5 mL of 
treatment media.  Cells were incubated with treatment media for 24 hours.  The Promega 
Dual Luciferase Reporter Assay was used to perform luciferase assays (E1910, Promega).  
Cells were lysed in 1x Passive Lysis Buffer and lysates stored at -20°C until reading.  
Luciferase and Renilla activity in lysates were determined by using the Polar Star Optima 
plate reader (BMG Labtech).  Luciferase values for each well were normalized to the 
amount of Renilla activity. 
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Cell Treatments 
Control treatment media consisted of MEM media (51200-038, Gibco), 5% 
charcoal-dextran stripped serum (FB-04, Omega Scientific), and 2mM L-glutamine 
(SH30034.01, Hyclone). 10 mM 17β-estradiol (E2758, Sigma-Aldrich) stock prepared in 
ethanol was diluted to prepare E2 treatment media.  10 mM 2-hydroxy-4-
methoxybenzophenone (H36206, Sigma) and propyl 4-hydroxybenzoate (P53357, Sigma) 
stocks were prepared in DMSO (D8418, Sigma) and diluted to make BP3 and PP treatment 
media. 
Immunofluorescence 
Cells were plated on glass coverslips in 12 well plates at a density of 2x105 
cells/well in normal growth media.  After overnight incubation, the media was removed, 
cells were washed with 1x phosphate buffered saline (PBS), and then fixed in 4% 
paraformaldehyde for 15 minutes at room temperature.  Cells were permeabilized with 
0.5% TritonX-100 for 10 minutes at 4°C and washed 3 times with 1x PBS: Glycine 
(130mM NaCl, 7mM Na2HPO4, 3.5mM NaH2PO4, 100mM Glycine) for 15 minutes each 
at room temperature.  Blocking was performed in immunofluorescence buffer (130mM 
NaCl, 7mM Na2HPO4, 3.5mM NaH2PO4, 7mM NaN3, 0.1% BSA, 0.2% TritonX-100, 
0.005% tween-20) with 10% donkey and goat serum for 1-2 hours.   A second blocking 
was performed using immunofluorescence buffer with 10% donkey and goat serum and 
20ug/mL goat anti-mouse F(ab’)2 (ab6668, Abcam) for 30-40 minutes.  Primary antibody 
incubation was performed with 1:500 human mitochondrial antibody (ab92824, Abcam) 
and 1:200 vimentin antibody (ab92547, Abcam) overnight at 4°C.  Cells were washed with 
1x PBS: Glycine 3 times for 15 minutes each, incubated with secondary antibody for 1 
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hour (1:500 Cell Signaling 4408S and Abcam ab150076), washed, and mounted using 
Vectashield mounting media with DAPI (H-1500, Vector Laboratories).  Images were 
obtained under 200x magnification (model BZ-X700 microscope). 
 
Results 
Characterization of HMECs 
Using a previously published method for conditional immortalization of human 
breast epithelial cells, we expanded a subset of donor primary breast cells for 
characterization of estrogenic responses (Figure 3.1).  Donor age, BMI, type of surgery, 
ethnicity, and parity status were recorded for each donor (Table 3.1).  Briefly, primary 
human mammary epithelial cells (HMECs) were isolated from digestion of donor tissue 
samples and plated in 2D tissue culture.  To conditionally immortalize these primary cell 
lines, we put them into co-culture with irradiated NIH 3T3 mouse fibroblasts and added a 
rock inhibitor (Y27632).  This allowed for expansion of these primary lines for further 
analysis and are now referred to as conditionally immortalized HMECs (ciHMECs).   
Our collaborator Stephanie Morin from the Schneider lab performed PCR 
characterization of these HMECs for basal epithelial markers keratin 14 (KRT14) and 
keratin 5 (KRT5), luminal epithelial marker keratin 18 (KRT18), and basal/mesenchymal 
cell marker vimentin (VIM).  Upon analysis, this characterization revealed 3 subgroups: 
one group with low expression of all markers, one large group with low expression of 
KRT18 and VIM but moderate to high levels of KRT14 and KRT5, and one with low 
expression of all keratins but high expression of VIM (Table 3.3 and Figure 3.2).  Based 
on expression of these markers, we concluded that the cells isolated from this method were 
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largely basal epithelial cells, with variable expression of KRT14 and KRT5.  This 
characterization was also performed on 4 stably immortalized HMEC lines obtained from 
other labs (MCF10A, 76N Tert, ME16C2, HME-CC), which all had low expression of 
KRT18 and VIM while 3 of 4 also had low KRT14 and KRT5.   
Further characterization of these ciHMEC lines demonstrated that some (5 of 6) 
lines retained the ability to form primary mammospheres in a limiting dilution 
mammosphere assay, indicating some cells in these populations may resemble basal 
stem/progenitor cells (Figure 3.3a-c).  Five stably immortalized HMEC lines (MCF10A, 
76N Tert, ME16C2, HME-CC, H16N2) were also tested, and 3 of 5 lines had some primary 
mammospheres (Figure 3.3a-b).  Interestingly, the estimated number of mammosphere 
forming cells (MFC) in the ciHMECs (10.6 MFC/1000 cells) was significantly higher than 
in the stably immortalized HMEC lines (2.4 MFC/1000 cells, Figure 3.3c, p < 0.05).  This 
suggests that ciHMEC culturing conditions may support the growth of basal epithelial cells 
with stem/progenitor characteristics. 
 
Measuring Estrogenic Responses in HMECs 
Because ERα positive luminal epithelial cells are lost when HMECs are plated in 
2D tissue culture conditions, we sought to use transient transfection experiments with 
estrogen receptors and an ERE reporter to measure variation in estrogen-induced responses 
in our ciHMEC cell lines.  To do this we first optimized our transient transfection protocol 
for HMECs, which we found were more sensitive to transfection media conditions than 
cancer cell lines.  HMECs cultured in clearing media (10% charcoal stripped FBS, 
10ug/mL insulin, 2mM L-Glutamine, MEM media) prior to transfections, to reduce 
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estrogenic background, were found to have higher numbers of dead floating cells and no 
successful uptake of plasmid DNA (data not shown), so this step was omitted for all future 
transfection experiments.  Two alternative transfection protocols using either 
Lipofectamine 2000 or Fugene 6 reagents were tested for optimal efficiency in HMEC cells 
(Figure 3.4).  Transfection efficiency was markedly improved with Lipofectamine 2000 
reagent compared to Fugene 6.  No luciferase readings were detected with Fugene 6 and 
significantly lower Renilla transfection control levels were observed (Figure 3.4a and b, 
respectively).  When Lipofectamine transfected luciferase values were normalized to 
Renilla, we were able to observe a significant increase in transactivation with 10nM E2, 
30uM BP3, and 10uM PP treatment in ciHMEC line 910 (Figure 3.4c).  The results of this 
experiment suggested that Lipofectamine transfection reagent was more suitable for 
transfection of ciHMEC cells, and thus was used for all subsequent experiments. 
Further optimization was performed to determine the optimal amount of ESR1 
plasmid DNA required to measure estrogenic responses in HMECs.  In 76N Tert cells, 
transient transfections were performed using ESR1 plasmid DNA levels ranging from 
0.03ug/well to 1.5ug/well while keeping ERE-luciferase reporter and renilla plasmid 
amounts consistent (Figure 3.5).  At all levels of ESR1 used, a significant increase in 
transactivation was seen in 10nM E2 treated cells compared to control (Figure 3.5a).  The 
highest amount of relative light units of luciferase was observed at 0.125ug/well ESR1 and 
decreased at higher plasmid levels.  Renilla relative light units were also greatest at 
0.125ug/well ESR1 and decreased with higher plasmid concentration, but renilla levels 
were consistent from 0.03ug/well to 0.125ug/well ESR1 (Figure 3.5b).  When normalized 
to renilla transfection control, values for all control treated wells reflected similar amounts 
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of transactivation and the same was true for all 10nM E2 treated wells (Figure 3.5c).  For 
future experiments, we decided to use 0.125ug/well ESR1; this amount of ESR1 appeared 
to be saturating. 
 
BP3 and PP are Estrogen Receptor Agonists in HMECs 
In order to determine if xenoestrogens benzophenone-3 (BP3) and propylparaben 
(PP) are agonists for ESR1 and/or ESR2 in human breast epithelial cells, we first used 3 
stably immortalized HMECs to generate dose responses to each compound.  This was 
measured using ERE-luciferase assays, where the amount of transactivation was compared 
with ESR1 only, ESR2 only, and both ESR1 and ESR2.  In all 3 lines, BP3 and PP were 
capable of transactivation with all combinations of receptors, and the level of 
transactivation increased with increasing doses (Figure 3.6).  Activity observed with both 
xenoestrogens was similar for ESR1 only and both ESR1 and ESR2 transfections, 
suggesting that with these agonists, the activity of ESR1 is not enhanced or suppressed by 
ESR2.   
BP3 transactivation with ESR1 and both receptors in the 76N Tert line reached 
approximately 60% of the activity observed with 10nM E2 treatment and ESR1 only 
transfection (Figure 3.6a, gray dotted lines indicate 10nM E2 and ESR1 activity).  In the 
other two lines, BP3 transactivation with ESR1 and both receptors reached the full activity 
seen with 10nM E2 (Figure 3.6b-c).  With ESR2 only, 10nM E2 treatment induced lower 
overall levels of transactivation; this was also observed with BP3 and PP treatment.  BP3 
treatment and ESR2 transfection reached approximately 40% of transactivation levels 
induced with ESR2 and 10nM E2 treatment (green dotted lines) in the 76N Tert and HME-
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CC lines (Figure 3.6a and c).  This level was close to 100% in the ME16C2 line (Figure 
3.6b).  Our results show that BP3 can act as an agonist for both ESR1 and ESR2 but 
generates greater activity with ESR1. 
PP induced transactivation with ESR1 alone and both receptors in the 76N Tert and 
HME-CC lines which reached approximately 80% of the level induced by 10nM E2 
treatment (Figure 3.6d and f).  The ME16C2 line was more sensitive to PP treatment, as 
the amount of transactivation reached the same levels as 10nM E2 treatment (Figure 3.6e).  
With ESR2 only, all 3 lines reached 100% transactivation levels compared to 10nM E2 and 
ESR2 transfection (Figure 3.6d-f).  Overall, this data suggests that BP3 and PP can act as 
agonists for both ESR1 and ESR2, but that most of the transactivation induced is due to 
ESR1.   
 
Limited Variation in Responses to E2, BP3, and PP in ciHMECs 
After determining that BP3 and PP were acting primarily through ESR1 in our 
immortalized HMECs, we performed a luciferase reporter screen in our ciHMEC donor 
lines to identify individuals who are more sensitive to estrogen or xenoestrogen exposure.  
Because little activity was seen with ESR2, we decided to transfect only ESR1 into these 
cell lines at saturating levels.  We also chose single saturating doses of BP3 and PP; 30 uM 
BP3 reflects the 95th percentile of exposure in pregnant women, while 10uM PP is 3-fold 
higher than the 95th percentile exposure level (Philippat et al., 2013).  We performed 
luciferase assays in a total of 11 lines, including 4 immortalized (HME-CC, 76N Tert, 
MCF10A, ME16C2) and 7 ciHMEC donor lines (Figure 3.7).  All HMEC and ciHMEC 
lines responded to E2, BP3, and PP relative to control treated wells.  This suggests BP3 
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and PP are estrogenic in ciHMEC lines.  We observed a 2.5-fold variation in response to 
E2 treatment, 2.3-fold variation to BP3, and 3.6-fold variation to PP treatment (Figure 
3.7).  Similar levels of activation were seen with most HMEC lines in response to BP3 and 
PP treatment (p > 0.05), but the 876 and 698 primary HMEC lines were more sensitive to 
BP3 than PP (P < 0.05).  The 76N Tert, MCF10A, and 569 primary HMEC exhibited 
significantly more activity when treated with E2 compared to either xenoestrogen (P < 
0.05), but the remaining 10 HMEC lines had similar activity levels with E2, BP3, and/or 
PP (P > 0.05).  The 811 line displayed a consistently lower response to E2, BP3, and PP 
compared to the other 12 HMEC lines.   
Based on the results obtained from our human breast explant model, we had 
expected to see more inter-individual variation in responses in our ciHMEC donor cell 
lines.  We hypothesized that the limited levels of variation could be due to using saturating 
levels of ESR1 or high doses of xenoestrogen treatment.  It is possible that if we had 
performed dose response curves to estrogen and each xenoestrogen in every cell line, we 
would observe differing EC50 values for each patient, reflective of differing sensitivity.  
Another possibility is that the coregulators involved in estrogen receptor signaling are 
present at very low levels in these cell lines, as it has been shown that specific coactivators 
can enhance luciferase responses in breast cancer cell lines (Wolf et al., 2007; Kong et al., 
2011).  To investigate this possibility, we checked mRNA expression of FOXA1 and 
GATA3 in our ciHMEC lines (Figure 3.8a-b).  Expression of both coactivators was 10 to 
12-fold lower than in MCF7 breast cancer cells, which may contribute to the limited 
responses in our luciferase assays.  However, more work would be needed to make this 
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conclusion. 
 
Feeder Cell Contamination in ciHMEC cultures 
While our conditional immortalization method allowed us to expand multiple donor 
primary breast epithelial cell lines for phenotypic characterization, we encountered 
difficulties working with the mouse NIH 3T3 fibroblast cell line.  Previous publications 
have described the use of irradiation or mitomycin c to halt proliferation in NIH 3T3 cells 
for use as feeder cell layers.  We also used differential trypsinization to limit the number 
of feeder cells carried over during passaging.  However, with these methods, we still 
observed NIH 3T3 feeder carry over in certain ciHMEC lines (Figure 3.9).  
Immunofluorescence staining with a vimentin antibody, which marks fibroblasts and 
mesenchymal cells, and a human specific mitochondrial antibody in 4 higher passage 
ciHMEC lines revealed 3 of 4 lines carried some amount of NIH 3T3 contamination 
(Figure 3.9d-f).  Primary HMECs, which had never been co-cultured with NIH 3T3 cells, 
were used as a negative control for detection of the contaminating mouse cells (Figure 
3.9a).  Of the 3 contaminated lines, 753 had only a few observable NIH 3T3 cells, 698 
contained approximately 50% human and 50% mouse cells, and 569 contained only a 
handful of human cells remaining (Figure 3.9d, e, and f, respectively).  Compared to 
normal NIH 3T3 cells, the contaminating cells sometimes appeared to have altered 
morphology (Figure 3.9b vs f).   
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Discussion 
Previous in vitro work using HMECs to study the normal biological responses of 
mammary epithelial cells was limited by the early senescence of HMECs in 2D culture and 
limited expansion capabilities.  Transformation with TERT, adenovirus E6/E7, Myc, SV40 
large T-antigen, ZNF217, and BMI-1 are methods which have been used to expand subsets 
of HMECs, but these methods ultimately disturb normal biological functions through loss 
of p53, retinoblastoma protein, p16INK4a, or oncogenic transformation (Wang et al., 1998; 
Dyson et al., 1989; Münger et al., 1989; Scheffner et al., 1990; Huschtscha et al., 2001; 
Nonet et al., 2001; Dimri et al., 2002; Martinez-Zapien et al., 2016; Fischer et al., 2017).  
Our main concern with using these methods to characterize inter-individual variation in 
responses to estrogen or xenoestrogens was that these biological changes may influence 
the HMECs’ responses to stimuli.  Therefore, we sought to utilize the conditional 
reprogramming method (Liu et al., 2012; Palechor-Ceron et al., 2013), or conditional 
immortalization, for expansion of our HMEC lines.  This method is thought to gradually 
reprogram the epithelial cell population but does induce TERT expression, though the 
conditional reprogramming phenotype is believed to be reversible upon removal of the 
ROCK inhibitor and feeder cells (Suprynowicz et al., 2012; Palechor-Ceron et al., 2013).  
Using this method, we expanded a subset of HMEC lines from our panel of women donors 
from the Rays of Hope Registry.  Our goal was to use this subset to characterize the 
variation in responses to estrogen and xenoestrogen treatment to determine if some women 
are uniquely sensitive to these exposures and then determine the mechanism(s) responsible.   
A recent paper by Kumar et al. used conditional immortalization to expand low 
passage cultures of HMECs for permanent immortalization with TERT to generate 
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immortalized HMEC lines from a panel of normal breast tissue (Kumar et al., 2018).  
Though this approach has the potential issue of subpopulation selection, they were able to 
preserve a small luminal cell population with ERα expression, luminal cell markers 
(FOXA1 and GATA3), and mammosphere forming capability.  Our method of HMEC 
isolation and culture promoted the growth of epithelial cells with primarily basal epithelial 
markers (Table 3.3 and Figure 3.2), but we did observe variability in the expression of 
KRT5, KRT14, KRT18, and VIM markers between donor HMECs.  These results were 
confirmed with flow cytometry for an epithelial cell marker EpCAM and Keratin 14 (data 
not shown).  The low KRT18 expression in these HMEC lines suggests that any luminal 
epithelial cell populations were lost during culturing, which agrees with other published 
results (Fridriksdottir et al., 2015; Lee et al., 2018).  This is likely due to reduced adherence 
of luminal epithelial cells (Soule and McGrath, 1986; Keller et al., 2010), slower growth 
rates compared to basal epithelial cell populations (Keller et al., 2010; Fridriksdottir et al., 
2015), increased stress responses in luminal cells (Lee et al., 2018), microenvironment 
changes (Miyano et al., 2017), or loss of differentiated phenotypes (Keller et al., 2010; 
Breindel et al., 2017). 
Consistent with previous reports that conditionally reprogrammed epithelial cells 
acquire an adult stem-like phenotype (Suprynowicz et al., 2012, 2017; Breindel et al., 
2017), we found that our ciHMECs had primary mammosphere forming cells in ultra-low 
attachment conditions (Figure 3.3) and the number of these cells was increased compared 
to spontaneous and TERT immortalized HMECs.  Of the 6 ciHMEC lines tested, 5 were 
able to form primary mammospheres, compared to only 3 of 5 stably immortalized 
HMECs.  Interestingly, though previous reports have shown MCF10A are capable of 
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forming mammospheres (Arendt et al., 2014), we did not observe mammosphere 
formation.  It is possible that the number of mammosphere forming cells in the MCF10A 
line were below our detectable limit, as others have noted their ability to form 
mammospheres is low (Qu et al., 2015). 
Although our prior work has shown significant inter-individual variation in 
response to estrogen treatment (Dunphy et al., 2020) and others have shown effects on drug 
response, cell metabolism, cytokine response, and irradiation sensitivity (Roden et al., 
2011; Snijders et al., 2012; Yard et al., 2016; Schneider et al., 2017), we only detected low 
variation between the 7 ciHMEC and 4 stably immortalized HMEC lines in response to 
estrogen or xenoestrogen treatment in our luciferase reporter assays (Figure 3.7).  There 
was up to 2.5-fold variation in response to E2 treatment, 2.3-fold variation to BP3, and 3.6-
fold variation to PP treatment.  It is possible that if we had performed dose response 
characterization on each HMEC line, we may be able to detect differences in EC50 values 
that could be more reflective of inter-individual variation.  Another alternative is that we 
could not observe greater differences between lines due to using saturating levels of ESR1 
(Figure 3.5) or low levels of estrogen receptor coactivators, including FOXA1 and GATA3 
(Figure 3.8).  Lastly, it is possible that we simply did not analyze a large enough number 
of HMECs to find the subpopulation with increased sensitivity to these compounds.   
Our results are consistent with other previous work that BP3 and PP are estrogenic 
(Schlumpf et al., 2001; Byford et al., 2002; Kerdivel et al., 2013; Schlotz et al., 2017; Majhi 
et al., 2020) and act as ligands for ERα and ERβ (Figure 3.6).  While BP3 metabolites may 
have greater affinity for ERβ (Molina-Molina et al., 2008), we observed greater affinity for 
ERα for both BP3 and PP.  Though they have potential to act as ligands for both estrogen 
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receptors, it is unclear if this would translate into a biologically relevant response.  BP3 is 
not known to induce breast cancer cell proliferation (Schlotz et al., 2017; Majhi et al., 2020) 
but can increase cell motility in long term exposure (Alamer and Darbre, 2018) and alter 
ductal formation in mammary gland development (LaPlante et al., 2018).  PP can induce 
proliferation in breast cancer cells and increases cell motility (Byford et al., 2002; Khanna 
et al., 2014; Majhi et al., 2020).  Both xenoestrogens form estrogen receptor dependent 
DNA:RNA hybrids in response to estrogen treatment, but only BP3 treatment caused DNA 
damage in estrogen treated breast cancer cells (Majhi et al., 2020).  Regardless of whether 
BP3 and PP are able to induce all or some of the biological responses induced by estrogen 
treatment, their ability to act as estrogen receptor ligands in all HMEC lines tested 
highlights their potential risk during susceptible windows of development or to those that 
may be uniquely sensitive to estrogen and xenoestrogen exposure. 
Our major concern when starting this work with ciHMEC lines was the possibility 
for contamination of mouse fibroblast feeder cells in the ciHMEC cultures.  Though it is 
well documented that irradiation of mouse 3T3 feeder cells or treatment with mitomycin-
C is sufficient to arrest cell growth (Chugh et al., 2016, 2017), our work has highlighted 
the potential for a small population of 3T3 cells to undergo phenotypic changes and become 
resistant to irradiation induced senescence (Figure 3.9).  While some ciHMEC lines tested 
were unaffected, others contained 50% or greater contamination.  Differential 
trypsinization normally removes the 3T3 population from the ciHMEC culture, but this 
irradiation resistance subpopulation is also more resistant to trypsinization.  Optimization 
of this method for future use could include fluorescent labeling of 3T3 cultures to identify 
contamination more easily, or infection with recombinant plasmid containing a 
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hygromycin phosphotransferase-thymidine kinase fusion gene to allow negative selection 
with ganciclovir.   
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Table 3.1: Donor information for primary human mammary epithelial cells 
Donor age, BMI, type of surgery, ethnicity, and parity status for all HMECs collected at 
PVLSI by Dr. Sallie Schneider and the limited donor information known about five 
previously established immortalized HMEC lines. 
 
ID Number or 
Cell Line 
Age BMI Surgery Ethnicity Parity 
563 19 26.8 
Reduction 
Mammoplasty 
Caucasian Nulliparous 
569 29 26.0 
Reduction 
Mammoplasty 
Caucasian Nulliparous 
698 48 48.9 Mastectomy Caucasian Nulliparous 
753 42 24.7 Mastectomy Caucasian Parous 
811 50 34.6 Mastectomy Caucasian Parous 
833 42 36.5 
Prophylactic 
Mastectomy 
Caucasian Parous 
847 59 16.5 Mastectomy Latina Parous 
876 44 24.8 Mastectomy Caucasian Parous 
MCF10A 36 Unknown Mastectomy Unknown Parous 
76N Tert Unknown Unknown 
Reduction 
Mammoplasty 
Unknown Unknown 
ME16C2 53 Unknown Mastectomy Unknown Unknown 
HME-CC Unknown Unknown Unknown Unknown Unknown 
H16N2 36 Unknown Mastectomy Unknown Unknown 
 
 
 
 
Table 3.2: RT-qPCR primers 
RT-qPCR primer pairs used on Mx3005P real-time PCR system.  
 
Gene Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
Keratin 14 TTC TCC TCT GGA TCG CAG TC ATG ACC TTG GTG CGG ATT T 
Keratin 5 TGC AGA CTC AGT GGA GAA GG TCC AGA GGA AAC ACT GCT TG 
Keratin 18 CAC AGT CTG AGG TTG GA GAG CTG CTC CAT CTG TAG GG 
Vimentin ACG AAG AGG AAA TCC AGG AG CAG AGA GTC AGC AAA CTT GGA 
Gata3 GAG AGA GAG ACG GAG GGA GA GTC ACC TGG GTA GCG AAG AG 
Foxa1 GGA ACA GCT ACT ACG CAG AC ATG TTG CCG CTC GTA GTC AT 
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Table 3.3: Keratin expression profiles of HMEC lines 
RT-qPCR results for keratin 14 (KRT14), keratin 5 (KRT5), keratin 18 (KRT18), and 
vimentin (VIM).  Expression is shown relative to human universal RNA from breast tissue, 
normalized to beta-actin (ACTB), and log2 transformed.  Passage number is shown for 
ciHMEC lines.  Data provided by Stephanie Morin. 
 
Cell Line KRT14 KRT5 KRT18 VIM 
563 P20 3.78 4.50 -3.32 -3.64 
569 P8 4.07 4.37 -5.06 -4.32 
698 P14 6.32 5.04 -2.94 -1.60 
753 P12 1.06 2.18 -3.18 0.32 
811 P4 4.81 4.28 -3.06 -1.43 
833 P4 2.52 2.65 -3.06 -1.94 
847 P1 -0.71 -1.51 -1.29 -1.15 
876 P6 2.04 3.40 -3.32 -1.32 
MCF10A 0.14 -2.18 -0.27 -6.64 
76N Tert -0.10 -2.84 -1.51 -2.64 
ME16C2 0.77 -1.15 -2.84 -0.22 
HME-CC 2.93 2.99 -1.65 -5.46 
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Figure 3.1: Overview of Conditionally Immortalized HMEC model 
Primary human mammary epithelial cells (HMECs) were isolated from digestion of human 
donor breast tissue samples at PVLSI and put into 2D tissue culture conditions.  For 
conditional immortalization, primary HMECs were cocultured with irradiated NIH 3T3 
mouse feeder cells in the presence of a rock inhibitor (Y27632).  This allowed expansion 
of conditionally immortalized HMECs (ciHMEC). 
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Figure 3.2: ciHMEC PCR Characterization 
Heatmap of the keratin expression profiles for HMEC lines shown in table 3.3 and 
additional HMEC lines (total of 61 lines analyzed, 51 unique HMECs and 4 immortalized 
HMEC lines).  Heatmap was created from log2 transformed data using R studio with a 
scale of 5.  Hierarchical clustering was performed.  Yellow indicates high expression, black 
indicates average expression, and blue indicates low expression relative to universal human 
breast RNA. 
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Figure 3.3: ciHMEC Lines Can Form Primary Mammospheres 
Primary mammosphere forming assays were used to determine the number of 
mammosphere forming cells (MFC) in stably and conditionally immortalized HMEC lines. 
A preliminary mammosphere forming assay (a-b) was used to select HMEC lines for 
further analysis. Cells were cultured in ultra-low attachment 96-well plates for 7 days. (a) 
Representative images of mammosphere formation in three HMEC lines (563, HME-CC, 
and 876). (b) Examples of no mammosphere formation in three HMEC lines (76N TERT, 
MCF10A, 847). (c) Extreme limiting dilution assays (ELDA) were performed to determine 
the number of MFC in each HMEC line. Only lines that had mammosphere in preliminary 
mammosphere forming assay were tested.  Error bars represent 95% confidence interval. 
Scale bars indicate 100uM.  Data provided courtesy of Dr. Gat Rauner. 
  
a 
b 
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Figure 3.4: Comparison of Lipofectamine 2000 and Fugene 6 reagents 
ERE-luciferase results for ciHMEC 910 comparing the efficiency of lipofectamine 2000 
and fugene 6 transfection reagents.  Relative light units for (a) luciferase and (b) renilla 
transfection control showed higher readings for lipofectamine.  No luciferase readings were 
detected for fugene transfected cells.  (c) Ratio of luciferase to renilla, relative to 
lipofectamine control treated cells. 
a 
b 
c  
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Figure 3.5: Increasing amounts of ESR1 DNA in ERE-luciferase assays 
ERE-luciferase assay performed with 76N Tert cells with increasing amounts of ESR1 
plasmid DNA.  Relative light units shown for (a) luciferase and (b) renilla transfection 
control.  (c) Ratio of luciferase to renilla shows saturating levels of activity at 0.125ug of 
ESR1, which was used for further experiments.  With higher amounts of DNA, decreases 
in both luciferase and renilla were observed. 
  
a 
b 
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Figure 3.6: Benzophenone-3 and propylparaben dose response curves in HMECs 
ERE-luciferase assay dose response curves for (a-c) benzophenone-3 (BP3) and (d-f) 
propylparaben (PP) in three stably immortalized HMEC lines: 76N Tert, ME16C2, and 
HME-CC.  Activity is shown relative to transactivation with 10nM E2 and ESR1 (gray 
lines).  Blue lines indicate ESR1 transfection, red for ESR2, and purple for both receptors.  
Green dotted lines indicate transactivation with 10nM E2 and ESR2. 
  
a b 
c 
d e 
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Figure 3.7: Limited variation in response to E2, BP3, and PP in HMECs 
Four stably immortalized (HME-CC, 76N Tert, MCF10A, ME16C2) and eight 
conditionally immortalized HMEC lines were transfected with ESR1 for luciferase assays 
with control or single doses of E2, BP3, or PP.  10nM E2, 30uM BP3, and 10uM PP 
induced significant transactivation compared to control in all cell lines (p < 0.05).  Parity 
status and age are shown for ciHMECs.  Activity is shown relative to experimental control 
for each individual line.  Luciferase readings were normalized to renilla transfection 
control.   
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Figure 3.8: FOXA1 and GATA3 expression in ciHMECs 
RT-qPCR analysis of FOXA1 and GATA3 expression in seven ciHMEC lines, with MCF7 
cells as a comparison.  Gene expression is not normalized. 
  
a 
b 
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Figure 3.9: NIH 3T3 contamination in ciHMEC lines 
Immunofluorescence staining for vimentin (red), a marker of fibroblasts and epithelial 
cells, and a species specific human mitochondrial marker (green), which only labels human 
cells.  Differential trypsinization was performed before plating cells for staining. 
Representative images of (a) a primary HMEC line, which has never been cocultured with 
NIH 3T3 cells, shown in (b).  Two ciHMEC lines tested had low or very low carryover of 
mouse feeder cells (c-d), one line had significant levels of contamination (e), and one line 
had almost no human cells remaining (f).  Passage numbers indicated.  Scale bars are 
100uM. 
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CHAPTER 4 
ESTROGEN-INDUCED RESPONSES IN INDUCIBLE ERΑ HMECS 
 
Introduction/Rationale 
Early studies examining the effects of estrogen in the human breast utilized breast 
biopsies from donors during different stages of the menstrual cycle.  However, these studies 
were rarely able to follow individual donors across menstrual stages and comparisons had 
to be made using pooled population data.  As the levels of endogenous estrogen (Dall and 
Britt, 2017) and responses to estrogen (Dunphy et al., 2020) vary among women, a better 
model for studying estrogen signaling in the human breast was needed.   Breast cancer cell 
lines, such as T47D and MCF7 cells, have been used extensively to study the effects of 
estrogen receptor signaling, but they are not reflective of the normal breast epithelium.  
These cancer cells acquire mutations during carcinogenesis and express higher levels of 
ERα than normal breast epithelium, which has heterogenous ERα expression (Battersby et 
al., 1992; Söderqvist et al., 1993; Gabrielson et al., 2016).  Another key difference is that 
breast cancer cell lines use autocrine signaling pathways to induce proliferation after 
estrogen treatment (Tan et al., 2009).  In normal breast epithelium, paracrine signaling is 
hypothesized to be responsible for estrogen-induced proliferation as proliferating cells do 
not express ERα (Clarke et al., 1997; Russo et al., 1999; Shoker et al., 1999b).  ERα positive 
proliferating cells are only observed in hyperplasia and carcinoma samples (Shoker et al., 
1999b).  Secretion of growth factors including AREG, FGF, and EGF are required for 
mediating ERα induced proliferation through paracrine signaling (Ciarloni et al., 2007; 
Fillmore et al., 2010; Harrison et al., 2013).  For these reasons, breast cancer cell lines are 
not an ideal model for studying estrogen-induced responses in the normal breast. 
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Primary human mammary epithelial cell (HMEC) models are a cell model which is 
reflective of the normal breast, but these were originally limited by senescence and loss of 
ERα in 2D culture.  Multiple methods to bypass HMEC senescence were developed 
including transformation with HPV E6 and E7, human telomerase (TERT), Myc, SV40 
large T-antigen, zinc-finger protein ZNF217, and BMI-1.  It is known, however, that loss 
of p53, retinoblastoma protein, and p16INK4a occurs as a result of these transformations 
(Wang et al., 1998; Dyson et al., 1989; Münger et al., 1989; Scheffner et al., 1990; 
Huschtscha et al., 2001; Nonet et al., 2001; Dimri et al., 2002; Martinez-Zapien et al., 2016; 
Fischer et al., 2017).  Anchorage independent growth, reduced apoptotic responses, and 
altered gene expression resulting from these methods also suggest transformation can occur 
(Wang et al., 1998; Thibodeaux et al., 2009).  However, these HMEC models are still one 
of the better options for studying normal breast biology.   
As an alternative to stable immortalization, another model called conditional 
reprogramming was developed involving expansion of primary HMECs by treatment with 
a rho-associated protein kinase (ROCK) inhibitor and co-culture with irradiated mouse 
fibroblasts (Liu et al., 2012; Palechor-Ceron et al., 2013).  Studies have suggested that 
conditionally immortalized HMECS (ciHMECs) created with this method represent a stem 
like epithelial population (Suprynowicz et al., 2012, 2017).  Other culture methods for 
HMECs have also noted to result in loss of differentiation markers (Breindel et al., 2017).  
One group has reported successful use of the ciHMEC method to expand ERα positive 
luminal epithelial cells, but this population decreases during passaging (Jin et al., 2017).  
Our experience with this method has proven that feeder cell contamination is a large 
potential issue.  We also have found that stably immortalized cells appear to behave 
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similarly to ciHMECs in reporter assays of estrogen-induced transactivation.  Others have 
used a combination of conditional reprogramming and Tert immortalization to obtain ERα 
positive HMECs (Kumar et al., 2018).   
More recent models of the human breast have been developed which retain ERα 
positive luminal epithelial cells, but these have their own limitations.  Recent studies have 
identified protocols for development of 3D breast organoids from primary HMECs and 
cancerous breast tissue (Sokol et al., 2016; Sachs et al., 2018; Djomehri et al., 2019; Florian 
et al., 2019; Goldhammer et al., 2019).  Breast organoids contain luminal and basal 
epithelial cell populations, can organize into ductal structures, retain the ERα positive cell 
population, and are responsive to hormone treatment.  We have found, however, that 
propagation of breast organoids from normal breast tissue is limited as they can only be 
expanded for a short number of passages.  Another model, human breast explants, can also 
only be maintained for a limited amount of time (up to 4 weeks) but provide similar benefits 
to breast organoids.  Breast explants from normal tissue retain all breast cell types, tissue 
morphology, ERα expressing luminal epithelial cells, and response to hormone treatment 
(Zhuang et al., 2003; Eigeliene et al., 2006, 2008, 2012, 2016; Tanos et al., 2013; Dunphy 
et al., 2020).  Ultimately, the use of breast explant models is limited by the amount of tissue 
obtained by donors and therefore only a finite number of experiments can be performed.   
Due to current limitations of breast organoid and explant models, HMECs are still 
one of the better models for studying human breast biology.  However, even after bypassing 
the senescence block to expand HMEC populations, the ERα expressing population of 
epithelial cells is lost over time (Fridriksdottir et al., 2015; Jin et al., 2017; Lee et al., 2018).  
Expression of ERα is limited to luminal epithelial cells in the normal breast.  Luminal 
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epithelial cells make up 10-25% of cells isolated from human breast tissue (Garbe et al., 
2009) but may be more prevalent in breast tissue of older women (Lee et al., 2015).  Many 
have hypothesized that the ERα positive luminal cell population is lost in 2D culture due 
to reduced adherence (Soule and McGrath, 1986; Keller et al., 2010), faster growth of basal 
epithelial cells (Keller et al., 2010; Fridriksdottir et al., 2015), triggering stress responses 
in luminal epithelial cells (Lee et al., 2018), changes to the microenvironment (Miyano et 
al., 2017), or epigenetic reprogramming that results in the loss of the differentiated 
phenotype (Keller et al., 2010; Breindel et al., 2017).  With optimal conditions, ERα 
positive luminal epithelial cells are still lost in early passages and the number of passages 
is ultimately limited by the original percentage present (Lee et al., 2018).  This means that 
HMEC models primarily represent basal epithelial cell populations, and in order to study 
the effects of estrogen in these cells we have to introduce exogenous ERα expression. 
In order to study ERα induced responses in HMECs, many have tried to introduce 
expression of this receptor with mixed results.  Previous studies have shown that 
overexpression of ESR1 in the ER negative breast cancer line MDA-MB-231 is not able to 
induce normal estrogen-induced proliferation (Garcia et al., 1992; Lazennec and 
Katzenellenbogen, 1999) and instead causes activation of anti-proliferative pathways 
through aberrant cell cycle regulation (Moggs et al., 2005).  Additionally, while exogenous 
expression of ESR1 in MDA-MB-231 cells can induce target gene TFF1 expression, PGR 
upregulation is not restored (Lazennec and Katzenellenbogen, 1999; Moggs et al., 2005).  
In MCF10A cells, exogenous expression of ESR1 has been shown to lead to a modest 
increase in proliferation with E2 treatment when EGF is removed from media (Pilat et al., 
1996; Abukhdeir et al., 2006; Pugazhendhi and Darbre, 2010).  Additionally, expression 
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of estrogen receptor targets genes TFF1 and PGR was increased by E2 treatment in 
MCF10A cells (Abukhdeir et al., 2006).  These studies illustrate that in breast cancer and 
normal HMEC cell lines, restored expression of ERα alone is not sufficient to restore 
estrogen responsiveness.   
Exogenous expression of ERα may not be able to induce normal biological 
responses to estrogen for a number of reasons.  For example, in ERα negative basal breast 
cancer cells, epigenetic silencing of estrogen receptor target genes, including PGR (Leu et 
al., 2004) is present, which may explain why exogenous expression does not impart normal 
E2 responses.  Abnormal responses induced in breast epithelial cells during overexpression 
of ERα may also be due to prolonged high expression of this receptor.  MCF7 breast cancer 
cells demonstrate estrogen independent growth and expression of ER target genes with 
overexpression of exogenous ERα (Tolhurst et al., 2011).  Overexpression of ERα in 
MDA-MB-231 breast cancer cells only results in E2-induced proliferation and target gene 
response when used in combination with overexpression of other regulatory factors, 
including forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA3) (Kong et al., 
2011).  Expression of ESR1, FOXA1, and GATA3 in E2 treated MDA-MB-231 cells results 
in a gene expression profile more like E2 treated MCF7 cells, though these expression 
profiles are not identical.  In HMECs, estrogen- induced proliferation can be induced when 
exogenous ESR1 is combined with exogenous expression of Polycomb-group gene BMI1 
(Duss et al., 2007).  Additionally, transduction with ESR1 and BMI1 in HMECs induces 
expression of target genes GREB1 and PRLR but does not affect PGR or TFF1 expression.  
These results demonstrate that even expression of these factors in combination does not 
fully induce estrogen regulated gene response.  A recent study in mouse mammary 
 106 
epithelium demonstrated that forced expression of ERα is lost over time, suggesting either 
silencing of ERα or selection against ERα positive epithelial cells (Cornelissen et al., 
2019).  Contrary to the results of Kong et al. in MDA-MB-231 breast cancer cells, 
Cornelissen et al. found that exogenous expression of ERα combined with FOXA1 and 
GATA3 was not sufficient to induce estrogen receptor target gene expression (Areg and 
Ccnd1) or estrogen-induced proliferation in mouse mammary epithelial cells.   
The goal of this study was to develop inducible ERα HMEC lines and utilize this 
model to study factors which may enhance or restrict estrogen signaling and sensitivity to 
estrogen.  We used 4 stably immortalized HMEC lines: 76N Tert (Band and Sager, 1989; 
Shamanin and Androphy, 2004), MCF10A (Soule et al., 1990), HME-CC (Troester et al., 
2004), and ME16C2 (Troester et al., 2004).  The 76N Tert, HME-CC, and ME16C2 HMEC 
lines were immortalized by expression of telomerase (TERT).  The MCF10A line is 
spontaneously immortalized, likely through the loss of p16INK4A, p14ARF, and 
p15INK4B tumor suppressors (Iavarone and Massague, 1997).  All 4 HMEC lines are 
considered basal epithelial cell lines with expression of KRT5 and KRT14 (Prat et al., 
2013), although some groups have shown the 76N Tert and MCF10A lines also have some 
expression of luminal epithelial markers KRT8 and KRT18 (Zhao et al., 2010; Qu et al., 
2015).   
In order to investigate estrogen-induced responses in our 4 HMEC lines and 
examine the role of estrogen receptor coregulators, we developed a doxycycline inducible 
ESR1 expression construct using an inducible lentiviral backbone.  We hypothesized that 
ERα induced responses among individuals may be influenced by individual expression of 
estrogen receptor coregulators.  Induced expression of ESR1 with 100ng/mL of 
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doxycycline was sufficient to increase E2-induced transactivation in luciferase reporter 
assays.  Although 2 of our 4 inducible ERα HMEC showed even higher transactivation 
levels with increased doses of doxycycline, we limited our dose to 100ng/mL to avoid 
adverse metabolic effects of doxycycline (Ahler et al., 2013).  This dose of doxycycline 
was sufficient to induce ERα protein levels comparable to MCF7 cells in all 4 lines.  With 
induced expression of ERα, 3 of our 4 HMEC lines demonstrated modest proliferation with 
estrogen treatment.  Expression of estrogen receptor target genes AREG and PGR was 
unregulated by estrogen treatment, however.  Conditioned media from 2 iERα HMEC lines 
suggests that the estrogen-induced growth in these HMEC lines is due to cell intrinsic 
factors, supporting the idea that estrogen receptor coregulators may play an important role.  
However, expression of FOXA1 and GATA3 did not correspond with E2-induced 
proliferation in our 4 HMEC lines.  This work suggests FOXA1 and GATA3 are not 
sufficient to restore estrogen responses in HMECs and that there may be other coregulators 
or other cell intrinsic factors influencing estrogen sensitivity. 
 
Materials and Methods 
pIND-ESR1 Construct Design 
An N-terminal FLAG tagged inducible ESR1 expression construct was generated 
using the pINDUCER14 vector (Meerbrey et al., 2011).  First, FLAG sequence was 
amplified from pFLAG-CMV-2 (Andersson et al., 1989) using forward primer 5’-
ATACCGGTACCATGGACTACAAAGACGATGACGAC-3’ and reverse primer 5’-
TCGACCGGTACGCGTGCGATCGCTGAATTCGCGGCAAG-3’.  This sequence was 
cleaned using the Monarch PCR and DNA Cleanup Kit (NEB #T1030) and ligated into 
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pINDUCER14 after digestion of both plasmids with AgeI, dephosphorylation with shrimp 
alkaline phosphatase (NEB #M0371S), and extraction from gel electrophoresis (DNAland 
Scientific #GP1001).  Sequencing was performed to confirm insertion. 
ESR1 coding sequence was amplified from pIRES-hrGFPII-ESR1 containing the 
ESR1 coding sequence (Open Biosystems #MHS6278-211691051) in the pIRES-hrGFPII 
vector (Stratagene #240157).  ESR1 was amplified with forward primer 5’-
GCAGAAATGACCATGACCCTCCACACCAAAGC-3’ and reverse primer 5’- 
TAAACGCGTTCAGACCGTGGCAGGGAAACCCT-3’.  ESR1 was ligated into 
pINDUCER14-FLAG by digestion with EcoRI and MluI and cleaned as described above.  
Two linker sequences were inserted between FLAG and ESR1 to keep the sequence in 
frame (Linker A: 5’-AATTGCGCGATCGCGG-3’ and Linker B: 5’-
AATTCCGCGATCGCGC-3’) .  Sequencing of the final construct (pINDUCER14-FLAG-
ESR1, or pIND-ESR1) confirmed insert orientation, all inserts were in frame, and that the 
ESR1 sequence was identical to the Homo Sapiens ESR1 gene (primers: forward 5’- 
CGGTGGGAGGCCTATATAAG-3’, reverse 5’- ACTTATATACGGTTCTCCCC-3’).  
pIND-ESR1 expresses a constitutive GFP reporter and tetracycline inducible ERα with N-
terminal FLAG tag.  Cloning was performed by Puneet Singh in the AMB program. 
Cell Culture 
76N Tert, MCF10A, ME16C2, and HME-CC cells were grown in F-media: DMEM 
-pyruvate (Gibco #11965-092), Ham’s F12 (Gibco #11765-054), 5% FBS, 250ng/mL 
hydrocortisone (Sigma #H4001), 10ng/mL human epidermal growth factor (Tonobo 
Biosciences #21-8356-U100), 8.6ng/mL cholera toxin (Millipore Sigma #227035), 10 
ug/mL human insulin (Sigma #I9278-5ML), and 1X antibiotic/antimycotic (Caisson Labs 
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ABL02-100ML).  239T cells were cultured in DMEM:F12 (Sigma #D8900) with 10% 
FBS, 15ug/mL gentamycin (Gibco #15750-060), and 1X antibiotic/antimycotic.  T47D 
cells were grown in DMEM:F12 supplemented with 10% FBS, 15ug/mL gentamycin, 
2mM L-Glutamine, and 1X antibiotic/antimycotic and cleared in 10% CSS, 2mM L-
Glutamine, 10ug/mL human insulin, and MEM media for 48-72 hours prior to experiments.  
All cells were incubated at 37˚C with 5% CO2 and passaged every 2-3 days. 
Generation of inducible ERα HMEC lines 
 293T cells were lifted with 0.05% trypsin and plated in 60 mm tissue culture dishes 
at 2.5x106 cells/dish and left overnight.  Transfection was performed next day using 3.5ug 
pIND-ESR1, 3ug psPAX2 (Addgene #12260, gag, pol, and rev packaging vector), and 2ug 
pMD2.G (Addgene #12259, vsv-g packaging vector) in antibiotic free media with 
Lipofectamine 2000 (Invitrogen).  After 24 hours, media was refreshed and replaced with 
293T growth media.  At 48 and 54 hours post initial transfection, viral media was collected 
and filtered using a 0.45-micron filter (Corning #431220) and added to HMEC lines in a 
1:1 ratio with F-media twice, 6 hours apart.  After 24 hours, viral media was replaced with 
F-media.  FACS was performed using pooled HMECs in 1% FBS/PBS by selecting for 
GFP positive cells using FACSAria II (Becton-Dickinson).  Uninfected parental HMECs 
were used as a negative control to set background fluorescence. 
Cell Treatments 
Control treatment media consisted of MEM media (51200-038, Gibco), 5% 
charcoal-dextran stripped serum (FB-04, Omega Scientific), and 2mM L-glutamine 
(SH30034.01, Hyclone). 10 mM 17β-estradiol (E2758, Sigma-Aldrich) stock prepared in 
ethanol was diluted to prepare E2 treatment media, and 10mM ICI (Tocris #1047) in 
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ethanol was used to prepare ICI treatment media.  Doxycycline was added to treatment 
media at 100ng/mL except in dose response experiments.  Alamar blue proliferation assay 
control treatment media was the same as above with the addition of 10ug/mL human 
insulin. 
ERE-Luciferase Assays 
HMECs were plated in 24 well tissue culture plates at 1 x 105 cells/well in F-media. 
After an overnight incubation, growth media was replaced with 0.3 mL/well Opti-MEM 
reduced serum media (11058-021, Gibco).  Plasmid DNA and Lipofectamine 2000 reagent 
(11668019, ThermoFisher) were diluted in Opti-MEM media before adding 200 µL/well. 
Uninfected cells were transfected with 0.125 µg of pIND-ESR1, 1.5 µg of 3X ERE-TATA-
Luciferase reporter, and 0.02 µg pRL-CMV Renilla plasmid using Lipofectamine 2000 
(Invitrogen).  iERα HMECs were infected with 3X ERE-TATA-Luc and Renilla.  After 6 
hours of transfection, transfection media was replaced with 0.5 mL of control media.  The 
next morning, treatment media containing 0-200ng/mL doxycycline was added.  Promega 
Dual Luciferase Reporter Assay was used to perform luciferase assays (E1910, Promega).  
Cells were lysed in 1x Passive Lysis Buffer after 24-hour treatment and lysates stored at -
20°C until reading.  Luciferase and Renilla activity in lysates were determined by using 
the Polar Star Optima plate reader (BMG Labtech).  Luciferase values for each well were 
normalized to the amount of Renilla activity. 
Western Blot for ERα 
Cells were lysed in ice cold RIPA lysis buffer [50 mM Tris–HCl pH 8.0, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 1% Sodium deoxycholate, 0.1% SDS, 1% protease 
inhibitors (Sigma-Aldrich #P8340), 1% phosphatase inhibitor #2 (Sigma-Aldrich #P5726), 
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and 1% phosphatase inhibitor #3 (Sigma-Aldrich #P0044)].  Lysates were centrifuged at 
13,000 rpm for 15 minutes at 4˚C to remove cellular debris.  BCA protein assay was 
performed to quantify protein concentration (Thermo Scientific #23225).  Equal amounts 
of protein (25ug or 28ug, as indicated) were separated using SDS-PAGE on 10% 
acrylamide gels under denaturing conditions and blotted onto PVDF membrane (Millipore 
#IPVH00010).  Blocking was performed using 5% nonfat dry milk in TBST (10mM Tris-
HCl pH 7.5, 150mM NaCl, 0.05% tween-20) for 1 hour.  Blots were incubated with 1:100 
anti-ERα (Abcam [Sp1] #ab16660, Lot #GR3202692-2) overnight at 4˚C.  During 
optimization, other antibodies for ERα were also tested: MC-20 (1:500 Santa Cruz #sc-
542, Lot #H0415), F-10 (1:200 Santa Cruz #sc8002, Lot #D0708), and C1355 (1:1000 
Millipore Sigma #06-935, Lot #3169865).  See Table 4.1 for antibody information. 
The next day, blots were washed 3 times with TBST and then incubated for 1 hour 
with HRP-conjugated secondary antibody (1:5000, GE Healthcare #NA934V).  Bands 
were detected using enhanced chemiluminescence solution and imaged on G-box 
(Syngene).  The blots were washed with TBST and incubated with anti-β actin (1:5000, 
Sigma #A1978, or Cell Signaling #4967 [for F-10 blot]) overnight at 4˚C.  Washing, 
secondary antibody incubation (1:5000, GE Healthcare #NA931C), and detection were 
performed as described above.  Expected molecular weights were 67 kDa for ERα and 42 
kDa for β actin. 
Alamar Blue Proliferation Assay 
Cells were plated in 5% CSS, 2mM L-Glutamine, 10ug/mL insulin, and MEM 
media at 4000, 7000, or 10000 cells per well on five 96-well plates (one for each day), with 
7 replicates per treatment and one empty row for a blank.  The next day, treatment media 
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was added (control, 10nM ICI, 10nM E2) diluted in 5% CSS, 2mM L-Glutamine, 10ug/mL 
insulin, and MEM media.  Each day, Alamar blue reagent was added (final concentration 
10%) and plates were read 4, 8, and 24 hours after addition.  BioTek Synergy 2 plate reader 
(BioTek) readings were performed at 570nm and 600nm.  Media was refreshed on day 3.  
Plates were read for 5 days unless cells appeared confluent.  Percent Alamar blue reduction 
was calculated using the Alamar blue protocol (DAL1100, Invitrogen). 
Conditioned Growth Media 
 HMECs were plated at 1.6x106 cells/T75 in 5% CSS, 2mM L-Glutamine, 10ug/mL 
insulin, and MEM media.  T47D cells were plated at 1.2x106 cells/T75 after clearing in 
10% CSS, 2mM L-Glutamine, 10ug/mL insulin, and MEM media for 48-72 hours.  The 
next day, treatment media was added (control, 10nM ICI, 10nM E2) diluted in 5% CSS, 
2mM L-Glutamine, 10ug/mL insulin, and MEM media.  48 hours after treatment, media 
was collected and replaced with fresh media.  Conditioned media was filtered with a 0.2-
micron syringe filter, diluted 1:1 in fresh media, and used to treat cells in proliferation 
assays.  After an additional 48 hours, this process was repeated, and conditioning cells were 
discarded.   
RT-qPCR   
RNA isolation was performed using TRIzol according to manufacturer’s 
recommendation (15596018, ThermoFisher Scientific).  cDNA was synthesized using 1 ug 
of RNA with the Protoscript II First Strand cDNA synthesis kit (E6560L, New England 
Biolabs).  RT-qPCR was performed in a thermocycler (CFX96 Real-Time thermocycler, 
BioRad).  See Table 4.2 for primer sequences.  Expression is relative to an inter-run 
calibrator (IRC) consisting of pooled cDNA from a subset of human breast tissue samples. 
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Results 
pIND-ESR1 Construct is Functional in HMECs 
To create HMEC lines with inducible ERα expression, a doxycycline inducible 
ESR1 expression vector was created using the pINDUCER14 vector (Meerbrey et al., 
2011) and the Homo sapiens ESR1 coding sequence with an N-terminal FLAG tag, referred 
to as pIND-ESR1 (Figure 4.1).   This construct contains an internal ribosome entry site 
(IRES), which drives constitutive GFP expression (Figure 4.2).  A human EF1-α promoter, 
from EEF1A1, drives expression of a reverse tetracycline-transactivator (rtTA), which will 
bind to doxycycline (Dox) when present and activate the tetracycline response element 
(TRE2) to induce expression of FLAG-tagged ESR1.  To determine if this construct was 
functional, we first performed transient transfection into the 76N Tert HMEC line and 
performed a luciferase reporter assay (Figure 4.3a-c).  After 24-hour treatment with E2, 
there was a significant 3-fold increase in transactivation in the cells transfected with pIND-
ESR1 (p < 0.05), which was not observed in cells without the receptor (ERE reporter only 
controls).  While there was a significant 1.8-fold increase in activity with E2 treatment in 
the cells without induced ESR1 expression (no Dox), there was a larger significant increase 
when 100ng/mL of doxycycline was added to induce ESR1 expression (p < 0.05).  This 
suggested that the construct is indeed functional, but that there may be low levels of leaky 
expression in transient transfection experiments. 
 
Generation of iERα HMEC lines 
We next sought to generate 4 HMEC lines with inducible ESR1 expression (iERα) 
using the pIND-ESR1 vector.  After lentiviral infection, each HMEC line was pooled and 
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FACS sorting was used to isolate populations which successfully incorporated pIND-ESR1 
and therefore expressed GFP constitutively (Figure 4.4, Figure 4.6, Figure 4.8, Figure 
4.10).  Each HMEC line was also checked post FACS to determine the percentage of GFP 
expressing cells, and these lines were called 76N Tert-ESR1, MCF10A-ESR1, ME16C2-
ESR1, and HME-CC-ESR1 (Figure 4.5, Figure 4.7, Figure 4.9, Figure 4.11).  The 76N 
Tert-ESR1 were 90% GFP positive, MCF10A-ESR1 were 70% positive, ME16C2-ESR1 
were 99% positive, and HME-CC-ESR1 were 90% positive.  These 4 HMEC lines are our 
iERα HMECs.   
 
Luciferase Reporter Assays in iERα HMECs 
After generating the four iERα HMEC lines, we performed luciferase assays to test 
the function of the inducible ESR1 with increasing concentrations of doxycycline (Figure 
4.12 through Figure 4.14).  For all 4 iERα HMECs the amount of transactivation with 
10nM E2 treatment was similar for each dose of doxycycline, except 0ng/mL.  A 
significant dose dependent increase was observed at higher doses of doxycycline for the 
MCF10A-ESR1 and HME-CC-ESR1 lines (Figure 4.13 and Figure 4.14, p < 0.05), but 
this was not present in the other 2 lines.  In the MCF10A-ESR1 and ME16C2-ESR1 lines, 
there was significant activation upon treatment with E2 with 0ng/mL Dox, suggesting there 
may be leaky expression of ESR1 in these cell lines (Figure 4.13 and Figure 4.15, p < 
0.05).  This was not present in the 76N Tert-ESR1 and HME-CC-ESR1 lines (Figure 4.12 
and Figure 4.14, p > 0.05).  In the MCF10A-ESR1 line, the level of transactivation with 
leaky receptor expression and E2 treatment was not significantly different from 100ng/mL 
or 150ng/mL with E2 treatment after Renilla normalization (p > 0.05), but the raw 
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luciferase readings were significantly lower (Figure 4.13a and c, p < 0.05).  Renilla 
readings were significantly lowered in the 0ng/mL doxycycline and E2 treated cells, which 
caused discrepancy between the normalized and raw data (Figure 4.13b, p < 0.05).  
Similarly, the ME16C2-ESR1 line had significantly lower renilla values for cells treated 
with any dose of doxycycline and 10nM E2 (Figure 4.15b, p < 0.05).  There was significant 
background activity in the ME16C2-ESR1 cells treated with control media and any dose of 
doxycycline.  This background activity is not due to normalization, as the raw luciferase 
values were significantly higher than the no dox treated control cells (Figure 4.15a).   
In order to compare activity between these 4 HMEC lines, we set transactivation 
relative to the 76N Tert-ESR1 cells.  When activity for all HMECs was set relative to the 
76N Tert-ESR1 line, transactivation was similar in the 76N Tert-ESR1 and HME-CC-ESR1 
lines, slightly lower in the MCF10A-ESR1 line, and higher in the ME16C2-ESR1 line 
(Figure 4.16 and Figure 4.17).  However, because the MCF10A-ESR1 and ME16C2-ESR1 
had decreases in renilla readings with doxycycline and E2 treatment, we decided to 
compare fold change for each cell line in raw luciferase values, renilla values, and 
normalized luciferase values.  In the 76N Tert-ESR1 line, the normalized fold change with 
doxycycline and E2 treatment compared to control was 5 to 8-fold (Figure 4.18a) and was 
similar in the raw luciferase values (Figure 4.18b), which was expected because the renilla 
values remained unchanged.  The MCF10A-ESR1 line had a normalized fold change of 3 
to 5.6-fold (Figure 4.19a), which was like the fold change in raw luciferase values for the 
doxycycline treated cells (Figure 4.19b).  The increase in transactivation observed in the 
uninduced cells treated with E2 was skewed by the drop in renilla values, as the fold change 
in raw luciferase values was 1.8 compared to 2.7 in the normalized values.  This suggests 
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that there is a small increase in activity in the MCF10A-ESR1 cells with doxycycline 
treatment to induce ESR1, though the leaky expression is still present.  The HME-CC-ESR1 
cells had a 3 to 5-fold increase in activity with Dox and E2 treatment and, similarly to the 
76N Tert-ESR1 cells, this did not differ when comparing the normalized fold change 
(Figure 4.20a) and raw luciferase values (Figure 4.20b).   
Lastly, in the ME16C2-ESR1 cells the normalized fold change in cells treated with 
doxycycline and E2 was 37 to 60-fold (Figure 4.21a) compared to 23 to 40-fold in the raw 
luciferase values (Figure 4.21b), indicative of the effects of lowered renilla values.  
Interestingly, the uninduced ME16C2-ESR1 cells had the highest fold change in both 
normalized and unnormalized readings (11-fold for both).  This is likely because in the 
doxycycline treated cells, the control treatment had significant background activity which 
was not observed in the uninduced cells (Figure 4.15).  This background activity was 
reduced with 10nM ICI treatment, which suggests that there was a small amount of 
estrogenic activity in the control treated cells.  This data suggests that the ME16C2-ESR1 
cells are highly sensitive to E2 treatment in luciferase reporter assays, 76N Tert-ESR1 and 
HME-CC-ESR1 are approximately equal in response, and the MCF10A-ESR1 cells may 
be less sensitive.   
 
ERα Protein Expression in iERα HMECs 
To check if ERα protein was expressed in the iERα HMEC lines, western blot 
analysis was performed.  Antibody optimization was performed using a total of 4 anti-ERα 
antibodies: mouse monoclonal F-10, rabbit monoclonal MC-20, rabbit monoclonal Sp1, 
and rabbit polyclonal C1355.  MCF7 cell lysates were used as a positive control and 
parental 76N Tert lysates for a negative control in blots to examine ERα expression in 76N 
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Tert-ESR1 lysates with 100ng/mL Dox or 200ng/mL Dox.  The expected molecular weight 
for ERα was 67 kDa.  MC-20 and C1355 antibodies detected bands in all samples, 
including the negative control (Figure 4.22b and d).  The MC-20 antibody detected two 
bands between 50 kDa and 75 kDa, while the C1355 antibody detected 3 bands in the 76N 
Tert lysates and 2 bands in the MCF7 lysate ranging from 37 kDa to 75 kDa.  The F-10 
antibody also detected 2 bands in the MCF7 lysate and 76N Tert-ESR1 lysates, one around 
75 kDa and one between 37 kDa and 50 kDa (Figure 4.22a).  Interestingly, the larger 
protein band was not detected in the 76N Tert parental lysate.  The Sp1 antibody appeared 
to be the most specific for ERα, as only one band was detected, and this band was absent 
in the 76N Tert parental lysate (Figure 4.22c).  Incubating these blots with anti-β-actin 
antibody confirmed protein was loaded evenly (Figure 4.23).  For all future ERα westerns, 
the Sp1 antibody was used.  It is likely that the other ERα antibodies were demonstrating 
nonspecific binding.   
Next, each of our 4 iERα HMEC lines was examined for ERα protein expression.  
In all 4 lines, ERα protein was detected upon doxycycline treatment and was not detected 
in the absence of doxycycline (Figure 4.24).  Therefore, if any of the lines have leaky ESR1 
expression (as indicated in luciferase assays), it does not lead to detectable protein levels.  
Quantification of the ERα detected in these 4 lines, after normalization to β-actin, revealed 
that 10nM E2 treatment does not appear to downregulate ERα expression in these cell lines 
(Figure 4.25, Figure 4.26, Figure 4.27, and Figure 4.28).  76N Tert-ESR1, MCF10A-
ESR1, and HME-CC-ESR1 appear to have ERα levels approximately equal to that in MCF7 
cells with 100ng/mL doxycycline treatment.  The ME16C2-ESR1 line may have more ERα 
than the MCF7 cells (Figure 4.24 and Figure 4.28), but this would need to be confirmed 
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with more replicates of MCF7 cell lysates.  These results indicated that all 4 iERα HMECs 
express ERα proteins at levels which could carry out estrogen-induced responses. 
 
Estrogen-Induced Proliferation and ERα Target Gene Responses 
After confirmation that the 4 iERα HMECs produce ERα protein, we next sought 
to determine if this induced ERα could produce a biological response.  In breast cancer cell 
lines and normal mammary gland epithelial cells, it is well documented that treatment with 
estrogen induces cell proliferation.  Therefore, Alamar Blue proliferation assays were 
performed with each cell line.  With induced ERα expression and 10nM E2 treatment for 
4 days, the 76N Tert-ESR1, MCF10A-ESR1, and HME-CC-ESR1 HMEC lines showed 
modest but significant increases in proliferation compared to control or 10nM ICI treated 
cells by day 4 (Figure 4.29a-d and Figure 4.30a).  The proliferation induced resulted in 
an approximately 20-25% increase in Alamar Blue reduction.  The ME16C2-ESR1 cells, 
however, did not demonstrate any E2-induced proliferation (Figure 4.30b).   
Next, E2 induction of ERα target genes AREG and PGR were examined after 24-
hour treatment with E2 and 72-hour treatment with doxycycline.  PGR was not detected in 
any of the iERα HMECs (data not shown).  AREG was detected in all 4 lines, but its 
expression did not appear to be regulated by E2 treatment (Figure 4.31).  Compared to 
untreated T47D breast cancer cells and normal breast tissue, AREG expression in the 76N 
Tert-ESR1, HME-CC-ESR1, and ME16C2-ESR1 lines was constitutively high.  MCF10A-
ESR1 expression of AREG was like that found in normal breast tissue and untreated T47D 
cells, but expression was not changed with 10nM E2 treatment.  In 76N Tert-ESR1 cells 
without ERα induced, 10nM ICI treatment resulted in a small but significant increase in 
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AREG (p < 0.05).  Treatment with 10nM E2 and doxycycline significantly reduced AREG 
expression (p < 0.05).  In HME-CC-ESR1 cells, treatment with doxycycline and 10nM ICI 
increased AREG relative to control treated cells without ERα expression, though this was 
not significant when compared to the control doxycycline treated cells.  Lastly, in the 
doxycycline treated ME16C2-ESR1 cells, treatment with 10nM ICI significantly increased 
AREG while treatment with 10nM E2 significantly decreased expression (p < 0.05).  It is 
clear from these results that the modest E2-induced proliferation observed in 3/4 iERα 
HMECs does not correspond with AREG or PGR target gene regulation.  In addition, the 
76N Tert-ESR1 and ME16C2-ESR1 lines may exhibit negative regulation of AREG when 
ERα is expressed after estrogen treatment. 
 
E2-Induced Proliferation in iERα HMECs is Due to Cell Intrinsic Factors 
We next performed conditioned growth media assays to determine if the modest 
E2-induced proliferation observed in 3/4 iERα HMECs is due to cell intrinsic factors or 
secreted growth factor production.  Previous studies in normal breast epithelium support a 
paracrine signaling model for estrogen-induced proliferation, where estrogen receptor 
positive luminal epithelial cells produce growth factors that stimulate the proliferation of 
nearby estrogen receptor negative cells.  However, in breast cancer cells estrogen-induced 
proliferation can occur through autocrine signaling, as treatment with epidermal growth 
factor receptor (EGFR) inhibitors does not block proliferation.   
In our iERα HMECs, we wanted to determine if autocrine or paracrine signaling 
was contributing to estrogen-induced proliferation.  For this, we used 76N Tert-ESR1 and 
MCF10A-ESR1 cells, as they both exhibited E2-induced growth.  Conditioned growth 
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media assays were performed as outlined in Figure 4.32.  Conditioned growth media was 
collected from these two iERα cell lines 2 days and 4 days after treatment with control, 
10nM ICI, or 10nM E2 and treatment with 100ng/mL doxycycline.  Media was also 
collected from T47D cells with the same treatments.  The conditioned media filter sterilized 
and added to parental HMEC lines lacking ERα (76N Tert and MCF10A) on day 1 and day 
3 of proliferation assays.  76N Tert parental cells exhibited no significant change in 
proliferation with conditioned media from doxycycline treated 76N Tert-ESR1 cells in our 
first experiment (Figure 4.33).  In a follow up experiment with T47D conditioned media 
as an additional treatment, there was a small but significant increase in proliferation with 
E2 treatment in the 76N Tert-ESR1 media treated cells (Figure 4.34), but analysis of the 
fold change between day 2 and day 5 Alamar Blue reduction revealed no significant 
increase from control treated cells.  No significant change was observed with conditioned 
media from T47D cells (Figure 4.34).  Comparison of the fold change in Alamar Blue 
reduction between normal growth media, T47D conditioned media, and 76N Tert-ESR1 
conditioned media treated cells revealed a similar fold change between all treatment groups 
(Figure 4.34d), suggesting that the 76N Tert parental cells are not responsive to the 
conditioned growth media from 76N Tert-ESR1 or T47D cells.   In MCF10A parental cells, 
no significant change in proliferation was observed in treatment with MCF10A-ESR1 
conditioned media (Figure 4.35b), and small but significant increases or decreases were 
observed in normal growth media or T47D conditioned media with E2 treatment (Figure 
4.35a and Figure 4.35c).  Comparison of fold change in Alamar Blue reduction among 
treatment groups revealed a small but significant increase in proliferation when treated with 
T47D control or 10nM ICI conditioned media (Figure 4.35d).  This data suggests that the 
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proliferation observed in our 3/4 iERα HMECs is due to intracellular factors and not 
secretion of factors into the media.   
To confirm the results of our conditioned media experiments from 76N Tert and 
MCF10A parental cell lines, we performed the same experiments with T47D breast cancer 
cell lines.  Our lab and numerous others have shown that T47D cell proliferation is 
increased with estrogen treatment.  We wanted to determine if conditioned media from 
76N Tert-ESR1 or MCF10A-ESR1 cells could enhance the proliferative response of T47D 
cells, which would suggest there is a secreted factor present in the media.  T47D cells 
treated with conditioned media from 76N Tert-ESR1 cells exhibited a significant increase 
in proliferation with 10nM E2 media, and this increase was enhanced with media from 
10nM E2 treated 76N Tert-ESR1 cells (Figure 4.36a-b).  However, this increased 
proliferation is likely due to the high amounts of AREG produced by the 76N Tert-ESR1 
cells (Figure 4.31), as proliferation was also enhanced in T47D cells treated with 
conditioned media from control and 10nM ICI treated 76N Tert-ESR1 cells.  Additionally, 
T47D cells treated with conditioned media from 76N Tert-ESR1 cells without doxycycline 
treatment showed a significant increase, which suggests the increased proliferation is due 
to high basal AREG levels in the 76N Tert line (Figure 4.36c).  T47D cells treated with 
conditioned media from MCF10A-ESR1 cells exhibited a significant increase in 
proliferation with 10nM E2 treatment and was slightly enhanced by treatment with 
conditioned media from MCF10A-ESR1 cells treated with 10nM E2 (Figure 4.37).  
However, since the increase was also observed in cells treated with media from MCF10A-
ESR1 cells without doxycycline treatment, it is likely not the mechanism driving E2-
induced proliferation in our MCF10A-ESR1 cells.  These results indicate that any increased 
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proliferation observed in T47D cells treated with media from 76N Tert-ESR1 cells is likely 
due to constitutively high AREG expression in these cells, as the enhanced proliferation 
was not seen with MCF10A-ESR1 conditioned media, which are not producing high levels 
of AREG (Figure 4.31).  This can be confirmed with further experiments using inhibitors 
of epidermal growth factor receptor to block proliferation due to AREG.  Collectively, this 
data suggests that the E2-induced proliferation in 3/4 iERα HMECs is due to cell intrinsic 
factors, not secreted factors.   
 
FOXA1 and GATA3 Expression is Not Sufficient for ERα Induced Responses 
As recent literature has suggested that the ERα coactivators FOXA1 and GATA3 
are essential for carrying out estrogen-induced biological responses, especially in 
previously ER negative cell lines with exogenous ERα expression, we checked mRNA 
expression of these two cell intrinsic factors in our parental HMEC lines.  If this hypothesis 
is correct, we would expect the 3 HMEC lines which responded to E2 with proliferation 
(76N Tert-ESR1, MCF10A-ESR1, HME-CC-ESR1) to have higher expression of these two 
factors or a lack of expression in the unresponsive ME16C2-ESR1 line.  The 76N Tert cells 
had the highest expression of FOXA1, followed by the MCF10A line, HME-CC line, and 
the ME16C2 cells (Figure 4.38a).  While the 76N Tert and MCF10A cells had significantly 
higher expression of FOXA1 than the ME16C2 cells, expression between the HME-CC and 
ME16C2 were not significantly different.  Additionally, the amount of FOXA1 expressed 
in the ME16C2 cells was similar to that seen in normal breast tissue.  GATA3 expression 
was highest in the MCF10A cells, followed closely by the 76N Tert cells (Figure 4.38b).  
The expression in these two cell lines was comparable to normal breast tissue.  The HME-
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CC and ME16C2 cell lines, in contrast, had significantly lower GATA3 expression.  
However, there was also no significant difference between the HME-CC and ME16C2 
GATA3 expression levels.  This data suggests that, while FOXA1 and GATA3 may be 
necessary for ERα induced responses, expression of these factors is not sufficient to impart 
E2-induced responses.  A summary of responses from each iERα HMEC generated in this 
study is shown in Table 4.3.   
 
Discussion 
Although Tert and spontaneously immortalized HMECs lose expression of 
p16INK4A, p14ARF, and/or p15INK4B, our results suggest that they are a useful model 
for studying regulation of estrogen-induced responses in breast epithelial cells.  The 4 iERα 
HMEC lines developed here are capable of estrogen response element transactivation upon 
E2 treatment, express levels of ERα similar to MCF7 cells, and 3 of 4 lines demonstrate 
modest E2-induced proliferation.  Like many other primary breast epithelial cell models, 
these HMECs exhibit primarily basal epithelial keratin expression profiles (Prat et al., 
2013), although some have suggested that the 76N Tert and MCF10A lines have luminal 
KRT8/KRT18 expressing subpopulations (Zhao et al., 2010; Qu et al., 2015).  Even though 
these HMECs are primarily basal epithelial cells, our results illustrate that they can be used 
to study factors which enhance or restrict estrogen-induced responses. 
Exogenous expression of ESR1 in both breast cancer cell lines (MDA-MB-231) and 
HMECs has been shown to bind E2 as an agonist (Pilat et al., 1996; Lazennec and 
Katzenellenbogen, 1999) and generate significant levels of transactivation with estrogen 
response element reporters (Pilat et al., 1996; Lazennec and Katzenellenbogen, 1999; 
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Pugazhendhi and Darbre, 2010; Kong et al., 2011), but this does not always equate to E2-
induced biological responses.  In MDA-MB-231 basal breast cancer cells, exogenous ESR1 
expression has consistently been demonstrated to result in decreased proliferation (Jiang 
and Jordan, 1992; Zajchowski et al., 1993; Lazennec and Katzenellenbogen, 1999).  
However, these cells can still control mRNA expression of some growth factors (TGFα 
and TGFβ2) associated with proliferation (Jeng et al., 1994) and increase expression of 
some ER target genes (TFF1) with E2 treatment (Lazennec and Katzenellenbogen, 1999). 
In HMECs, response to E2 treatment after exogenous ESR1 expression has 
produced conflicting reports.  Most studies report that MCF10A or other HMECs with 
exogenous ESR1 are capable of transactivation in reporter assays (Pilat et al., 1996; Wolf 
et al., 2007; Kong et al., 2011) but have no change in proliferation with E2 treatment 
(Zajchowski et al., 1993; Pilat et al., 1996; Thomas et al., 1998).  However, others report 
modest increases in MCF10A proliferation of 1.3-fold (Pugazhendhi and Darbre, 2010) or 
1.5 to 2-fold increases in MCF10A clones expressing ESR1 in the absence of EGF 
(Abukhdeir et al., 2006).  All of our 4 iERα HMEC lines are responsive to E2 treatment in 
reporter assays (Figure 4.12, Figure 4.13, Figure 4.14, and Figure 4.15), but only 3 of 4 
(76N Tert-ESR1, MCF10A-ESR1, and HME-CC-ESR1) demonstrated a 20-25% increase 
in proliferation with 10nM E2 treatment (Figure 4.29 and Figure 4.30), compared to ~60% 
in estrogen responsive T47D breast cancer cells (Figure 4.36a and Figure 4.37a).  While 
our proliferation media does not contain added EGF, it is likely that our serum still contains 
residual amounts of EGF and treatment with EGFR inhibitors may increase our 
proliferative phenotype in these lines.  In studies where no change in proliferation was 
observed, MCF10A cells demonstrated no change in expression of ER target genes TFF1 
 125 
or PGR mRNA (Pilat et al., 1996) while our MCF10A-ESR1 and other HMEC lines 
expressed no detectable PGR (data not shown).  Studies that showed proliferation with E2 
treatment in MCF10A cells also observed induced expression of TFF1 and PGR 
(Abukhdeir et al., 2006).  We did not examine expression of TFF1 in our HMECs, but 
expression of AREG and PGR did not appear to be regulated by E2 treatment (Figure 4.31).   
Recent papers have suggested that ERα mediated responses to E2 treatment can be 
induced through exogenous expression of other factors.  Most primary HMECs do not 
express of ERα, but transduction with ESR1 and BMI1, a Polycomb-group gene which is 
capable of suppressing the p53 and Rb pathways and increases stem cell renewal, allows 
for growth of HMECs stably expressing ERα (Duss et al., 2007).  These ERα/BMI1 
expressing HMECs exhibit a 50% increase in proliferation with E2 treatment and increases 
in expression of ER target genes GREB1, PGR, and PRLR, while expression of ER target 
gene TFF1 remains unchanged.  This suggests that many but not all E2-induced responses 
can be generated in HMECs with BMI1.  Other work suggests that expression of ERα 
coregulators FOXA1 and GATA3 are necessary for generating normal E2-induced 
responses in ER negative breast cells.  While expression of ESR1 alone is able to 
transactivate ERE luciferase reporters, co-expression of FOXA1 and GATA3 is required to 
induce proliferative responses (Kong et al., 2011).  In MDA-MB-231 cells, a 2-fold 
increase in proliferation is observed with E2 treatment and these 3 factors; in BT-549 breast 
cancer cells, a 40% increase in proliferation is observed with ESR1, FOXA1, and GATA3 
compared to a 30% decrease in proliferation with ESR1 alone and E2 treatment.  
Comparison of E2-ER mediated transcriptional profiles of MDA-MB-231 cells with ESR1, 
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FOXA1, and GATA3 are closer to MCF7 profiles, but expression of key target genes is still 
missing (Kong et al., 2011).   
Our conditioned media experiments support the hypothesis that other intrinsic 
cellular factors are involved in E2-induced proliferation in our 3 iERα HMECs (Figure 
4.33 through Figure 4.37), but our data suggests that expression of FOXA1 and GATA3 
are not sufficient to impart E2-induced proliferation in our ME16C2-ESR1 HMEC line 
(Figure 4.38).  Conditioned media from 2 iERα HMECs which demonstrate E2-induced 
proliferation is not able to increase proliferative responses in T47D cells (Figure 4.36 and 
Figure 4.37) or increase proliferation in parental HMECs without ERα expression (Figure 
4.33, Figure 4.34, and Figure 4.35).  Expression of FOXA1 and GATA3 is significantly 
higher in the 76N Tert-ESR1 and MCF10A-ESR1 lines, but expression of these two factors 
is not significantly different between the ME16C2-ESR1 and HME-CC-ESR1 cells, which 
proliferate in response to E2 (Figure 4.29 and Figure 4.30).   
It is interesting that Kong et al. suggested that lack of FOXA1 and GATA3 was 
responsible for the abnormal phenotypes in MDA-MB-231 breast cancer cells with 
exogenous ESR1 because others have demonstrated low basal expression of FOXA1 (Wolf 
et al., 2007) in these cells, but co-expression of ESR1 and GATA3 is not sufficient to 
generate E2-induced proliferative responses (Kong et al., 2011).  This would suggest that 
increased expression of FOXA1 is needed, which our results contradict.  Our results are 
supported by another recent paper that expressed exogenous ESR1 in mouse mammary 
epithelial cells, where co-expression of FOXA1 and GATA3 also was not sufficient to 
impart responsiveness to E2 treatment (Cornelissen et al., 2019).  This group, however, 
attributed this result to the differences in number of FOXA1 and GATA3 binding sites 
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between mice and humans, suggesting mice rely less on these pioneer factors.  Our results 
suggest that, in HMECs, FOXA1 and GATA3 expression is not sufficient to induce 
complete responsiveness to estrogen.  These results in combination suggest the presence 
of other coregulators involved in regulation of E2-induced responses, which may influence 
sensitivity to estrogen in individuals as well. 
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Table 4.1: Antibody information for Western Blot Analysis 
Antibodies used in western blots on HMEC cell lysates.   
 
 
Target 
Name of Antibody, 
Catalog Number 
Manufacturer 
Dilution 
Used 
Species 
Estrogen 
receptor alpha 
(ERα) 
Sp1, #ab16660 Abcam 1:100 
Rabbit, 
monoclonal 
Estrogen 
receptor alpha 
(ERα) 
MC-20, #sc-542 
Santa Cruz 
(discontinued) 
1:500 
Rabbit, 
monoclonal 
Estrogen 
receptor alpha 
(ERα) 
F-10, #sc-8002 Santa Cruz 1:200 
Mouse, 
monoclonal 
Estrogen 
receptor alpha 
(ERα) 
C1355, #06-935 
Millipore 
Sigma 
1:1000 
Rabbit, 
polyclonal 
β-actin AC-15, #A1978 Sigma 1:5000 
Mouse, 
monoclonal 
β-actin #4967 Cell Signaling 1:5000 
Rabbit, 
polyclonal 
 
 
 
 
 
 
 
Table 4.2: RT-qPCR primer sequences 
Primer sequences used in RT-qPCR of HMECs.  Used on BioRad CFX thermocycler.   
 
 
Gene Sequence: 5’ to 3’ 
Amphiregulin (AREG) 
Fwd – CGG AGA ATG CAA ATA TAT AGA GCA C 
Rev – CAC CGA AAT ATT CTT GCT GAC A 
Progesterone receptor (PGR) 
Fwd – TTT AAG AGG GCA ATG GAA GG 
Rev – CGG ATT TTA TCA ACG ATG CAG 
Forkhead box protein A1 
(FOXA1) 
Fwd – GGA ACA GCT ACT ACG CAG AC 
Rev – ATG TTG CCG CTC GTA GTC AT 
GATA binding protein 3 
(GATA3) 
Fwd – CAC AAA ATG AAC GGA CAG AAC A 
Rev – GTT GTG GTG GTC TGA CAG TT 
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Table 4.3: Summary of HMEC responses 
Summary of data from chapter 4 illustrating the responses of each cell line across all assays 
performed.  Clonality of each iERα HMEC line can be inferred from the initial percent 
GFP positive cell population during and after FACS sorting.  Fold change in luciferase 
assays is relative to 10nM ICI treated cells.  ERα protein expression is shown as a 
percentage of quantified levels in MCF7 cells (n = 2 for iERα HMECs, n = 1 for MCF7).  
AREG expression is shown relative to fresh breast tissue IRC.  Significant E2-induced 
proliferation is also indicated. 
 
 
Cell 
Line 
Initial 
% GFP 
positive 
% GFP 
positive 
after 
FACS 
Fold 
change in 
luciferase 
assays 
ERα 
Expression 
(% of 
MCF7 
level) 
Relative 
Expression 
of AREG 
and PGR 
E2-induced 
proliferation 
76N Tert 5% 90% 5-8 
Similar 
(107%) 
AREG: 9-
15 
PGR: none 
Yes 
MCF10A 17% 70% 3-5.6 
Similar 
(99%) 
AREG: 0.3 
PGR: none 
Yes 
HME-
CC 
19% 90% 3-5 
Similar 
(130%) 
AREG: 5-8 
PGR: none 
Yes 
ME16C2 72% 99% 37-60 
Increased 
(720%) 
AREG: 5-
23 
PGR: none 
No 
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Figure 4.1: Inducible ESR1 expression in pINDUCER14 backbone 
A FLAG tagged ESR1 coding sequence was cloned into the lentiviral pINDUCER14 
backbone, to create pIND-ESR1.  An internal ribosome entry site (IRES) drives constitutive 
GFP expression.  The human EF1-α promoter (EEF1A1) drives expression of reverse 
tetracycline-transactivator (rtTA), which will bind to the tetracycline response element 
(TRE2) only in the presence of doxycycline to induce ESR1 transcription.  ESR1 has a 
FLAG tag expressed on the N-terminal region.  Cloning performed by Puneet Singh, 
former AMB master’s student. 
 
 
 
 
 
pINDUCER14-FLAG-ESR1 
(pIND-ESR1) 
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Figure 4.2: GFP expression in 293T cells transfected with pIND-ESR1 
293T cells were transfected with the pIND-ESR1 construct and confirmed constitutive GFP 
expression in all cells containing the plasmid.  (a) Phase contrast image of 293T cells and 
(b) fluorescent image of cells with filter for GFP.  Images were taken one day after 
transfection.   
  
a 
b 
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Figure 4.3: Transient transfection of 76N Tert cells with pIND-ESR1 
Transfection of 76N Tert cells with pIND-ESR1.  76N Tert cells were transfected with 
pIND-ESR1, an ERE luciferase reporter, and a renilla transfection control.  No receptor 
control cells (ERE-Ctrl and ERE-E2) were transfected with reporter but no pIND-ESR1.  
Cells were treated with control, 10nM ICI, or 10nM E2 for 24 hours.  (a) Luciferase, (b) 
Renilla, and (c) normalized data shown.  Results showed some leaky expression of ESR1 
in the cells without doxycycline treatment, as a significant increase in transactivation with 
10nM E2 was observed.  However, transactivation with doxycycline treatment and 10nM 
E2 produced a significantly higher level of transactivation.  Error bars indicate SEM. (* p 
< 0.05). 
a 
b 
c 
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Figure 4.4: FACS of 76N Tert cells after lentiviral infection with pIND-ESR1 
After infection with pIND-ESR1, (a) 76N Tert cells (b) expressing GFP indicated 
successful incorporation of pIND-ESR1.  This subpopulation was selected using FACS 
sorting (c) with the parameters shown.  Side scatter area (SSC-A) and forward scatter area 
(FSC-A) were used to isolate viable cells, SSC width (W) and height (H) were used to 
remove doublets, FSC-W and FSC-H confirmed selection of single cells, and PE-Texas 
Red was used to detect autofluorescence.  Parental 76N Tert cells were used as a negative 
control to set background autofluorescence.  Approximately 5% of 76N Tert cells were 
GFP positive.  Images were taken with 10x objective. 
  
a b 
c 
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Figure 4.5: Post FACS check of 76N Tert-ESR1 
After FACS for GFP expressing 76N Tert cells, an aliquot was checked for purity.  Side 
scatter area (SSC-A) and forward scatter area (FSC-A) were used to isolate viable cells, 
SSC width (W) and height (H) were used to remove doublets, FSC-W and FSC-H 
confirmed selection of single cells, and PE-Texas Red was used to detect autofluorescence.  
Approximately 90% of the sorted cell population expresses GFP, which are considered the 
76N Tert-ESR1 cell line. 
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Figure 4.6: FACS of MCF10A cells after lentiviral infection with pIND-ESR1 
After infection with pIND-ESR1, (a) MCF10A cells (b) expressing GFP indicated 
successful incorporation of pIND-ESR1.  This subpopulation was selected using FACS 
sorting (c) with the parameters shown.  Side scatter area (SSC-A) and forward scatter area 
(FSC-A) were used to isolate viable cells, SSC width (W) and height (H) were used to 
remove doublets, FSC-W and FSC-H confirmed selection of single cells, and PE-Texas 
Red was used to detect autofluorescence.  Parental MCF10A cells were used as a negative 
control to set background autofluorescence.  Approximately 17% of MCF10A cells were 
GFP positive.  Images were taken with 10x objective. 
 
a b 
c 
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Figure 4.7: Post FACS check of MCF10A-ESR1 
After FACS for GFP expressing MCF10A cells, an aliquot was checked for purity.  Side 
scatter area (SSC-A) and forward scatter area (FSC-A) were used to isolate viable cells, 
SSC width (W) and height (H) were used to remove doublets, FSC-W and FSC-H 
confirmed selection of single cells, and PE-Texas Red was used to detect autofluorescence. 
Approximately 70% of the sorted population expresses GFP, which are considered the 
MCF10A-ESR1 cell line. 
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Figure 4.8: FACS of HME-CC cells after lentiviral infection with pIND-ESR1 
After infection with pIND-ESR1, (a) HME-CC cells (b) expressing GFP indicated 
successful incorporation of pIND-ESR1.  This subpopulation was selected using FACS 
sorting (c) with the parameters shown.  Side scatter area (SSC-A) and forward scatter area 
(FSC-A) were used to isolate viable cells, SSC width (W) and height (H) were used to 
remove doublets, and FSC-W and FSC-H confirmed selection of single cells.  PE-Texas 
Red showed minimal autofluorescence.  Parental HME-CC cells were used as a negative 
control to set background autofluorescence.  Approximately 19% of HME-CC cells were 
GFP positive.  Images were taken with 20x objective. 
a b 
c 
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Figure 4.9: Post FACS check of HME-CC-ESR1 
After FACS for GFP expressing HME-CC cells, an aliquot was checked for purity.  Side 
scatter area (SSC-A) and forward scatter area (FSC-A) were used to isolate viable cells, 
SSC width (W) and height (H) were used to remove doublets, and FSC-W and FSC-H 
confirmed selection of single cells.  PE-Texas Red showed minimal autofluorescence.  
Approximately 90% of the sorted cell population expresses GFP, which are considered the 
HME-CC-ESR1 cell line. 
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Figure 4.10: FACS of ME16C2 cells after lentiviral infection with pIND-ESR1 
After infection with pIND-ESR1, (a) ME16C2 cells (b) expressing GFP indicated 
successful incorporation of pIND-ESR1.  This subpopulation was selected using FACS 
sorting (c) with the parameters shown.  Side scatter area (SSC-A) and forward scatter area 
(FSC-A) were used to isolate viable cells, SSC width (W) and height (H) were used to 
remove doublets, FSC-W and FSC-H confirmed selection of single cells, and PE-Texas 
Red was used to detect autofluorescence. Parental ME16C2 cells were used as a negative 
control to set background autofluorescence.  Approximately 72% of ME16C2 cells were 
GFP positive.  Images were taken with 10x objective. 
a b 
c 
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Figure 4.11: Post FACS check of ME16C2-ESR1 
After FACS for GFP expressing ME16C2 cells, an aliquot was checked for purity.  Side 
scatter area (SSC-A) and forward scatter area (FSC-A) were used to isolate viable cells, 
SSC width (W) and height (H) were used to remove doublets, FSC-W and FSC-H 
confirmed selection of single cells, and PE-Texas Red was used to detect autofluorescence. 
Approximately 99% of the sorted cell population expresses GFP, which are considered the 
ME16C2-ESR1 cell line. 
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Figure 4.12: Doxycycline dose response in 76N Tert-ESR1 
Luciferase reporter assays in the 76N Tert-ESR1 line with 24-hour control, 10nM ICI, or 
10nM E2 treatment and either 0ng/mL, 100ng/mL, 150ng/mL, or 200ng/mL doxycycline. 
(a) Luciferase, (b) Renilla, and (c) Luciferase normalized to Renilla.  Error bars indicate 
SEM.  Significance is calculated with comparison to control treatment of same doxycycline 
dose unless otherwise indicated by lines.  (* p < 0.05). 
a 
b 
c 
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Figure 4.13: Doxycycline dose response in MCF10A-ESR1 
Luciferase reporter assays in the MCF10A-ESR1 line with 24-hour control, 10nM ICI, or 
10nM E2 treatment and either 0ng/mL, 100ng/mL, 150ng/mL, or 200ng/mL doxycycline. 
(a) Luciferase, (b) Renilla, and (c) Luciferase normalized to Renilla.  Error bars indicate 
SEM.  Significance is calculated with comparison to control treatment of same doxycycline 
dose unless otherwise indicated by lines.  (* p < 0.05). 
a 
b 
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Figure 4.14: Doxycycline dose response in HME-CC-ESR1 
Luciferase reporter assays in the HME-CC-ESR1 line with 24-hour control, 10nM ICI, or 
10nM E2 treatment and either 0ng/mL, 100ng/mL, 150ng/mL, or 200ng/mL doxycycline. 
(a) Luciferase, (b) Renilla, and (c) Luciferase normalized to Renilla.  Error bars indicate 
SEM.  Significance is calculated with comparison to control treatment of same doxycycline 
dose unless otherwise indicated by lines.  (* p < 0.05).  
a 
b 
c 
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Figure 4.15: Doxycycline dose response in ME16C2-ESR1 
Luciferase reporter assays in the ME16C2-ESR1 line with 24-hour control, 10nM ICI, or 
10nM E2 treatment and either 0ng/mL, 100ng/mL, 150ng/mL, or 200ng/mL doxycycline. 
(a) Luciferase, (b) Renilla, and (c) Luciferase normalized to Renilla.  Error bars indicate 
SEM.  Significance is calculated with comparison to control treatment of same doxycycline 
dose unless otherwise indicated by lines.  (* p < 0.05). 
a 
b 
c 
 145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Luciferase Reporter Assays with 76N Tert-ESR1 and MCF10A-ESR1 
ERE-luciferase reporter assays with 76N Tert-ESR1 and MCF10A-ESR1 cell lines with 
increasing concentrations of doxycycline.  Cells were treated with control, 10nM ICI, or 
10nM E2 for 24 hours.  Data is normalized to renilla transfection control and set relative 
to 76N Tert-ESR1 no dox control.  Error bars indicate SEM.  Significance is calculated 
with comparison to control treatment of same doxycycline dose unless otherwise indicated 
by lines.  (* p < 0.05). 
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Figure 4.17: Luciferase Reporter Assays with HME-CC-ESR1 and ME16C2-ESR1 
ERE-luciferase reporter assays with HME-CC-ESR1 and ME16C2-ESR1 cell lines with 
increasing concentrations of doxycycline.  Cells were treated with control, 10nm ICI, or 
10nM E2 for 24 hours.  Data is normalized to renilla transfection control and set relative 
to 76N Tert-ESR1 no dox control.  Experiment was performed at the same time as Figure 
4.12.  Error bars indicate SEM.  Significance is calculated with comparison to control 
treatment of same doxycycline dose unless otherwise indicated by lines.   (* p < 0.05). 
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Figure 4.18: Fold change in ERE-Luc responses in 76N Tert-ESR1 
Fold change in ERE-luciferase reporter data from 76N Tert-ESR1 with increasing 
concentrations of doxycycline relative to ICI treatment.  Cells were treated with control, 
10nm ICI, or 10nM E2 for 24 hours.  Fold change is shown for (a) luciferase normalized 
to renilla and (b) both raw luciferase and ratio (normalized data). Error bars indicate SEM. 
(* p < 0.05). 
  
a 
b 
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Figure 4.19: Fold change in ERE-Luc responses in MCF10A-ESR1 
Fold change in ERE-luciferase reporter data from MCF10A-ESR1 with increasing 
concentrations of doxycycline relative to ICI treatment.  Cells were treated with control, 
10nm ICI, or 10nM E2 for 24 hours.  Fold change is shown for (a) luciferase normalized 
to renilla and (b) both raw luciferase and ratio (normalized data). Error bars indicate SEM. 
(* p < 0.05). 
  
a 
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Figure 4.20: Fold change in ERE-Luc responses in HME-CC-ESR1 
Fold change in ERE-luciferase reporter data from HME-CC-ESR1 with increasing 
concentrations of doxycycline relative to ICI treatment.  Cells were treated with control, 
10nm ICI, or 10nM E2 for 24 hours.  Fold change is shown for (a) luciferase normalized 
to renilla and (b) both raw luciferase and ratio (normalized data). Error bars indicate SEM. 
(* p < 0.05). 
  
a 
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Figure 4.21: Fold change in ERE-Luc responses in ME16C2-ESR1 
Fold change in ERE-luciferase reporter data from ME16C2-ESR1 with increasing 
concentrations of doxycycline relative to ICI treatment.  Cells were treated with control, 
10nm ICI, or 10nM E2 for 24 hours.  Fold change is shown for (a) luciferase normalized 
to renilla and (b) both raw luciferase and ratio (normalized data). Error bars indicate SEM. 
(* p < 0.05).  
 
 
a 
b 
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Figure 4.22: ERα antibody optimization for Western blot analysis 
Summary of antibody optimization for Western blot analysis, using 35ug of protein per 
sample.  Samples: 1- MCF7 (positive control), 2- 76N Tert parental cells (negative control), 
3- 76N Tert-ESR1 with 100ng/mL doxycycline, 4- 76n Tert-ESR1 with 200ng/mL 
doxycycline.  Results with (a) F-10 monoclonal antibody, (b) MC-20 monoclonal antibody, 
(c) Sp1 monoclonal antibody, and (d) C1355 polyclonal antibody for ERα.   
  
a b 
c d 
1 2 3 4 4 3 2 1 
1 2 3 4 1 2 3 4 
MC-20 F-10 
Sp1 C1355 
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Figure 4.23: β actin expression during ERα antibody optimization for Western blot 
Summary of antibody optimization for Western blot analysis, using 35ug of protein per 
sample.  Samples: 1- MCF7 (positive control), 2- 76N Tert parental cells (negative control), 
3- 76N Tert-ESR1 with 100ng/mL doxycycline, 4- 76n Tert-ESR1 with 200ng/mL 
doxycycline.  β-actin protein expression in blots previously probed with (a) F-10 
monoclonal antibody, (b) MC-20 monoclonal antibody, (c) Sp1 monoclonal antibody, and 
(d) C1355 polyclonal antibody for ERα.   
 
  
a b 
c d 
1 2 3 4 4 3 2 1 
1 2 3 4 1 2 3 4 
MC-20 F-10 
Sp1 C1355 
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Figure 4.24: ERα protein expression in iERα HMEC lines compared to MCF7 
Western blot analysis showing detection of ERα protein using 1:100 dilution of ERα clone 
Sp1 antibody from Abcam.  Amount of protein loaded was either 28ug (or 25 ug if 
indicated).  β-actin is shown as a loading control.  ERα protein was detected in (a) 76N 
Tert-ESR1, (b) MCF10A-ESR1, (c) HME-CC-ESR1, and (d) ME16C2-ESR1 cells in the 
presence of doxycycline.  MCF7 cell lysates were used as a positive control, and parental 
HMECs were included as a negative control for ERα. 
 
 
 
 
 
 
 
  
a b 
c d 
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Figure 4.25: Quantification of ERα protein expression in 76N Tert-ESR1  
Quantification of western blot data from for 76N Tert-ESR1 HMEC line for (a) ERα, (b) 
β-actin, and (c) ERα normalized to β-actin.  2 replicates were used for each condition, 
except for the MCF7 cell positive control.  Error bars indicate SEM. 
 
 
  
a 
b 
c 
ERα 
β-actin 
ERα normalized to β-actin 
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Figure 4.26: Quantification of ERα protein expression in MCF10A-ESR1  
Quantification of western blot data from for MCF10A-ESR1 HMEC line for (a) ERα, (b) 
β-actin, and (c) ERα normalized to β-actin.  2 replicates were used for each condition, 
except for the MCF7 cell positive control.  Error bars indicate SEM. 
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Figure 4.27: Quantification of ERα protein expression in HME-CC-ESR1  
Quantification of western blot data from for HME-CC-ESR1 HMEC line for (a) ERα, (b) 
β-actin, and (c) ERα normalized to β-actin.  2 replicates were used for each condition, 
except for the MCF7 cell positive control.  Error bars indicate SEM. 
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ERα normalized to β-actin 
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Figure 4.28: Quantification of ERα protein expression in ME16C2-ESR1  
Quantification of western blot data from for ME16C2-ESR1 HMEC line for (a) ERα, (b) 
β-actin, and (c) ERα normalized to β-actin.  2 replicates were used for each condition, 
except for the MCF7 cell positive control.  Error bars indicate SEM. 
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Figure 4.29: E2-induced proliferation in 76N Tert-ESR1 and MCF10A-ESR1 
HMECs 
(a-b) 76N Tert-ESR1 and (c-d) MCF10A-ESR1 HMECs were treated with 100 ng/mL 
doxycycline and control, 10nM ICI, or 10nM E2 media for 4 days.  The amount of 
proliferation was measured each day by Alamar blue reduction.  Media was refreshed on 
day 3.  Two experiments were performed in each cell line, shown in separate graphs.  Error 
bars indicate SEM.  Significance calculated using T-test (* p < 0.05). 
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c 
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Figure 4.30: E2-induced proliferation in HME-CC-ESR1 and ME16C2-ESR1 
HMECs 
(a) HME-CC-ESR1 and (b) ME16C2-ESR1 HMECs were treated with 100ng/mL 
doxycycline and control, 10nM ICI, or 10nM E2 media for 4 days.  The amount of 
proliferation was measured each day by Alamar blue reduction.  Media was refreshed on 
day 3.  Error bars indicate SEM.  Significance calculated using T-test (* p < 0.05). 
 
  
a 
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Figure 4.31: AREG expression in iERα HMEC lines 
After 2-day treatment with doxycycline to induce ESR1 expression, HMECs were treated 
with control, 10nM ICI, or 10nM E2 for 24 hours.  Gene expression from RT-qPCR is 
shown relative to normal breast tissue.  Untreated T47D cells are included for reference.  
Error bars indicate SEM.  (* p < 0.05). 
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Figure 4.32: Overview of conditioned media assay 
Schematic overview of conditioned media assay.  Briefly, iERα HMECs (76N Tert-ESR1  
and MCF10A-ESR1) and T47D cells were treated with control, 10nM ICI, or 10nM E2 
media for 48 hours.  After 48 hours, the conditioned media was collected, filter sterilized 
using a 0.2-micron filter, diluted 1:1 with fresh media, and transferred to HMEC parental 
cells (76N Tert or MCF10A) and T47D cells.  New media was added to iERα HMECs and 
T47D cells to condition for another 48 hours and again added to the parental HMECs and 
T47D cells.  Alamar Blue growth assays were performed on parental HMECs and T47D 
cells, where conditioned growth media was added on day 1 and day 3 of treatment.  Cells 
were also grown in normal growth media (no conditioned media) as a control.   
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Figure 4.33: Conditioned Growth Media Assay in 76N Tert 
Alamar Blue proliferation assay was performed on 76N Tert parental cells (without ERα) 
using (a) normal growth media or (b) conditioned growth media from doxycycline treated 
76N Tert-ESR1 cells, diluted 1:1 with normal growth media.  (c) Fold change in Alamar 
Blue reduction between day 5 and day 1 cells is shown for normal and conditioned media 
experiments.  Error bars indicate SEM.  (p < 0.05). 
  
a 
b 
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Figure 4.34: Expansion of Conditioned Growth Media Assay in 76N Tert 
Alamar Blue proliferation assay was performed on 76N Tert parental cells (without ERα) 
using (a) normal growth media (b) conditioned growth media from doxycycline treated 
76N Tert-ESR1 cells, or (c) conditioned growth media from T47D cells.  (d) Fold change 
in Alamar Blue reduction between day 5 and day 2 cells is shown for normal and 
conditioned media (CM) experiments.  Error bars indicate SEM.  (* p < 0.05). 
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Figure 4.35: Conditioned Growth Media Assay in MCF10A 
Alamar Blue proliferation assay was performed on MCF10A parental cells (without ERα) 
using (a) normal growth media (b) conditioned growth media from doxycycline treated 
MCF10A-ESR1 cells, or (c) conditioned growth media from T47D cells.  (d) Fold change 
in Alamar Blue reduction between day 5 and day 2 cells is shown for normal and 
conditioned media (CM) experiments.  Error bars indicate SEM.  (* p < 0.05). 
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Figure 4.36: Conditioned Growth Media Assay in T47D with 76N Tert-ESR1 media 
Alamar Blue proliferation assay was performed on T47D cells using (a) normal growth 
media or (b) conditioned growth media from doxycycline treated 76N Tert-ESR1 cells, 
diluted 1:1 with normal growth media.  (c) Fold change in Alamar Blue reduction between 
day 5 and day 1 is shown for normal and conditioned media (CM, with and without Dox) 
experiments.  Error bars indicate SEM.  (* p < 0.05). 
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Figure 4.37: Conditioned Growth Media Assay in T47D with MCF10A-ESR1 media 
Alamar Blue proliferation assay was performed on T47D cells using (a) normal growth 
media or (b) conditioned growth media from MCF10A-ESR1 cells, diluted 1:1 with normal 
growth media.  (c) Fold change in Alamar Blue reduction between day 5 and day 1 is shown 
for normal and conditioned media (CM, with and without Dox) experiments.  Error bars 
indicate SEM.  (* p < 0.05). 
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Figure 4.38: FOXA1 and GATA3 expression in HMEC lines 
RT-qPCR expression of (a) FOXA1 and (b) GATA3 in untreated HMECs.  Gene expression 
is shown relative to normal breast tissue.  Error bars indicate SEM.  (* p < 0.05). 
  
a 
b 
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CHAPTER 5 
SUMMARY AND FUTURE 
 Chronic lifetime exposure to estrogen through early menarche, late menopause, 
hormone replacement therapy, and high serum estrogen levels all increase a woman’s risk 
for developing breast cancer.  These reproductive risk factors suggest that longer lifetime 
exposure to estrogen increases breast cancer risk.  Accordingly, estrogen is known to 
contribute to tumor growth/initiation and treatment with SERMs lowers incidence of breast 
cancer.  However, estrogen exposure can also decrease breast cancer risk through early in 
life pregnancy, which decreases breast cancer risk by up to 50%.  High dose estrogen 
treatment is also an effective antitumor therapy for postmenopausal women with breast 
cancer and is thought to sensitize tumors to estrogen-induced apoptosis.  This data suggests 
that high levels of estrogen exposure, depending on context, have antagonistic effects on 
breast cancer risk. 
Although all women are exposed to estrogen, only 1 in 8 women will develop breast 
cancer during their lifetime.  Familial breast cancer risk accounts for 27-30% of overall 
breast cancer risk, but 60-70% of familial breast cancer risk is due to currently unknown 
inheritable factors.  Rodent models demonstrate genetic susceptibility to estrogen-induced 
mammary tumor development and estrogen-induced responses in the mammary gland 
which are not linked to any known breast cancer risk genes, suggesting unique sensitivity 
to estrogen exposure.  We hypothesized that a subset of women may be more sensitive to 
estrogen and that these women may be at increased risk for developing breast cancer.   
Responses to estrogen exposure in the breast are mediated through estrogen 
receptors alpha and beta (ERα and ERβ).  Estrogen acts as a ligand for these receptors to 
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activate transcription of target genes in coordination with estrogen receptor coregulators, 
which modulate the activity of ERα and ERβ.  Estrogen receptor coregulators are expressed 
in a tissue specific manner.  Through the use of human breast ex-vivo and primary cell 
models, we sought to characterize the level of variation in estrogen receptor expression and 
estrogen-induced responses to determine if some individuals are more responsive to 
estrogen and if this correlates with ER expression or is due to downstream regulation of 
the estrogen signaling pathway.   
 In microarray data from over 100 donor breast tissue samples, we observed 
significant variation in ESR1 and ESR2 expression, and expression of these receptors 
changes with age.  Our data for ESR1 expression agrees with previously published data for 
ERα expression, suggesting that ESR1 expression can be used as an endpoint.  To examine 
if estrogen receptor expression correlates with estrogen-induced biological endpoints, we 
utilized a human breast explant model with over 20 donor tissue samples.  The breast 
explant model allowed us to examine responses within a single donor to control or E2 
treatment, which is advantageous to other studies of ERα expression which relied on data 
gathered from women at a single time point.  We again observed significant variation in 
ESR1 and ESR2 expression, with up to 80 or 100-fold variation between individuals.  For 
estrogen-induced endpoints, we examined transcriptional and functional E2 responses in 
our explant samples.  Global transcription levels indicated by R-loop formation were 
similar between donors, suggesting that E2 induces transcriptional responses regardless of 
individual genetic background.  When we looked at specific transcriptional targets, 
however, we observed quite variable responses.  Expression of ER target genes AREG, 
PGR, and TGFβ2 were consistently increased in nulliparous donors, but in parous donor 
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expression of these genes with E2 treatment increased in some donors and  decreased in 
others.  Some individual donors also had high basal levels of target gene expression.   
For functional endpoints of estrogen treatment, we examined PR, PCNA, and 
apoptotic responses among donors.  PR expression was significantly decreased in E2 
treated explants compared to fresh tissue timepoints, but there was no significance between 
control and E2 treated explants.  This data agrees with other published results in human 
breast tissue but differ from what is known in breast cancer cell lines.  E2-induced 
proliferation, assayed by PCNA expression, revealed a trending increase with E2 treatment 
but overall expression varied widely among individuals.  In mice, our lab has shown that 
irradiation induced apoptotic responses are enhanced by E2 treatment.  However, in our 
human breast explants we did not observe any significant increase in apoptotic cells 
compared to control treated tissues, though responses again varied by individual.   
Correlation analysis with E2 mediated transcriptional and functional responses 
revealed no significant correlation of ESR1 or ESR2 with any endpoints.  These results 
indicate that while there is significant variation in estrogen receptor expression among 
individuals and also variation in E2-induced responses, estrogen receptor expression alone 
is not dictating sensitivity to E2 treatment.  In order to expand upon these results, we began 
working with human primary breast epithelial cell models.  Conditionally reprogrammed 
primary human mammary epithelial cells (ciHMECs) and stably immortalized HMECs 
were used as individual donor samples to examine estrogen-induced responses as well as 
responses to environmental xenoestrogens BP3 and PP.   
Our primary HMECs enriched primarily for basal epithelial cell populations, which 
corresponds with what others have noted about the limited growth of luminal epithelial 
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cells in 2D culture.  Others have also noted that the conditional reprogramming culture 
method generates an epithelial population with some stem cell like properties.  
Accordingly, in mammosphere forming assays, we found that most ciHMEC lines were 
able to form mammospheres in ultra-low attachment conditions, compared to half of 
permanently immortalized HMEC lines.  One main drawback to HMEC models is that 
most HMECs do not express estrogen receptors, so for our HMEC studies we used transient 
transfection of the estrogen receptors along with reporter constructs as an endpoint.  Dose 
response experiments with E2, BP3, and PP treatment revealed that BP3 and PP are 
agonists for both ESR1 and ESR2, but transactivation is significantly higher with ESR1.  
Characterization revealed variation in ciHMEC responses to E2 (2.5-fold), BP3 (2.3-fold), 
and PP (3.6-fold) treatment, but the activity between donors cell lines was more consistent 
than what we had observed with our human breast explant model.  This data reveals that 
xenoestrogens BP3 and PP act as ligands for both ERα and ERβ, but their main activity is 
through ERα, and that xenoestrogen exposure has the potential to activate estrogen 
receptors in the majority of individuals and therefore could influence the effects of estrogen 
signaling on breast cancer development. 
Our last model for studying variation in estrogen-induced responses was our 
inducible ERα HMEC lines.  Using a doxycycline inducible vector, we generated an 
inducible ESR1 expression construct and stably infected 4 HMEC lines.  Characterization 
of these lines using luciferase reporter assays revealed significant transactivation with E2 
treatment in all 4 HMECs, but the amount of transactivation and potential leaky construct 
expression varied between the 4 HMEC lines.  We confirmed ERα protein expression by 
western blot, and expression levels of ERα were comparable to MCF7 breast cancer cells.  
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For biologically relevant responses, we examined proliferation and target gene expression 
in our 4 iERα HMECs.  In 3 of 4 iERα HMECs, we observed modest but significant 
proliferation induced by E2 treatment resulting in a 20-25% increase in proliferation.  
However, target gene expression was no longer regulated by estrogen, as PGR was not 
expressed in any lines and AREG expression was consistently high in 3 of 4 HMEC lines.   
The data from our 4 iERα HMEC lines complimented our observations from our 
human breast explant model, where we observe some variation in biological responses with 
E2 treatment.  In our 4 iERα HMECs, we observed significant proliferative responses to 
E2 in 3 of 4 lines, but clearly E2-induced responses are not consistent with what is known 
in breast cancer cell lines despite having similar levels of ERα.  We hypothesized that 
coregulators of estrogen receptor signaling expressed in these 4 cell lines could be 
modulating E2-induced responses, which was supported by the work of other labs showing 
that co-expression of FOXA1 and GATA3 with ESR1 is required in ER negative breast 
cancer cell lines to restore some E2-induced responses.  In order to test this hypothesis, we 
first determined if the proliferative responses observed in 3 of 4 iERα HMECs was due to 
cell intrinsic factors.  Conditioned media assays in 2 iERα HMEC and one breast cancer 
cell line revealed that the iERα HMEC proliferation does not appear to be stimulated by 
secretion of growth factors, which suggests that intracellular factors are responsible for 
modulating these responses.  Examination of FOXA1 and GATA3 expression in our HMEC 
lines, however, demonstrated that expression levels of these factors is not correlated with 
E2-induced proliferative responses.  Future work with these cell lines will involve somatic 
cell hybrid formation with breast cancer cell lines and our 4 iERα HMECs in order to 
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determine if there are intracellular factors in our HMECs that are restricting E2-induced 
responses. 
Collectively, these results demonstrate significant variation in estrogen receptor 
expression and estrogen-induced responses among individuals.  This data mirrors results 
in rodent models which have demonstrated genetic susceptibility to estrogen-induced 
responses and tumor formation, where individual genetic background appears to amplify 
or suppress the effects of estrogen exposure.  Our human breast explant model data 
demonstrated that estrogen receptor expression level is not correlated with E2-induced 
responses, suggesting that other factors in the estrogen signaling pathway are mediating 
individual sensitivity to estrogen.  As estrogen receptor coregulators are known to modulate 
estrogen receptor activity and are expressed in a tissue specific manner, we hypothesized 
that these coregulators may be responsible for determining individual sensitivity to 
estrogen.  Our iERα HMECs are a useful model for studying estrogen-induced responses 
and illustrate that cell intrinsic factors appear to mediate E2-induced proliferative 
responses.  However, unlike other studies which suggest FOXA1 and GATA3 are 
necessary and sufficient for E2-induced responses, we found that FOXA1 and GATA3 
expression is not sufficient to restore E2-induced biological responses.   
In order to determine whether specific coregulators of estrogen receptor signaling 
may alter E2-induced biological responses and expression of ER target genes, a single cell 
RNA sequencing (scRNA-seq) approach can be used with the models outlined here.  Many 
recent studies have utilized scRNA-seq to examine the differentiation of basal and luminal 
progenitors in the mammary gland.  One group suggests that the differentiation of 
progenitor cells into mature basal and luminal epithelial cells occurs along a continuum 
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(Bach et al., 2017), while others seem to agree that epithelial cells form distinct clusters of 
basal and luminal epithelial cells which can be further classified by expression profiles (Pal 
et al., 2017; Nguyen et al., 2018; Sun et al., 2018; Chen et al., 2019).  In human breast 
tissue scRNA-seq analysis, 2 luminal cell populations and 1 basal cell population are 
identified, with some inter-individual variability noted in certain sub clusters (Nguyen et 
al., 2018; Chen et al., 2019).  The luminal epithelial subtypes are defined as either 
secretory, which do not express estrogen receptors, or hormone-responsive, which express 
ESR1 and PGR (Bach et al., 2017; Nguyen et al., 2018).  While ESR1 is most highly 
expressed in hormone-responsive luminal epithelial cells, some cells from basal and 
secretory luminal clusters also express low levels of ESR1 in the human breast (Chen et 
al., 2019).  For our future work, we would be interested in isolating the hormone-responsive 
luminal epithelial cell cluster to examine expression of estrogen receptor coregulators. 
As estrogen receptor coregulators control estrogen-induced signaling inside ERα 
positive cells, scRNA-seq can be used to isolate hormone-responsive luminal epithelial 
cells from digested human breast donor tissue samples using previously identified profiles 
in the human breast (Nguyen et al., 2018; Chen et al., 2019).  This cluster of cells can be 
further examined to select those which express ESR1, and expression of estrogen receptor 
coregulators can be compared within this cell population.  Once these cells are selected, 
expression of ER coregulators can be compared between human breast tissue donors and 
compared to E2-induced responsiveness determined in human breast explant or HMEC 
experiments.  Alternatively, scRNA-seq can be used to analyze coregulator expression in 
our 4 iERα HMEC lines to compare ER coregulator expression in E2-proliferative cell 
lines (76N Tert-ESR1, MCF10A-ESR1, and HME-CC-ESR1) to our unresponsive cell line 
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(ME16C2-ESR1) and ERα positive breast cancer cell lines T47D or MCF7.  We 
hypothesize that these experiments would lead to the identification of ER coregulators 
which correlate with increased or decreased E2-responsiveness.  These experiments would 
determine if ER coregulators are rate-limiting for estrogen receptor signaling. 
Overall, we demonstrate that some individuals are more sensitive to estrogen 
exposure, this sensitivity is most likely not due to estrogen receptor levels alone, and cell 
intrinsic factors such as estrogen receptor coregulators appear to modulate these responses.  
Further work to expand upon the role of estrogen receptor coregulators on mediating 
estrogen sensitivity is still needed, but these results provide a potential mechanism for the 
antagonistic roles of estrogen in mediating breast cancer risk.  This data also suggests that 
a subpopulation of women is more sensitive to estrogen and thus may be more at risk of 
breast cancer development through estrogen exposure. 
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